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GENERAL ABSTRACT 
Prolonged exercise has been associated with depressed immune function, and hence an 
increased risk of infection. However, several nutritional supplements may reduce or 
overcome this problem. Thus, the aims of this thesis were to investigate the effects of some 
nutritional supplements on athletes’ immune function. In study 1 (Chapter 3), effects of 
several vaccine stimulant dose on whole blood culture cytokine production was carried out to 
determine effective vaccine stimulant dose; which was found to be between a dilution of 
4000 (dose 4) and 1000 (dose 6) of the original vaccine. This finding was used for the other 
studies (Chapter 4 and 5). In addition, the relationship between data obtained from Evidence 
Investigator analyser and enzyme linked-immuno-sorbent assay (ELISA) for IL-10 was 
analysed and the results show a positive strong correlation between them. In study 2 (Chapter 
4), in vitro effects of various immunomodulatory nutritional compounds on antigen-
stimulated whole blood culture cytokine production was investigated and it was found that 
caffeine and quercetin showed tendency towards decrease cytokine production as the doses 
were increased. On the other hand, an upward trend was evident with kaloba, where high 
dose of kaloba seemed to increase the cytokine production. Since kaloba appeared to act as an 
immunostimulant in vitro, its effects on the immune response to prolonged exercise were 
examined in study 3 (Chapter 5). However, 7 days kaloba supplementation (20 mg of the root 
extract) did not alter athletes’ immune response although prolonged moderate intensity 
exercise significantly decreased S-IgA secretion rate and concentration post-exercise with the 
values returning to baseline by 1 h post-exercise. A 14-strain probiotic supplement effects on 
salivary antimicrobial proteins at rest and in response to an acute bout of prolonged exercise 
was investigated in study 4 (Chapter 6). Unfortunately, 30 days supplementation of the 14-
strain probiotic appeared not enough to induce any significant effects on salivary 
antimicrobial proteins. Lastly, in study 5 (Chapter 7), the effects of a Lactobacillus probiotic 
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on healthy people, who tend to have a higher than normal incidence of infection due to 
exercise stress-induced immune impairment was studied. In summary, this 16-week 
intervention study on 267 athletes found that regular ingestion of the probiotic reduced the 
extent to which training was negatively affected in endurance athletes when infection was 
present, and increased both S-IgA concentration and secretion rate over time. But it did not 
appear to reduce URTI incidence or the duration and severity of URTI episodes. Two major 
confounding factors, namely the unexpectedly low incidence of URTI during the winter 
period and the lower baseline S-IgA in the probiotic group may have prevented potential 
beneficial effects of probiotic supplementation from being identified. 
Key words: nutritional supplements, cytokine, S-IgA, kaloba, probiotic, URTI, immune 
function, exercise. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 The immune system.  
The human body has a complex, self-identification defence system called the 
immune system which protects the host from infection by pathogens that may lead to 
various diseases. Since the types of pathogens are diverse, this defence system 
produces different types of immune response which can be schematically divided into 
two types called innate and acquired immunity (Pinchuk, 2002; Male, 2003; 
Sompayrac, 2003). Innate immunity is a natural protective mechanism that we are 
born with and it comprises physical barriers (skin, mucus, enzymes, commensal flora, 
etc.), and physiological barriers (Decker, 1999). It is mainly represented by 
monocytes, natural killer (NK), macrophages, and dendritic cells (DC) (Sansoni et al., 
2008). Innate immunity is a non-specific cellular and humoral response, which serves 
as the first line of defence system. It produces an immediate response and fights 
against many but not all pathogens.  
On the other hand, acquired (adaptive) immunity is highly specific in 
response, inducible, and discriminatory (Clancy, 1998). It is activated when the innate 
immunity is unsuccessful eliminating the pathogens. B and T lymphocytes play a 
major role at this stage (Sansoni et al., 2008). However, acquired immunity takes 
several days or weeks after the first exposure to pathogen to produce a response. 
Interestingly, it produces an immune memory, so that when the same pathogens 
invade the body for the next time, it will produce a faster and greater response 
(Decker, 1999).  Basically, the immune response has two phases: recognition and 
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effector phases. In the recognition phase, the immune system tries to identify the 
pathogen while in the effector phase, the pathogen will be eliminated or at least 
restrained sufficiently to control the damage created by the pathogen (Male, 2003). 
The various immune system components (both innate and adaptive) are shown in 
Table 1.1. 
Table 1.1: Main elements of the immune system (Gleeson, 2006). 
Innate components                                        Adaptive components 
Cellular: 
Natural killer cells (CD16+, CD56+) 
Phagocytes (neutrophils, eosinophils,    
basophils, monocytes (CD14+), 
macrophages 
Soluble: 
Acute-phase proteins 
Complement 
Lysozymes 
Cytokines (interleukins (IL), interferons 
(IFN), colony-stimulating factor 
(CSF), tumour necrosis factor (TNF) 
Cellular: 
T-cells (CD3+, CD4+, CD8+) 
B-cells (CD19+, CD20+, CD22+) 
 
 
 
 
Soluble: 
Immunoglobulins (Ig)- IgA, IgD, IgE, 
IgG, IgM 
CD = Clusters of Differentiation or Cluster Designators 
1.1.1 Factors that affect immune function. 
It is clear that defence mechanisms of human body largely depend on the 
effectiveness of the immune system. There are several factors that have been 
demonstrated to have a profound influence on the immune system, including age, 
inflammatory or autoimmune disease, exercise, psychological stress, and diet 
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(Gleeson, 2006). This explains why each individual’s immunity is different from each 
other. It is generally assumed that the aging process progressively deteriorates and 
subsequently shows significant adverse changes on the structure and function of the 
immune system (Makinodan and Kay, 1980; Herbert and Cohen, 1993; Castle, 2000). 
However, the evidence suggests that innate immunity is better preserved, while 
adaptive immunity is deteriorates (Hirokawa et al., 1994; Franceschi et al., 2000). 
Immunosenescence is established to be associated with increased risk of infectious 
disease, malignancy, and autoimmune disorders (Miller, 1991; Graham et al., 2006). 
It has been reported that, there are losses of phagocytic capacity, increases of early 
pro-inflammatory cytokines (IL-1ß, IL-6, and TNF), reduced dendritic cell (DC) 
traffic, decreased number of naïve T cells, higher numbers of memory cell types, 
decreased T and B cell proliferation, and reduced expression of important surface 
molecules for intercellular interaction in the elderly (Miller, 1996; Pawelec and 
Solana, 1997; Ginaldi et al., 1999). Hirokawa et al. (1994) proposed that 
physiological thymic involution, which includes changes in thymic hormone 
production and overall function of thymus ability is responsible for those age-related 
changes in T-cell-dependent immune function. Thymic involution is believed to start 
at the age of puberty and is almost complete at the end of the sixth decade of life 
(Sansoni et al., 2008). Yet, age-related changes in immune function are not 
unavoidable and irrevocable since there is a complex relationship between this factor 
and other factors (psychological stress, diet, exercise, etc.) (Fiatarone et al., 1989). 
Psychological stress is another factor that can affect immune function where 
even a fairly, mild stress can result in immune dysregulation (Glaser and Kiecolt-
Glaser, 2005; Graham et al., 2006). Stress is defined as what one feels when life’s 
demands exceed one’s ability to meet those demands (Kelly, 1999). School 
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examinations or tests were found to diminish NK cell cytotoxic activity (NKCA) 
(Kang et al., 1997), increase neutrophil and platelet numbers and decrease eosinophil, 
monocyte, basophil, and lymphocyte numbers in the circulation (Qureshi et al., 2002), 
and delay the wound healing process (Kiecolt-Glaser et al., 1998; Marucha et al., 
1998). Chronic stress leads to greater impact on immune function compared with 
acute stress since acute stress causes only a temporary decrease in immune function 
while chronic stress will result in continued impairment in immune function manifest 
as decreased NKCA and decreased salivary secretory IgA (S-IgA) secretion (Kelly, 
1999). It was found that stress and age are interactive and that psychological stress 
can imitate, worsen (Graham et al., 2006), and speed up (Kiecolt-Glaser and Glaser, 
2001) the effects of aging on immune function. The same decline in immune 
functions appears to occur in psychologically stressed individuals and aged 
individuals (Burns and Goodwin, 1997; Kiecolt-Glaser et al., 1998; Epel et al., 2004; 
Hawkley and Cacioppo, 2004). 
Gender also affects both humoral and cell-mediated immune responses (Chao 
et al., 1995). Statistics shows that incidence of autoimmune disease, i.e., systemic 
lupus erythematosus, Hashimoto’s thyroiditis, and rheumatoid arthritis, is higher in 
females than males (Olsen and Kovacs, 1996; Gaillard and Spinedi, 1998; Butts and 
Sternbrg, 2004). Kiecolt-Glaser and Newton (2001) reported that following conflicts 
in married people, women show greater immune dysregulation than men. The 
suggested explanation was that female possesses higher levels of Immunoglobulin 
(Ig) than males (Gaillard and Spinedi, 1998; Butts and Sternbrg, 2004). It is also 
believed that differences in sex steroids are responsible for this gender differences in 
immune response (Schuurs and Verheul, 1990; Olsen and Kovacs, 1996). A study 
conducted in 2001 revealed that a predisposition to acute stress by women during the 
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luteal phase of their menstrual cycle affects immune function by suppressing the 
immune response, decreasing the CD4/CD8 ratio, and decreasing NK cells as a 
percentage of total lymphocytes (Pehlivanoglu et al., 2001). In relation to exercise, 
females had greater macrophage antiviral resistance than males in both control-
sedentary and moderate exercise groups (Brown et al., 2006). In a separate study, 
researchers discovered that exercise (cycling for 60 min at 70% maximum oxygen 
uptake, VO2max) induced increases in total leukocytes, lymphocytes, and NK counts 
that were 35% greater or more in girls compared with boys of similar pubertal status 
(Timmons et al., 2006). 
It is known that engaging in regular moderate physical activity can enhance 
immune function and protect against upper respiratory tract infection (URTI) (Nieman 
et al., 1990; Nehlsen-Canarella et al., 1991). However, immune function can be 
detrimentally affected during and after prolonged, strenuous exercise, thus increasing 
the infection risk (Mackinnon, 2000; Pedersen and Toft, 2000). Thus, it was suggested 
that exercise-induced changes in immune function depend on the exercise intensity 
and duration (Gleeson and Bishop, 1999) and the training status of the individual 
(Keast et al., 1988; MacKinnon, 1989). The effects of different types of exercise on 
immune function and infection risk will be further discussed in the following sections.  
Certain nutritional strategies have been shown to limit exercise-induced 
immune dysfunction and are thus recommended to athletes engaged in heavy training 
and competition. These nutritional strategies include ensuring adequate intake of 
macronutrients (carbohydrate, protein, and fat), avoidance deficiencies of 
micronutrients (e.g. the minerals Iron, Zinc, Copper, and the Vitamins A, B12, C, D, E 
and Folic acid), and taking supplements such as antioxidants, probiotics, herbs, and 
. 
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bovine colostrum. However, questions remain about their efficacy in reducing 
infection risk or ameliorating symptoms and duration of infections. There are 
numerous studies in this field to help athletes to cope with the exercise-induced 
immune function dysregulation and thus to reduce the risk of infection. The details of 
how these nutritional supplements work in this area will be explained later in this 
chapter.  
1.2 Effects of exercise on immune function. 
 Cumulating evidence has shown that impaired immune function may increase 
infection risk, which in turn is associated with health impairment and performance 
decrement in athletes. Thus, athletes and fitness enthusiasts are very concerned about 
the effects of exercise on immune function. It is well established that exercise-induced 
immunodepression depends on the intensity and duration of exercise (Keast et al., 
1988; MacKinnon, 1989; Gleeson and Bishop, 1999; Gleeson and Walsh, 2012). 
Numerous studies have been conducted regarding the effects of exercise on immune 
function where it is generally indicated that regular moderate intensity exercise 
enhances immune function above those having sedentary lifestyle. In contrast, 
prolonged exercise and periods of intensive training and competition may impair 
immune function.  
1.2.1 Prolonged exercise and immune function. 
According to Gleeson (2006a), post-exercise depression of immune function is 
most pronounced when the exercise is continuous, prolonged (> 1.5 h), of moderate to 
high intensity (55 – 75% of aerobic capacity), and performed without food intake. 
Prolonged exercise may impair both innate and adaptive immune function (Gleeson 
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and Walsh, 2012). Several studies reported that suppression of type 1 cytokines were 
found immediately after a prolonged intensified exercise, and persisted for 24 h 
(Starkie et al., 2001; Lancaster et al., 2005). Furthermore, Libicz and colleagues 
(2006) reported that there was negative cumulative effect of an intense exercise 
repeated daily on basal levels of S-IgA on elite triathletes. In a separate study, it was 
also reported that S-IgA secretion was decreased after prolonged bouts of exercise 
(Bishop and Gleeson, 2009). 
Other evidence demonstrated that during and for several hours after an 
exercise trial to exhaustion before, immediately after, and following 2 weeks of 
recovery from a 6-day intensified training period, production of IL-2 and IFN-γ by T 
lymphocytes were inhibited, while a 6-day period of intensified training decreased the 
percentage of type 1 T cells in circulation in the resting state (Lancaster et al., 2004). 
It was suggested that bouts of intense prolonged exercise induce decreased number 
and function of leukocytes as a result of increased stress hormone secretion, thus 
resulting in the entry of less mature leukocytes into circulation, particularly NK cells 
(Gleeson, 2005).  
In 2001, analysis of blood samples collected after a  competitive marathon run 
revealed decreased number of cells producing IL-1α and IL-6, increased numbers of 
monocytes with less cytokine production, and marked increases in the plasma 
concentrations of  IL-6, TNF-α, adrenaline (epinephrine), and noradrenaline 
(norepinephrine) (Starkie et al., 2001). Subsequently, Gomez-merino and colleagues 
(2003) conducted a study on 26 male soldiers, where they found that S-IgA activity 
was lower and circulating IL-6 was higher in the soldiers after a 5-day military course 
following 3 weeks of combat training. Studies conducted on rats indicated that 8 
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weeks of exercise on running wheels caused decreases in T cell activity, increases in 
B cell proliferation (Lin et al., 1993), and induced an immune response that mimicked 
some aspects of fever (Rowsey et al., 2009). Production of IL-2 was found to be lower 
in an animal study in which rats exercised by running at 60 – 70% VO2max for 30 
min which was then extended up to 60 min per day for 5 days per week for 10 weeks 
(Lin et al., 1993). Another study found that cycling at an intensity of 10% above the 
ventilatory threshold level in sedentary males for 8 weeks, 3 days per week, 20 min 
per day, did not significantly increased the total circulating leukocyte number, but 
significantly decreased the CD3+ and CD4+ counts as much as 13 and 17%, 
respectively (Unal et al., 2005). Thus, it is believed that prolonged strenuous exercise 
have a temporary negative impact on immune function. 
1.3 Exercise and infection risk. 
 Based on numerous studies conducted regarding the relationship between 
exercise and infection risk up to 1994, it has been proposed that the relationship 
between exercise intensity or training volume and risk of upper respiratory tract 
infection (URTI) may be best explained in the form of ‘J’-shaped model (Nieman, 
1994). As shown in Figure 1.1, the ‘J’-shaped model suggests that regular moderate 
intensity exercise decreases the relative risk of URTI compared with a sedentary 
lifestyle while prolonged high intensity exercise or periods of strenuous exercise 
training increase the relative risk of URTI above that of a physically inactive 
individual. According to Malm (2006), the ‘J’-shaped model was proposed based on 
the findings of a small number of studies before 1994, where most of the studies 
investigated the relationship between prolonged, high intensity exercise (e.g. 
marathon and ultramarathon running) and the URTI risk in the weeks that followed. 
. 
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Furthermore, this hypothesis was built based from observational and case series 
surveys (Moreira et al., 2009).  
There are several factors that may influence infection risk other than exercise 
and these include: vaccine history and time since inoculation, previous infections, 
nutrition status, and pathogen exposure. This suggests that infection is a risk for 
anybody, and anywhere. On average, children experience between six and eight colds 
per year, while adults may have between two and four colds per year (Lissiman et al., 
2009). However, elite athletes, compared to subelite athletes, tend to maintain their 
health status even after they have completed heavy exercise training. Hence, in 2006, 
based on a re-evaluation of previous studies, Malm proposed an ‘S’-shaped 
relationship (Figure 1.2) between exercise load and risk of infection. However, he 
recommended that this ‘S’-shaped model be verified using data from a large number 
of subjects since it was limited to one runners’ training log over 16 years (Malm, 
2006). This finding may be attributed to physiological fitness of that elite athlete, 
thereby healthy enough to compete even after a strenuous training period. In addition, 
it may be due to genetic factors. 
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Figure 1.1: ‘J’-shaped model of the relationship between varying amounts of 
exercise and risk of upper respiratory tract infection (Nieman, 1994). 
 
 
Figure 1.2: ‘S’-shaped model of the relationship between exercise load and infection 
rate (Malm, 2006). 
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It is generally assumed that illness will decrease performance and the ability to 
train hard or compete. Even small changes in several immune parameters may alter 
resistance to URTI. Thus, information of how to decrease risk of infection is valuable 
especially to athletes and fitness enthusiasts.  It  has been  suggested that individuals 
should avoid overtraining, have adequate rest and recovery during the training cycle 
and after competition, limit exposure to potential sources of infection, ensure 
adequate nutrition, and take selected supplements (vitamin C, probiotics, herbs, 
antioxidants, etc.) to prevent URTI (Mackinnon, 2000). It is thought that periods of 
prolonged and intense training are associated with high risk of infection because 
during this period, also known as open window period, virus and bacteria can gain a 
foothold (high susceptibility for pathogen entrance) (Nieman, 2000). Linde (1987) 
suggested that athletes tend to develop more frequent but not necessarily more severe 
URTI than the general public, and changes in URTI incidence are related to training 
volume and intensity. 
An interesting article published in 2009 reviewed 30 published studies that 
had investigated the effect of exercise, physical activity, sport, and training on 
susceptibility to URTI and included 4 descriptive, 18 observational, and 8 
interventional studies (involving 8595 athletes and 1798 non-athletes) (Moreira et al., 
2009). This systematic assessment covered areas of agreement, areas of controversy, 
and areas timely for developing research (growing points). Among the 30 reviewed 
studies, areas of agreement included: moderate activity may enhance immune 
function, whereas prolonged, high-intensity exercise temporarily impairs immune 
competence; athletes experience a higher rate of URTI after training and competition 
compared with less active individuals; increasing physical activity in previously 
sedentary people is associated with a decreased risk of URTI. On the other hand, areas 
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of controversy among these 30 studies are: elite athletes may have a decreased 
susceptibility to URTI; poorly known individual determinants (e.g. genetic factors, 
fitness, nutritional status or disposition towards developing allergic hypersensitivity 
reactions) might affect the relationship between exercise and URTI.  
1.3.1 Prolonged exercise and infection risk. 
There is growing evidence to indicate that regular moderate exercise decreases 
the risk of acquiring URTI, while too much or too little exercise intensity may raise 
the infection risk. In a large scale study over 12 weeks involving over 1000 
participants, it was recently reported that regular moderate intensity exercise reduces 
URTI incidence by ~ 20 – 45% compared with a sedentary lifestyle (Nieman et al., 
2011). In addition, among athletes, it was suggested that relatively short duration or 
less competitive events were not associated with elevated risk of URTI (Nieman et al., 
1989). In response to this, recreational or non-competitive athletes believe that they 
are more protected against URTI compared with others.  
Therefore, there is a perception among top athletes, coaches, and sport 
physicians that athletes are at a higher risk of getting infections during period of 
intense exercise training and after major competition (Peters, 1997; Mackinnon, 
1989), because during these periods there is a chronic mild depression of some 
immune parameters (Mackinnon and Hooper, 1996). It was suggested that prolonged 
bouts of strenuous exercise have a temporary negative effect on immune function 
(Gleeson and Walsh, 2012). Furthermore, the depression of immune function is most 
pronounced when the exercise is continuous, prolonged (> 1.5 h), of moderate to high 
intensity (55 – 75 % VO2max), and performed without food intake (Gleeson, 2006a). 
. 
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It was previously observed that URTI incidence was elevated as much as 6-
fold in runners compared with matched non-participants in the first 1 – 2 weeks after 
an endurance event (Peters and Bateman, 1983; Nieman et al., 1990). An 
observational, case-control study in 1983 revealed that 1 week after the two Oceans 
Marathon in 1982, there were significantly more self-reported symptoms of URTI in 
runners compared with individually matched controls who did not run. In addition, 
this self-reported URTI incidence was higher in the fastest runners (likely to be both 
the fittest and the ones who had the highest training loads), with no differences 
between the slower runners and controls (Peters and Bateman, 1983). Nieman and 
colleagues (1989) conducted a prospective study on 273 marathon runners with a 2-
month training period prior to a 5-km, 10-km, or half-marathon race. The outcome 
was that self-reported URTI symptoms were more common in runners who trained 
more than 15 miles per week. Furthermore, they found that there was no increase in 
infectious episodes during the week following the run compared with the week prior 
to the race. In one study, Gleeson and colleagues (2011b) reported that high levels of 
physical activity are associated with a higher risk of URTI, where they found that 
those who exercised ≥ 11 h/week (HIGH) had significantly more URTI episodes than 
those who exercised 3 – 6 h/week (LOW). They also found an elevated level of anti-
inflammatory cytokines IL-4 and IL-10 in response to antigen challenge in the HIGH 
group, and suggested that this may explain the higher incidence of infection in the 
HIGH group. 
The mucosal immune system provides resistance to respiratory infection, with 
the major secretory immunoglobulin being IgA. Thus, IgA play a role in the first line 
of defence against infectious agents on mucosal surfaces (Gleeson and Pyne, 2000). 
Numerous studies have observed a decline in S-IgA levels after prolonged intense 
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exercise in endurance athletes, which in turn is sometimes associated with an 
increased incidence of URTI symptoms. A review article reported that low levels of 
S-IgA and IgM, particularly IgA1 subclass are associated with an increased risk of 
respiratory illness (Gleeson, 2000). Nevertheless, this association remains to be 
confirmed in well-controlled large scale studies. In 2005, a study was conducted on 
21 male cadets from a military school who took part in a commando training (3 weeks 
of commando training followed by a 5-day combat course) (Tiollier et al., 2005). It 
was found that after the 3 weeks of training, S-IgA concentration was unchanged, but 
it was reduced after the 5-day combat course with a return to baseline values within 1 
week of recovery. In addition, they found that the incidence of URTI was increased 
during the trial but was unrelated to S-IgA levels. Hence, they concluded that a 
stressful event results in an adverse effect on mucosal immunity and incidence of 
URTI, yet the relationship between S-IgA levels and illness remains uncertain.  
In a separate study, researchers investigated the association between tennis 
training and competition, the incidence of URTI and S-IgA in 17 elite female tennis 
players (Novas et al., 2003). Results from this 12-week observational study showed 
that increased training duration and load, and competition level was positively 
associated with incidence of URTI. Salivary IgA was reduced markedly after a 1 h 
tennis training session (whole unstimulated saliva samples were collected before and 
after selected 1 h training sessions at 2-weekly intervals). Besides, this study reported 
that over the 12-week period, pre-exercise S-IgA concentration and secretion rate 
were directly associated with the amount of training undertaken during the previous 
day and week. The decline in S-IgA after 1 h of intense tennis play was also 
positively associated to the amount of training undertaken during the previous day and 
week. It was concluded that although suppression of S-IgA due to exercise may be a 
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risk factor; the occurrence of URTI in this study could not be accurately predicted 
(Novas et al., 2003).   
A year longitudinal study on American college football players reveals that 
there was a significant reduction in the concentration and secretion rate of S-IgA 
(Fahlman and Engels, 2005). As a result of this, it was found that the incidence of 
URTI in these football players was increased. Another study on elite professional 
athletes over 50 weeks of training found that there was a significant decrease in S-IgA 
concentration 3 weeks before the URTI episodes, and return to baseline value after 2 
weeks of infection (Neville et al., 2008). It was indicated that there is a one in two 
chance of contracting an URTI within 3 weeks if the S-IgA value is lower that 40% of 
an individual’s mean healthy value. This suggests that a decline of S-IgA 
concentration over 3 weeks is associated with elevated URTI incidence, where the 
magnitude of relative decrease in S-IgA was related to the URTI risk but independent 
of the absolute S-IgA concentration. These two studies somewhat support the theory 
that reduction in S-IgA level associated with increase susceptibility to URTI.   
In contrast, a 4-month winter training period in 20 highly trained international 
level male distance runners found no substantial relationship between intensity or 
training load  and number of illness episodes reported (Fricker et al., 2005). In 2006, 
Ekblom and colleagues observed no relation between training volume 6 months 
before the race, finishing time and socioeconomic and demographic factors and 3 
weeks before or 3 weeks after the Stockholm Marathon 2000. Furthermore, the 
incidence of infectious episodes 3 weeks after the race (post-IE) in runners, who had 
not experienced any infectious episodes in the 3 weeks before the race was 16%; 
whereas post-IE in runners who had experienced an infectious episode 3 weeks before 
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the race was 33%. They also found that younger runners were more likely to 
experience infectious episodes both before and after the race. Hence, this study does 
not support the common perception of intense training causing high infection risk, but 
does suggest that increased infection risk is somewhat related to engaging in 
strenuous exercise too soon after a recent infection (Ekblom et al., 2006).  
In general, the evidence indicates that moderate exercise training in sedentary 
or less active individuals reduces their infection risk but endurance athletes 
experience higher infection incidence after intense training and competition compared 
with sedentary individuals. There is limited evidence for a reduction of risk of 
infection in elite athletes. For some athlete group, there appears to be a dose-response 
relationship between infection risk and exercise load during training and competition. 
There are many other factors other than exercise load, that may increase the 
susceptibility to infection and S-IgA levels may play some role in resistance to 
respiratory illness. 
1.4 Nutrition and immune function. 
Early in the chapter, it was briefly discussed that diet may affect immune 
function. It was proposed that inadequate diets lead to immunodepression which in 
turn can increase susceptibility to infection (Gleeson and Bishop, 2000). Two 
available mechanisms (direct and indirect) may clearly explain this effect. Inadequate 
diets may induce a direct negative effect on immune function by altering the 
availability of nutrients, coenzymes, or cofactors involved in immune cell energy 
metabolism and protein synthesis. Otherwise, inadequate nutrition may cause an 
indirect negative effect on immune function through immunoregulatory effects of 
stress hormones and altered hormonal responses to stress (e.g. exercise), thereby 
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decreasing immune function. This may include decreased cell mediated immunity, 
cell proliferation, complement formation, phagocyte function, and antibody 
production or affinity (Walsh, 2006). However, there is insufficient evidence to 
associate this inadequate nutrition-induced immunodepression to increased risk of 
URTI in athletes. 
Numerous studies have been published regarding the effects of various types 
of diet and nutrition supplements on immune function, particularly in athletes. This 
growing field of study aims to provide sufficient evidence of the benefit of certain 
foods or supplements that may boost an athlete’s immune function, thereby reducing 
the infection risk. Macronutrients (carbohydrate, protein and fat), micronutrients, 
vitamins, herbs, and probiotics are among those dietary components that have been 
studied.  
As exercise results in increased energy expenditure, there is need for an 
increased in intake of macronutrients. Deficiency in macronutrients may lead to 
compromised performances, premature fatigue, and impact on muscle building, 
maintaining and repairing. Some researchers have investigated the effects of 
combination of diets (e.g. CHO and protein, CHO and vitamin) in order to reveal 
significant positive effects of these combinations on athletes’ immune function. 
Endurance athletes typically consume a low-fat-high-CHO diet (15% fat, 65% CHO, 
20% protein of total calories) (Venkatraman et al., 2000).  
The need for trace minerals may rise with exercise training since they are 
secreted through sweat produced during exercise, and are also lost through urine. 
Their concentration in blood and tissue is decreased after training and competition, 
where the magnitude of losses depend on mode and intensity of exercise, exercise 
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duration, environmental temperature, and mostly related to nutrition status of the 
individual (Konig et al., 1998). Zinc and iron are among these important trace 
minerals with roles in immune function besides copper, selenium, manganese, and 
magnesium. Zinc is a component of antioxidant enzymes and is thought to protect 
against increases in free reactive oxygen species, while iron is important in energy 
metabolism and synthesis of haemoglobin, myoglobin, and cytochromes (Speich et 
al., 2001). Hence, supplementation of these minerals may be beneficial to enhance 
athletes’ immune function. However, too much of them may lead to increase 
susceptibility to infection since their excess is somewhat associated with immune 
function impairment (Gleeson and Bishop, 2000). 
Many vitamins are precursors of coenzymes involved in energy metabolism 
and protein or nucleic acid synthesis. Several vitamins are essential for normal 
immune function: vitamin A, B-complex, C, D and E. Deficiency in vitamin B-
complex may lead to fatigue and muscle soreness. However, vitamin deficiency in 
athletes is less reported since vitamin loss via sweat and urine during exercise is 
negligible. 
The following sections describe some nutritional supplements that were 
examined in the studies reported in this thesis: probiotics, Kaloba (Pelargonium 
sidoides/ EPs7630), echinacea, quercetin, curcumin and caffeine. 
1.4.1 Probiotics. 
 Intestinal epithelia are constantly exposed to varied, dynamic enteric bacteria 
which comprise more than 500 species of anaerobic bacteria (Ohland and 
MacNaughton, 2010). Microbiota within the gastrointestinal (GI) tract give benefit to 
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their host whereby they maintain normal mucosal immune function, epithelial barrier 
integrity, motility, and nutrient absorption. Whenever this relationship between 
microbiota and host is disrupted, GI function and disease susceptibility may be altered 
(Collins and Bercik, 2009). Its defensive barrier functions to protect against an 
uncontrolled inflammatory response and includes a mucous layer, antimicrobial 
proteins (AMPs), secretory IgA, and epithelial junction adhesion complex (McGuckin 
et al., 2009). Although adult bacterial colonic flora are generally stable, it appears that 
age, nutritional requirement, immune status, use of antibiotic, stress, alcohol use, pH, 
transit time, and the presence of materials in the gut, may influence them (Collin and 
Gibson, 1999). Numerous studies have proposed that consumption of non-pathogenic 
bacteria, especially probiotics, may decrease paracellular permeability, provide innate 
defence, and enhance physical impediment of the mucous layer (Boirivant and 
Strober, 2007).  
Probiotics, also known as ‘friendly bacteria’, is a Greek word which means 
‘for life’ (Salminen et al., 1998). Officially, it is defined by World Health 
Organisation (WHO) as ‘live microorganisms which when administrated in adequate 
amounts confer a health benefit on the host’ (FAO, 2001). These non-pathogenic 
microorganisms can be found in fermented food products such as yoghurt, tempeh, 
kefir, sauerkraut, cabbage kimchee, soybean based miso, and natto (Nichols, 2007). A 
nationwide survey reported that approximately 2 million adults in the United States 
use probiotics for health reasons with middle aged females being the highest 
consumers (French, 2006). Lactobacillus species, Bifidobacterium species, 
Streptococcus species, and Escherichia coli are the commonly used bacterial 
probiotics. Lactococcus lactis and some Enterococcus species are also used. Both the 
Lactobacillus (L.) and Bifidobacterium (B.) species are lactic acid bacteria which 
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convert carbohydrate to lactic acid, which gives the sour taste to yoghurt and other 
similar products. Lactic acid reduces the pH, thus reducing the growth of spoilage 
organisms.  
To ensure its safety for human consumption, most of these microorganisms 
were isolated from healthy humans (Boirivant and Strober, 2007). To date, probiotics 
consumption in humans has a good safety record (Gueimonde et al., 2006). However, 
special precautions are needed when it is to be consumed by ill patients. Previous 
studies showed that passage of probiotics through the GI tract is typically between 3 
and 8 days (Klijn et al., 1995). To be classified as a genuine probiotic, these bacteria 
should have viability during processing, transport, and storage, ability to survive 
gastric transport, ability to adhere and colonise the GI tract, ability to antagonize 
pathogenic bacteria, and demonstrated clinical health outcomes (West et al., 2009). 
Yet, there is no optimum dosage established for probiotic ingestion to induce 
beneficial effects. The current dosage is between 108 and 1011 colony forming units 
(CFU) per day (Takashi et al., 2009; Kudsk, 2002). 
While probiotics are live microbial food ingredients, prebiotics are indigestible 
food ingredients that selectively promote the growth or activity of beneficial enteric 
bacteria, thereby benefiting the host (Gibson and Roberfroid, 1995). Combinations of 
probiotics and prebiotics are called synbiotics and are designed to improve the 
survival of ingested microorganisms and their colonization in the GI tract (Boirivant 
and Strober, 2007). Studies show that probiotics exert their effects either with or 
without colonization. Those with colonization (e.g. Bifidobacterium longum and 
Bifidobacterium thetaiotamicron) become part of human intestinal microflora 
(Sonnenburg et al., 2006; Pochart et al., 1992), while those without colonization (e.g. 
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Lactobacillus casei and Bifidobacterium animalis) exert their effects indirectly either 
in a transient manner as they pass through or more likely by remodelling or 
influencing the existing microbial community (Preidis and Versalovic, 2009; Pochart 
et al., 1992) with potential effects on mucosal and systemic immunity (Calder and 
Kew, 2002). 
The proposed mechanisms of action of probiotics include altering the 
expression levels of host cell-derived anti-microbial peptides and directly inhibiting 
growth or promoting killing of pathogens by producing anti-microbial molecules 
including short-chain fatty acids (SCFA) and bacteriocins or microcins (Collins and 
Bercik, 2009). Probiotic bacteria may also compete against invading pathogens for 
binding sites to epithelial cells and the overlying mucous layer, and augment levels of 
total and pathogen-specific secretory IgA upon infection, while typically not inducing 
production of probiotic-specific secretory IgA (Galdeano and Perdigon, 2006). 
Furthermore, probiotic bacteria may promote tolerogenic dendritic cell and regulatory 
T cell phenotypes, inhibit inflammatory cytokine production, and enhance NKCA (Ng 
et al., 2009). In addition, French (2006) reported that probiotics may speed the 
breakdown of organic waste fragments, cleaning the intestinal tract, increasing the 
production of important enzymes, assisting the regulation of digestion, relieving 
constipation, and strengthening the immune system. 
1.4.1.2 Probiotics and athletes’ immune function. 
Evidence of an ergogenic effect of probiotics on athlete performance is 
lacking but this is not surprising given that there is no rationale for such effect. 
However, probiotics may confer secondary health benefit to athletes by enhancing 
recovery from fatigue, improving the immune function, and maintaining healthy of GI 
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tract function (Nichols, 2007). Yet, the available published studies regarding 
probiotics’ benefit on athletes is limited. 
A recent published study reported that regular ingestion of L. salivarius 
probiotic in 66 highly active individuals during 16 weeks of spring training does not 
affect blood leukocyte counts, levels of salivary AMPs, and also not appears to be 
beneficial in reducing URTI frequency (Gleeson et al., 2012). However, previously it 
was found that daily probiotic (L. casei Shirota) supplementation in 84 highly active 
individuals for 16 weeks during winter period was beneficial in reducing URTI 
frequency, which might be related to better maintenance of S-IgA levels (Gleeson et 
al., 2011a). 
In a separate study, 20 healthy elite male distance runners received 3 capsules, 
twice per day for 28 days of L. fermentum VRI-003 (PCC) (1.2 x 1010) or placebo 
(Cox et al., 2010). Twenty-eight days after completing the first supplementation 
period, elite runners received the second supplement (PCC or placebo), followed by 
follow-up. The authors reported that there was less than half the number of days of 
respiratory symptoms in subjects with PCC compared with placebo. Furthermore, 
illness severity was lower, and unstimulated in vitro whole blood culture production 
of IFN-γ was 2-fold greater with PCC supplementation. There were no significant 
differences in mean change in S-IgA and plasma Ig-A levels or in IL-4 and IL-12 
serum levels between treatments. Another study which using the same strain of 
probiotic (minimum 1 x 109 L. fermentum (PCC) per day for 11 weeks) found that the 
probiotic lowered the respiratory illness symptoms in male competitive cyclists 
compared to those taking placebo (West et al., 2011). However, its effect on female 
cyclists was uncertain. 
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Clancy et al. (2006) conducted a study on 9 athletes with fatigue and impaired 
performance and symptoms consistent with re-activation of Epstein Barr virus (EBV) 
infection and 18 healthy athletes (control group), where athletes were given daily 
capsules of 2 x 1010 L. acidophilus LAFTI® L10 for 4 weeks. It was found that 
stimulated IFN-γ production by T cells which was low in the fatigued athletes was 
significantly increased in the fatigued athletes, to the same level as the healthy 
controls after the probiotic treatment.  
In a separate study, 5 male cyclists were given probiotics drink contains 1.3 x 
1010 L. casei Shirota or placebo daily for 2 weeks during training. Then, they 
completed a cycle ergometer exercise trial (Gleeson, 2008). This study found that the 
circulating CD4+ increased and the CD4+/CD8+ ratio improved at rest and post 
exercise. Another study found a smaller decrease in circulating NK cells after an 
exercise stress (60 minutes at 75% VO2max) after a month of daily supplementation 
with 500 ml probiotic (DN-114 001) drink containing 3.2 x 108 CFU/ml of L. casei 
(Pujol et al., 2000). These findings suggest that some probiotics may enhance 
athletes’ immune function. 
During 3 months of training after the Helsinki City Marathon, 141 marathon 
runners were  given a milk-based fruit drink (130 ml per day) which contained 4 x 
1010 CFU/ml of L. rhamnosus GG or placebo (Kekkonen et al., 2007). Then, they 
were followed-up for 2 weeks after the event. Results revealed that GI illness episodes 
showed a trend to be of shorter duration during training, significantly shorter duration 
after the marathon, but with no difference in GI illness incidence.  
 
. 
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1.4.2 Kaloba (Pelargonium sidoides / EPs7630). 
Kaloba is an extract derived from the root of plants that are indigenous to 
South Africa. It comes from the family Geraniaceae and genus Pelargonium and was 
traditionally used to treat dysentery, diarrhoea, colds, wounds, fatigue, fevers, hepatic 
complaints, generalized malaise, and respiratory tract infections such as tuberculosis, 
bronchitis, and sinusitis (Kolodziej, 2000; Lewu et al., 2006). Furthermore, studies 
reported that it is successfully employed for the treatment of ear, nose, and throat 
disorders as well as respiratory tract infections (Kolodziej and Kiderlen, 2007; 
Matthys and Funk 2008; Thale et al., 2008; Matthys et al., 2010). Besides, it was 
found that its usage is well tolerated, efficacious, safe, and no adverse effects. African 
geranium, umckaloaba, kalwerbossie, rabassamin, and zucol are among its common 
names. Kaloba composed of 6 main groups of constituents which include 
unsubstituted and substituted oligomeric prodelphinidins, monomeric and oligomeric 
carbohydrates, minerals, peptides, purine derivatives and highly substituted 
benzopyranones. 
To date, there is one study investigating the effects of this plant extract on 
athletes’ immune function available in literature (PubMed search). Luna and 
colleagues (2010) had investigated immune response induced by Pelargonium 
sidoides (Kaloba) extract in serum and nasal mucosa of athletes after exhaustive 
exercise. In that study, participants performed a high-intensity running session (~ 85% 
of VO2max) after 28 days of supplementation (3 x 30 drops/day of a solution of 80 g 
of extract/100 ml in solution). They found that saliva secretory IgA concentration was 
increased suggesting that Pelargonium sidoides able to modulate the immune 
response of athletes during intense physical activity. However, the post-exercise 
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sample was collected 48 h after exercise completed. The authors did not justify the 
selection of this sampling time point and it would be of interest to know if the IgA 
response to exercise was altered in the immediate post-exercise recovery period.  
 A study was conducted to determine its efficacy in the treatment of patients (1 
– 18 years old) with acute bronchitis, outside the strict indication for antibiotics 
(Kamin et al., 2012). Patients were given 7 days supplementation of either EPs7630 (1 
- 6 years: 3 x 10 drops per day; > 6 - 12 years: 3 x 20 drops per day; > 12 - 18 years: 3 
x 30 drops per day) or placebo. The mean total score of bronchitis-specific symptoms 
(BSS) was significantly more improved in the EPs7630 group throughout the 
supplementation period. Improvements were most pronounced for ‘coughing’ and 
‘rales at auscultation’. There were no serious adverse effects observed from either 
supplement. Thus, this study supports the traditional belief that this plant extract is 
effective in treating bronchitis. In a separate study, 400 patients (6 – 18 years old) 
were given 30 mg, 60 mg, or 90 mg of EPs7630 or placebo for 7 days (Kamin et al., 
2010b). They found that BSS total score (especially ‘coughing’, ‘sputum’ and ‘lung 
sounds’ (small clicking, bubbling, or rattling sounds) heard during auscultation) was 
significantly better with a dose of 60 and 90 mg of EPs7630.  
 Another study investigated the efficacy of EPs7630 in treating the common 
cold (Lizogub et al., 2007). Patients (103 males and females adult patients with at 
least 2 major and 1 minor or with 1 major and 3 minor cold symptom) received either 
30 drops (1.5 ml) of the liquid herbal drug preparation EPs7630 or placebo, 3 times 
per day for 10 days. It was found that the sum of symptom intensity differences 
improved, the decrement of the mean of cold intensity score was higher, percentage of 
patients cured after 10 days supplementation was higher, and the mean duration of 
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inability to work was lower in the EPs7630 group compared with placebo. As the 
adverse effects observed were not serious, it was concluded that EPs7630 is effective 
and tolerable in treating the common cold.  
1.4.3 Echinacea. 
 Immunomodulatory properties of Echinacea, the most widely consumed 
botanical product in the United States (Bardia et al., 2007), are unclear because of 
different methods of its preparation, different plant parts used, and heterogeneity of 
species. Three widely available species which include purpurea, angustifolia, and 
pallida, appear to have different immunomodulatory potential based on cytokine 
stimulatory properties (Barnes et al., 2005; Senchina et al., 2009). 
 Interestingly, a recent published study found that Echinacea supplementation 
(8000 mg/day, 4 times per day, for 28 days) significantly improved running economy 
(as indicated by a decrease in submaximal VO2max during the first 2 stages of 
maximal graded exercise tests) (Whitehead et al., 2012). In a study involving two 
different exercises; a VO2max test and a 90 min cycling at 85% of ventilatory 
threshold, blood samples pre- and post-exercise were stimulated in vitro with extracts 
from bloodroot (Sanguinaria canadensis) or coneflower (Echinacea tennesseenis) 
(Senchina et al., 2009). It was found that in the VO2max test and the 90-min bout, 
bloodroot extracts significantly increased cytokine production compared with 
controls. In a separate study, the effects of 4 weeks Echinacea supplementation on 
mucosal immunity and URTI incidence and duration before an exercise was examined 
compared with control group (without Echinacea supplementation) (Hall et al., 2007). 
This exercise involved 3 consecutive, 30 sec all-out efforts Wingate cycling tests with 
0.075 kg per kg body mass frictional resistance. Tests were separated by 3 min 
. 
. 
. 
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recovery. It was found that, in the control group, S-IgA level and secretion rate 
decreased following the intervention. Furthermore, URTI duration was significantly 
different between groups where it was found to be longer in the control group. This 
suggests that Echinacea may blunt the intense exercise-induced mucosal immune 
suppression and reduce the URTI duration.  
A double-blind, placebo-controlled, cross-over study on horses with 42 days 
supplementation of either Echinacea or placebo reported increased phagocytic ability 
of isolated neutrophils, boosted peripheral lymphocyte counts, and to some extent 
stimulate neutrophil migration from peripheral circulation in to the tissues (O’Neill et 
al., 2002). In addition, it was also found that the size and concentration of peripheral 
red blood cells and the concentration of haemoglobin and packed cell volume were 
increased. Researchers concluded that Echinacea supplementation act as a haematinic 
agent (an agent that stimulates the production of red blood cells or increases the 
amount of haemoglobin in the blood) and stimulate equine immunocompetence. 
1.4.4 Quercetin. 
Quercetin is a flavonol that can be found in fruits and vegetables which is 
believed to reduce infection risk during intense exercise since it has anti-inflammatory 
and antioxidant properties, beside its psychostimulant actions and its ability to 
stimulate mitochondrial biogenesis (Davis et al., 2009). A recent study found that 
quercetin supplementation (500 mg supplemental quercetin capsule) daily for 8 weeks 
in active male students had significantly increased VO2max, lean body mass, total 
body water, basal metabolic rate, and total energy expenditure (Askari et al., 2013). 
Similarly, another study also claimed that quercetin increased VO2max in untrained 
subjects (Davis et al., 2010). However, one study reported that quercetin (250 mg) 
. 
. 
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supplementation for 3 weeks on runners did not affect the ratings of perceived 
exertion (RPE) during a 160-km endurance run (Utter et al., 2009). An animal (mice) 
study also found no effects of 6 weeks quercetin supplementation on VO2 peak, speed 
at VO2 peak, or endurance time to exhaustion (Casuso et al., 2013). 
A study conducted in 2007 revealed that 2 weeks ingestion of quercetin (1000 
mg per day) did not affect exercise-induced immune function depression (NKCA, 
PHA-stimulated lymphocyte proliferation, polymorphonuclear oxidative-burst 
activity, and S-IgA output) in trained male cyclists who completed 3 h of cycling per 
day for 3 days (57% PPO) However, it was found that quercetin ingestion 
significantly reduced the URTI incidence in the cyclists (Nieman et al., 2007b). In a 
separate study, Nieman and colleagues reported that 3 weeks quercetin ingestion 
(1000 mg per day) by ultra-marathon runners before a competition (160 km) did not 
blunt the muscle damage, inflammation, increase in plasma cytokine and hormone 
concentrations, and alterations in leukocyte cytokine mRNA expression (Nieman et 
al., 2007a).  
In an animal study, mice were randomly distributed into four different groups: 
exercise-placebo, exercise-quercetin, control-placebo, and control-quercetin (Davis et 
al., 2008). Mice were fed with quercetin (12.5 mg/kg) via gavage for 7 days before 
they were exposed to the influenza virus A/Puerto Rico/8/34 (H1N1). The animals 
were intranasally inoculated at 30 min after the last bout of exercise (run to fatigue 
(approximately 140 min) on a treadmill for 3 consecutive days) or rest. The exercise-
induced increase in susceptibility to infection (morbidity, mortality, and symptom 
severity on days 5 – 7 after influenza virus inoculation) was blunted with quercetin 
supplementation. Morbidity in mice was identified by the presence of ruffled fur, 
. 
. 
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redness around the eyes, nose, or mouth and altered respiration which occurred 
around day 4 to day 5, hunched-back pose, which occurred around day 5 to day 6, and 
unresponsiveness, which occurred after 6 days. 
1.4.5 Curcumin. 
Curcumin which is contained in the rhizome of the plant is the major bioactive 
compound in turmeric (Curcuma longa). It has multiple biological activities such as 
anti-oxidants, anti-inflammatory, and anti-carcinogenic (Huang et al., 1991; Rao et 
al., 1995; Cai et al., 2013), thus used in folk medicine for the therapy of inflammatory 
and infectious diseases. In addition, a recent study suggested that curcumin reduces 
glomerulosclerosis (hardening of the glomerulus in the kidney), improves kidney 
function and could serve as a therapeutic agent during serum sickness (Jacob et al., 
2013). However, it has poor bioavailability and lack of solubility in aqueous solvents 
(Yadav et al., 2010), thus its optimal potential is difficult to discover. Studies reported 
that curcumin causes reduction in production of TNF-α, IL-1, and IL-8 (Chan, 1995; 
Hidaka et al., 2002).  
Furthermore, Yun et al. (2011) found that curcumin suppressed cytokine 
release in human monocytes cells. These findings suggest that curcumin is an 
immunosuppressant. Bharti and colleagues (2010) reported that curcumin dose-
dependently decreased IFN-α induction in cultures (peripheral blood lymphocytes), 
but has marginal effect on IL-4 expression. They also reported that curcumin 
effectively suppresses massive Th1 cytokines induction after renal transplantation.  
It was also suggested that curcumin ingestion and aerobic exercise training can 
increase flow-mediated dilation in post-menopausal women, hence can potentially 
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improve the age-related decline in endothelial function (Akazawa et al., 2012). In a 
separate study, curcumin supplementation in rats shows an inhibitory role, where it 
attenuated lead-induced neurotoxicity (Hosseinzadeh et al., 2013). 
1.4.6 Caffeine. 
Immunomodulatory effects of caffeine, a well-known psychostimulant 
substance, have been extensively studies and it appears that caffeine modulates both 
innate and adaptive immune responses. Caffeine is present in coffee and tea and is a 
member of the methylxanthine family of drugs; it is the most widely consumed 
psychoactive substance by humans (Fredholm et al., 1999). Numerous studies suggest 
caffeine has anti-inflammatory effects. For instance, one study found that caffeine 
supplementation 1 h before exercise increased IL-6 and IL-10 plasma levels (anti-
inflammatory cytokines) following a 15-km running competition in athletes (Tauler et 
al., 2013). Besides, studies have also reported that caffeine decreased lymphocyte 
proliferation (Kantamala et al., 1990; Rosenthal et al., 1992; Horrigan et al., 2005). It 
also appears that caffeine supplementation suppresses antibody production (Laux and 
Klesius, 1973; Saxena et al., 1984; Rosenthal et al., 1992). Furthermore, previous 
studies also showed that the production (whole blood culture) of pro-inflammatory 
cytokines such as TNF-α (Van Furth et al., 1995; Horrigan et al., 2004) and IFN-γ 
(Horrigan et al., 2005) were decreased with caffeine. 
It was suggested that many of caffeine’s immunomodulatory effects occur at 
concentrations that are relevant to normal human consumption (Horrigan et al., 2006). 
However, one study found that one large dose (6 mg/kg body mass) of caffeine did 
affect (attenuated) the exercise-induced increase in antigen-stimulated NK cell CD69 
expression 1 h following strenuous intermittent exercise (Fletcher and Bishop, 2011). 
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But, this effect was not evident when the caffeine was ingested in smaller amounts (2 
mg/kg body mass) on 3 separate occasions (this model is typical of habitual caffeine 
consumption) during the day. Overall, people in Ireland, UK, and US consume 
caffeine in amounts of approximately 200 mg/person/day, whilst over 400 
mg/person/day are consumed in the Netherlands, Sweden, and Norway. 
1.5 Summary. 
 Throughout this literature review, it is clearly shown that exercise-induced 
immunodepression depends on the duration and intensity of exercise, where 
prolonged and high intensity exercise is the most detrimental to human immune 
function. The relationship between the amount and intensity of exercise with the risk 
of upper respiratory tract infection was described in the J-shaped model as discussed 
previously. High-level athletes are at a higher risk to suffer from infections compared 
with recreational athletes because high-level athletes engage in high intensity training 
for longer periods especially when they are about to take part in competition. Various 
diet and nutritional supplement interventions have been studied and recommended by 
researchers to be taken to enhance immune function and subsequently reduce 
infection risk. However, the effects of some of these nutritional supplements on 
immune responses to exercise and/or URTI incidence are scarce in literature.  
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CHAPTER 2 
GENERAL METHODS 
2.1 Ethics approval. 
Each study obtained ethics approval from the local Research Ethics 
Committee. Before each study was conducted, participants were informed about the 
study background and procedures before they signed the written informed consent 
form (Appendix A). Participants recruited were all physically active and healthy. To 
confirm their overall health status, they were asked to complete a health screening 
questionnaire (Appendix B) before participating in each study.  
2.2 Maximal oxygen uptake (VO2max) determination. 
 During each first visit, participants completed the health screen questionnaire 
form and consent form. Then, their body mass and height were measured. After that, 
participants sat on an electrically braked cycle ergometer (Lode Excalibur, Holland) 
for a VO2max test. They began cycling at 95 watt (W) for 3 min (warm-up), and then 
the power output was increased to 165 W for the following 3 min. After that, the 
power output was increased by 35 W at every 3 min, until volitional exhaustion. 
Expired gas was collected in a Douglas bag during the final minute at each 3-min 
stage. In addition, heart rate (HR) and rating of perceived exertion (RPE) were 
measured during this period. Heart rate was measured using a telemetric device (Polar 
Electro, Kempele, Finland) and the Borg 6 – 20 point scale was used to estimate RPE 
(Borg, 1982). Participants were asked to give signal when they thought they could 
continue for only one more minute (i.e., as they approached volitional exhaustion). 
During this period, RPE and HR were measured and expired gas was collected in a 
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new Douglas bag. Verbal encouragement was also given at this point. After that, 
participants were allowed to cool down before leaving. 
 Expired gas samples collected in the Douglas bags were then analysed by an 
oxygen (O2) and carbon dioxide (CO2) analyser (Servomex series 1400, 
Crowborough, UK) and the volume of expired gas at each work rate was measured 
using a dry gas meter (Harvard apparatus, Cambridge, UK). From these results, 
VO2max was determined. The relationship between oxygen uptake and work rate was 
used to determine the work rate that was equivalent to 60% VO2max. This work rate 
was then used during the experimental trials. 
2.3 Familiarisation trial. 
Approximately 1 week after VO2max test, participants completed a 
familiarisation trial which was cycling at the work rate which would be required 
during the experimental trial (equivalent to ~ 60% VO2max) for 90 min on a cycle 
ergometer to familiarise them with the protocol of the study. This also ensured that 
the exercise intensity given did elicit a relative intensity of ~ 60% VO2max and 
participants were able to maintain the exercise for 90 min after an overnight fast. 
Expired gas was measured during the trial at minute 10, 30, 60 and 90. 
2.4 Analytical methods. 
2.4.1 Saliva sample collection. 
Participants came in the morning after an overnight fast. Before saliva samples 
were collected, participants were seated for at least 10 min. Saliva samples were 
obtained by 2 min unstimulated dribbling into a pre-weighed sterile bijou tube. They 
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were asked to sit on a chair, lean the head forward and let the saliva passively dribble 
into the tube; without using their tongue or any mouth movement. Whenever the 
saliva volume collected in 2 min was insufficient, the collection was continued further 
for another 1 or 2 min. The bijou tube (with saliva sample) was then weighed. 
2.4.1.1 Saliva volume/weight, flow rate, and saliva antimicrobial proteins secretion 
rate calculation. 
Following are how the saliva volume/weight, flow rate, and saliva 
antimicrobial protein secretion rate were calculated in this study: 
Saliva volume (ml) = Difference in weight (g) of bijou tube after collection of saliva 
assuming a saliva density of 1.0 g/ml  
Saliva flow rate (ml/min) = Saliva volume    (ml)    
                                             Collection time (min) 
Saliva antimicrobial protein secretion rate (µg/min) = Saliva flow rate (ml/min) X 
Saliva antimicrobial protein concentration (µg/ml) 
2.4.2 Saliva analysis. 
2.4.2.1 Saliva secretory immunoglobulin A (S-IgA) analysis. 
Saliva samples were analysed for S-IgA level by using a Salimetric S-IgA 
ELISA kit. Before analysis, saliva samples were thawed at room temperature and then 
spun for 2 min at 12,000 rpm in microcentrifuge. Then, a dilutor dispenser Hamilton 
400X (with 5 ml and 100 µl syringes) was used to deliver 10 µl of standard, control or 
sample to 4 ml of working conjugate solution into each labelled polypropylene tube. 
Each sample was done in duplicate. They were then incubated at room temperature 
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for 90 min. After 90 min incubation, 50 µl from each tube was pipetted into the 
microwell plate in duplicate. The plate was covered with an adhesive plate sealer. 
After that, it was incubated at room temperature for 90 min on a plate shaker set to 
250 rpm. Next, the plate was washed by using an automated washer before 50 µl of 
TMB was added to all wells. It was then incubated for 20 min in the dark without 
shaking. After that, 50 µl of stop solution was added to all wells. Then, the 
absorbance was read on Dynex Opsys plate reader at 450 nm wavelength. 
2.4.2.2 Lysozyme analysis. 
Before analysis was carried out, saliva samples were diluted 1000 times with 
Phosphate-Buffered Saline (PBS). Then, 50 µl of standards and saliva samples were 
pipetted into the designated duplicate wells. The plate was covered tightly with a 
plastic seal, and then incubated at room temperature for 1 h. Next, the plate was 
washed by using an automated washer. After that, 100 µl of the Lysozyme antiserum 
was added to each well. Once again, the plate was covered tightly with a plastic seal, 
and then incubated at room temperature for 1 h. After washing, 100 µl of the diluted 
Donkey anti-Goat IgG Peroxidase was added to each well and then incubated for 
another 1 h at room temperature. One volume of TMB solution (BT-497) was mixed 
with one volume of Hydrogen Peroxidase solution (BT-498) and then put aside. The 
plate was washed again, and then 100 µl of substrate mix was immediately added to 
all wells and incubated at room temperature, in the dark, for 15 min. Finally, 100 µl of 
stop solution was added to all wells, mixed by shaking and the absorbance measured 
at 450 nm on a Dynex Opsys plate reader within 15 min. 
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2.4.2.3 Lactoferrin analysis. 
Saliva samples were diluted 1000 times with PBS as described for lysozyme 
analysis. Firstly, 100 µl of standard/sample was added to each well. Then the plate 
was covered tightly with a plastic seal and incubated for 1 h at 37ºC. Next, the plate 
was washed by using an automated washer. Then, 100 µl of diluted anti-lactoferrin 
solution was added to each well. The plate was covered tightly with a plastic seal, and 
then incubated at for 1 h at 37ºC. Next, the plate was washed by using an automated 
washer. After that, 100 µl of diluted avidin-HRP (horseradish peroxidise) solution 
was added to each well. The plate was covered tightly with a plastic seal, and then 
incubated at for 15 min at 37ºC. Next, the plate was washed by using an automated 
washer. Then, 100 µl of OPD (o-phenylenediamine) was added to each well. The 
plate was covered tightly with a plastic seal, and then incubated at for 5 to 10 min at 
37ºC. Finally, 50 µl of stop solution was added, mixed by shaking, and the absorbance 
was read at 450 nm on a Dynex Opsys plate reader. 
2.4.2.4 Alpha (α)-amylase analysis. 
The assay was carried out in a micro-titration plate by using a kit (Amylase-
20, No. 577, Sigma). Firstly, saliva was diluted 1 in 100 in 1.0 mM calcium chloride 
(CaCl2) solution. Then, 20 µl of this diluted saliva was mixed with 180 µl of amylase 
reagent. Purified α-amylase from human saliva (A1031, Sigma) was used as s 
standard. The plate was then incubated for 1 min at 20ºC, and then the absorbance 
was read at 450 nm wavelength on a Dynex Opsys plate reader. Absorbance was read 
again after 2 min. Finally, amylase activity (units of enzyme activity corrected to 
37ºC) was calculated by using the following formula: 
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Amylase activity (U/L) = ∆A(The difference of absorbance reading) x 2515 
                           2 min 
2.4.3 Blood sample collections. 
 Blood samples collections were always performed after saliva sample 
collections. Blood samples were taken from an antecubital vein by venepuncture with 
a 21 gauge needle into heparin and/or K3EDTA collection tube/s using the vacutainer 
method. To make the vein become prominent, a tourniquet was used on the upper arm 
and was immediately released as soon as blood started to flow into the collection tube. 
Blood samples collected in K3EDTA tube were used for haematological analysis 
while blood samples collected in heparin tube were used for determination of antigen-
stimulated cytokine production. 
2.4.4 Haematological analysis. 
 On the same day as the blood sample collection, blood from the K3EDTA tube 
was used to measure haematological parameters (haematocrit (Hct), haemoglobin 
(Hb) concentration, red blood cell (RBC) count, and total and differential leukocyte 
counts) using an automated haematology analyser (Ac.T.5 diff, Beckman Coulter, 
UK). Each sample was measured twice and the average value was recorded. 
2.4.5 Cytokine array. 
2.4.5.1 One hundred times diluted vaccine dose preparation. 
Pediacel vaccine (containing purified diphtheria toxoid, purified tetanus 
toxoid, 5 purified components of the Bordetella pertussis bacteria, 3 types of 
inactivated poliovirus, and purified components Haemophilus influenzae type b) was 
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diluted 100 times by adding 50 µl Pediacel vaccine to 4.95 ml RPMI-1640 medium 
(Sigma-Aldrich, UK) in a bijou tube. This solution of diluted vaccine was kept at 4ºC 
and only used for up to 1 week. A new stock dilution was prepared each week when 
participants came to the laboratory.  
2.4.5.2 Whole blood culture incubation and supernatant storage. 
Since the effective dose range was found to be between dose 4 and 6 (1,000-
4,000-fold dilution of vaccine) (Chapter 3), we decided to use dose 5 (2,000-fold 
dilution of vaccine) in the second (Chapter 4) and third (Chapter 5) studies. On the 
same day as the blood sample collection, blood samples from heparin tube were 
incubated for 20 h. Firstly, on the culture plate, 50 µl of 100 x diluted vaccine was 
added to 0.7 ml of RPMI-1640 medium. Then 0.25 ml blood from heparin collection 
tube was added to it and gently mixed. RPMI-1640 medium contains sodium 
bicarbonate and L-glutamine which support the growth of the cultured cells. After 
that, the lid was placed on the culture plate before it was placed in the CO2 incubator 
(MiniGalaxy E, UK) (5% CO2, 37°C) for 20 h.  
After 20 h incubation, by using a 1 ml disposal pastette, blood culture was 
transferred from each well to separate labelled eppendorf tubes and spun for 4 min at 
12,000 rpm in a microcentrifuge (Thermo IEC, UK). After that, the supernatant fluid 
was aspirated using a 1 ml disposal pastette and placed in a labelled eppendorf tube. 
These were stored in a cryobox in a -20°C freezer until further analyses were carried 
out. 
Whole blood culture was used in this study instead of freshly isolated 
peripheral blood mononuclear cells (PBMCs) because whole blood culture system 
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represents more closely the natural environment with the presence of various 
immunomodulating and pro- and anti-inflammatory mediators of the blood. 
Furthermore, a whole blood culture system, which needs no purification procedure as 
needed in isolating PBMCs reduces the risk of cellular activation due to the 
purification procedure and avoids the disturbance in the ratios of different cell types. 
Table 2.1 shows the advantages and disadvantages of both methods. 
Table 2.1: Advantages and disadvantages of whole blood culture and freshly isolated 
PBMC methods (Hanekom et al., 2007). 
Assay 
approaches 
 
Advantages  Disadvantages  
 
Whole blood -Smaller blood volumes are 
required, compared with PBMC-
based assays. 
-Incubation with antigens is on 
a per-volume basis; T cell 
depletion may therefore result 
in loss of sensitivity and may 
require adjustment of blood 
volumes. 
-Assessment of a whole 
immunological compartment is 
accomplished - The measured T 
cell response will reflect cellular 
and soluble components that 
affect antigen presentation and T 
cell activation. 
-Whole blood may be used 
undiluted when incubation is ≤ 
18 hours, but longer term 
incubation requires dilution 
with RPMI, and therefore more 
resources. 
-The stimulation phase of this 
approach requires relatively few 
resources; assessment may often 
be completed in 2 phases: first 
immediate incubation with 
antigen, followed by 
cryopreservation of plasma, 
fixed white cells or RNA for 
later analysis, e.g., soluble, cell-
associated or mRNA expression 
analysis of cytokine in the 
respective samples. 
 
-The measured response 
reflects not only T cells, but 
other peripheral blood 
components also – for 
example, when cytokines 
levels are determined in plasma 
obtained from whole blood, 
measurements may reflect 
contributions of neutrophils 
and monocytes. 
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 -The need for immediate 
processing of collected blood 
limits versatility in what may 
be measured. 
Freshly isolated 
PBMC 
 
 
-PBMC-based assays are 
incubated on a per-cell basis, 
resulting in increased sensitivity 
in the face of T cell depletion, 
such as in HIV infection, 
compared with whole blood 
assays. 
-PBMC isolation requires more 
resources, compared with 
whole blood stimulation. 
-PBMC isolation may allow for 
a description of T cell responses 
without the influence of other 
whole blood components such as 
neutrophils and plasma. 
-PBMC isolation is associated 
with considerable cellular loss, 
requiring larger blood volumes.
  -Incubation of PBMC often 
involves introduction of 
foreign material, such as foetal 
calf or unrelated human serum; 
however, serum-free media 
may also be used. 
  -In short term assays, the 
cellular activation as a result of 
PBMC isolation may result in 
higher backgrounds, compared 
with similar incubation of 
whole blood. 
 
2.4.5.3 Evidence Investigator cytokine array. 
 Supernatant fluid stored in -20°C freezer was removed from the freezer and 
kept at room temperature to thaw for approximately 1 h before it was assayed for the 
cytokine concentrations using an Evidence InvestigatorTM cytokine and growth factors 
array kit (Randox, County Antrim, UK). Briefly, 200 µl of assay buffer and 100 µl of 
standard or sample were added to each well of the carrier. Then, for 60 min, it was 
incubated at 37°C at 370 rpm on the thermoshaker (Randox, UK). This allowed the 
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cytokines present in the sample to bind to the immobilised antibodies bound to the 
base of each carriers’ well. After that, the liquid from each well was decanted and 
washed by performing two quick washes and four 2-min soaks, followed by decanting 
the liquid and tapping the carrier onto lint free tissue paper. 
 Next, 300 µl of conjugate was added to each well and incubated at 37°C at 
370 rpm on the thermoshaker for 60 min. The wells were then washed as previously 
described before 250 µl of signal reagent (a mixture of luminol and peroxide) were 
added to each well followed by 2-min incubation in the dark. Finally, it was analysed 
by using the Evidence Investigator machine (Randox, UK). 
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CHAPTER 3 
STUDY 1: The effects of stimulant dose on whole blood culture cytokine 
production. 
Abstract 
One informative measure of immune function is the production of cytokines in 
response to an antigen challenge. Diseases, infections, psychological stress, and 
exercise are among those factors that cause immunodepression, and in this situation, 
cytokine production from activated white blood cells is lower than normal. Generally, 
cytokines are responsible for activation, proliferation or inhibition of proliferation, 
apoptosis, differentiation and chemotaxis. The aim of this study was to quantify the 
amounts of cytokines produced by stimulated whole blood culture (with a multi-
antigen Pediacel vaccine) with 7 different doses of vaccine in order to establish the 
most suitable effective dose for future studies. Six male and 6 female healthy 
participants (age: 26 ± 3 years; weight: 66.7 ± 11.2 kg; BMI: 22.7 ± 2.4 kg/m2) were 
recruited. Following an overnight fast from 21:00 and with no vigorous physical 
activity during the preceding 24 h, participants came to the laboratory between 09:00 
and 10:00. A resting blood sample was collected and incubated with appropriate 
volumes of RPMI-1640 medium and vaccine for 20 h (5% CO2, 37°C). Supernatants 
were subsequently removed for analysis of multiple cytokine production (IL-2, IL-4, 
IL-6, IL-8, IL-10, TNF-α, IFN-γ, IL-1α, and IL-1β) using an Evidence Investigator 
biochip array. In addition, IL-10 production was analysed by ELISA and the data 
obtained was then analysed for its correlation with data obtained from Evidence 
Investigator using Spearman correlation coefficient. Blood was also analysed for 
haematological parameters (haemoglobin concentration, haematocrit, red blood cell 
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count, and total and differential leukocyte counts). The main finding was that the most 
appropriate dose of stimulant was found to be between a 1,000-fold and 4,000-fold 
dilution of the original Pediacel vaccine. In addition, correlation between data 
obtained from Evidence Investigator and ELISA for IL-10 was moderately strong (r = 
0.828, n = 38, P < 0.001). 
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3.1 Introduction. 
The immune response to infection involves activation of innate and adaptive 
immune response by the action of cytokines. Numerous cytokines are released from 
activated white blood cells and have stimulatory effects on other effector cells. A 
cytokine is defined as an inducible protein of molecular weight greater than 5000 
Dalton which induces specific receptor-mediated effects on target cells or on the 
producer cell (Henderson and Nair, 1998). Generally, cytokines can be divided into 6 
different families (Table 3.1). Besides, they may also be divided into two main types: 
pro-inflammatory and anti-inflammatory. Pro-inflammatory cytokines (e.g., IFN-γ, 
TNF-α, and IL-2) are produced by Th1 cells while anti-inflammatory cytokines (e.g., 
IL-4 and IL-10) are produced by Th2 cells. However, some cytokines (e.g., IL-1β, IL-
6, and TNF-α) are produced by monocytes and macrophages. It is known that, when 
pathogen penetrates human body, pro-inflammatory cytokines will attack to kill the 
pathogen. This may cause an inflammation with signs such as pain, heat, redness, and 
swelling. This effect will be down-regulate by anti-inflammatory cytokines, where 
they will limit the sustained or excessive inflammatory reaction (Sultani et al., 2012). 
Thus, net effect of inflammatory response is determined by balance between pro- and 
anti-inflammatory cytokines. Nevertheless, it is important to aware that it may be 
misleading to clear-cut the classification of cytokine as either pro- or anti-
inflammatory. This is because the type, duration, and also the extent of cellular 
activities induced by one particular cytokine can be influenced considerably by the 
nature of the target cells, the micro-environment of a cell, depending, for example, on 
the growth and activation state of the cells, the type of neighbouring cells, cytokine 
concentrations, the presence of other cytokines, and even on the temporal sequence of 
several cytokines acting on the same cell (Ibelgaufts, 2010). 
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Cytokines are unique proteins that can have both effector and regulatory 
activities which influence activation of antimicrobial functions including proliferation 
or inhibition of proliferation, apoptosis, differentiation, and chemotaxis (Paul and 
Seder, 1994) of immune cells. Cytokine production is triggered by immune function 
disturbance that can be induced by factors such as disease, exposure to pathogens, 
infections, tissue damage, psychological stress, and exercise. Table 3.2 shows the 
principal sources of the cytokines and their primary functions. 
Table 3.1: Cytokine families (Gleeson, 2006). 
Family  Examples  
Interleukins (IL) 
Cytotoxic cytokines 
Colony-stimulating factors (CSF) 
Interferons (IFN) 
Growth factors (GF) 
Chemokines  
IL-1 to IL-7 
Tumour necrosis factor (TNF) 
IL-3, granulocyte-CSF 
IFN-α, -β, -γ 
Fibroblast GF, platelet-derived GF 
IL-8, Monocyte chemotactic protein-1 
(MCP-1) 
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Table 3.2: Cytokines and their principal sources, and functions (King, 2010). 
Cytokines Principal sources Functions  
IL-1α, IL-1β Macrophages and other 
antigen presenting cells 
(APCs). 
Co-stimulation of APCs and T cells, 
inflammation and fever, acute phase 
response, and haematopoiesis. 
IL-2 Activated Th1 cells and NK 
cells. 
Proliferation of B cells and activated T 
cells, and NK functions. 
IL-4 Th2 and mast cells. B cell proliferation, eosinophil and 
mast cell growth and function, IgE and 
class II MHC expression on B cells, 
and inhibition of monokine and Th1 
cytokine production. 
IL-6 Activated Th2 cells, APCs, 
contracting skeletal muscle, 
and other somatic cells such 
as hepatocytes and 
adipocytes. 
Acute phase response, B cell 
proliferation, thrombopoiesis, 
synergistic with IL-1 and TNF on T 
cells, inhibition of IL-1β and TNF- α 
production, and stimulation of IL-10, 
IL-1ra, and cortisol secretion. 
IL-8 Macrophages, other somatic 
cells 
Chemoattractant for neutrophils and T 
cells. 
IL-10 Activated Th2 cells, CD8+ T 
and B cells, and 
macrophages. 
Inhibits cytokine production, promotes 
B cell proliferation and antibody 
production, suppresses cellular 
immunity, and mast cell growth. 
TNF-α Primarily activated 
macrophages and 
adipocytes. 
Induces expression of other autocrine 
growth factors, increases cellular 
responsiveness to growth factors and 
induces signalling pathways that lead 
to proliferation. 
IFN-γ Activated Th1 and NK cells. Induces class I MHC on all somatic 
cells, induces class II MHC on APCs 
and somatic cells, and activates 
macrophages, neutrophils, and NK 
cells. 
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The Evidence Investigator system (Randox, Crumlin, UK) has an ability to 
measure multiple cytokine production in a single sample in response to an antigen. 
The Evidence Investigator utilise the basic principles of enzyme linked 
immunosorbent assay (ELISA) in a sandwich chemiluminescence immunoassay. High 
level of cytokine in a sample will increase the binding of antibody labelled with 
horseradish peroxidase (HRP), thus increasing the chemiluminescence signal emitted. 
The light signal generated is detected using digital imaging technology and compared 
to that from a stored calibration curve based on the known concentration of a range of 
9 standards. The concentration of analyte present in the sample is calculated from the 
calibration curve. 
However, knowledge about the effective dose of the stimulant (antigen) to be 
used in a whole blood culture assay of antigen-stimulated cytokine production is 
needed. Choosing an effective dose is important because at a suitable dose 
(somewhere in the mid-range of the dose response curve) the effects of an 
intervention (either positive or negative) can be observed. Thus, this study aimed to 
quantify the amounts of cytokines produced by stimulated whole blood culture over a 
range of stimulant doses. This may help us to decide the appropriate dose within the 
effective dose range to be used in any future studies. In addition, we investigated the 
relationship between data collected from an Evidence Investigator system and a high 
sensitivity ELISA method for the IL-10 response to the chosen stimulant. The latter 
was a commercially available multi-antigen, virus-based vaccine called Pediacel 
(Sanofi Pasteur). 
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3.2 Methods. 
3.2.1 Participants. 
Six male and 6 female healthy participants were recruited in this study from 
the students and staff of Loughborough University. Their mean age, weight, and body 
mass index (BMI) are 26 ± 3 years, 66.7 ± 11.2 kg, and 22.7 ± 2.4 kg/m2 respectively. 
3.2.2 Procedures. 
Participants were requested to come to the laboratory between 09:00 and 
10:00 following an overnight fast from 21:00. However, they were permitted to drink 
plain water. They were also asked to refrain from any vigorous physical activity in the 
preceding 24 h. Blood samples were collected into K3EDTA and lithium heparin 
collection tubes as described in the general methods (Chapter 2, section 2.4.3). 
3.2.3 Blood analysis. 
3.2.3.1 Haematological analysis. 
 Haematological analyses were carried out as described in the general methods 
(Chapter 2, section 2.4.4). 
3.2.3.2 One hundred times diluted vaccine dose preparation. 
This was prepared as described in the general methods (Chapter 2, section 
2.4.5.1). 
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3.2.3.3 Whole blood culture incubation and supernatant storage. 
Required volumes of RPMI-1640 medium were added into the culture wells, 
followed by required volume of 100 x diluted vaccine (as shown in the Table 3.3). 
Different volumes of 100 x diluted vaccine added into the wells produced different 
stimulant doses which were labelled as dose 1 to 7. After that, 0.25 ml of blood 
sample was added and incubated for 20 h as described in the general methods 
(Chapter 2, section 2.4.5.2). 
Table 3.3: Volume of 100 x diluted vaccine and RPMI added to each well for each 
blood sample. To these volumes, 0.25 ml heparinised blood was added to give the 
respective dilution factor. 
 
3.2.3.4 Evidence Investigator cytokine array. 
 This was carried out as described in general methods (Chapter 2, section 
2.4.5.3). 
3.2.3.5 Enzyme Linked-Immuno-Sorbent Assay (ELISA) for IL-10. 
 This assay was conducted in duplicate using a human high sensitivity IL-10 
ELISA kit (Diaclone, France). Firstly, 100 µl of standard diluent was added to the 
Well 
(Dose) 
100 x diluted 
vaccine (µl) 
RPMI-1640 
medium (ml) 
Dilution factor 
1 0 0.75 No vaccine 
2 5 0.745 20, 000 
3 10 0.74 10, 000 
4 25 0.725 4, 000 
5 50 0.7 2, 000 
6 100 0.65 1, 000 
7 500 0.25 200 
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standard wells B1, B2, C1, C2, D1, D2, E1, E2, F1 and F2. Then, 200 µl standard (25 
pg/ml) was pipetted into wells A1 and A2. Serial dilutions were made by transferring 
100 µl from A1 and A2 to B1 and B2. This procedure was repeated for the subsequent 
wells to give a range of standard from 50.00 to 1.56 pg/ml. One hundred µl from the 
content of the last wells used (F1 and F2) was discarded.  As a blank, wells G1 and 
G2 contained 100 µl standard diluent only. 
 After that, 100 µl sample (supernatant from blood culture) was added to the 
sample wells followed by 50 µl of diluted biotinylated anti-IL-10. Then the plate was 
covered with the plate cover and incubated for 2 h at room temperature (18 - 22°C) 
with slow shaking on the plate shaker (Denley, UK). After 2 h incubation, the plate 
was placed in the automated microplate washer (Anthos Labtec, France) which was 
set to the appropriate washing procedure, where liquid from each well was aspirated 
followed by dispensing of 0.3 ml of washing solution into each well, and then was 
aspirated again. This step was repeated two times. 
 Then, 100 µl of streptavidin-HRP solution 1 (prepared just before use) was 
added to all wells. Again, the plate was covered and incubated for 20 min at room 
temperature with slow shaking on the shaker followed by the washing procedure as 
described previously. Subsequently, 100 µl of amplifier dilution (prepared just before 
use) was added into the all wells and incubated for 15 min with slow shaking. After 
incubation, the plate was washed. Next, 100 µl of streptavidin-HRP solution 2 
(prepared just before use) was distributed into the all wells. Again, the plate was 
incubated for 20 min on the shaker and washed. After washing, 100 µl of ready-to-use 
TMB substrate solution was added to the all wells. Afterwards, it was incubated in the 
dark for 5 min at room temperature. Finally, 100 µl of stop reagent (H2SO4) was 
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added to the all wells to stop the enzyme-substrate reaction. Immediately after that, 
the plate was read using an OpsysMR ELISA plate reader (Dynex, UK) at 450 nm 
wavelength. 
3.2.4 Data analysis. 
 Data were analysed using the Statistical Package for Social Sciences (SPSS) 
version 17 (SPSS Inc., USA). Descriptive analysis was used to measure mean and 
standard deviation (SD). Statistical significance of differences between means was 
analysed using paired samples t-test and analysis for correlation between the IL-10 
concentrations determined by the two analytical methods was conducted using 
Spearman’s correlation coefficient. All the data were expressed as mean ± SD.  
3.3 Results. 
 Mean and SD for haematological parameters are presented in Table 3.4. All 
values fell within the normal range except for haematocrit value which was slightly 
lower. Overall, participants were considered healthy with no haematological 
problems. Figures 3.1 – 3.9 show the response of the measured cytokines to the 
different doses of stimulant (vaccine). Theoretically, the dose response curve should 
be S-shaped. This is because low dosage gives no or an insignificant response and at 
the upper end of the dose response curve higher dosage gives no further response (or 
even a reduced response), which may be attributed to the toxicity of the stimulant to 
blood leukocytes. As shown in the figures that follow, different cytokines give 
different range of dose active response. From these graphs, effective dose range can 
be determined and used in the future studies. The most suitable dose (dilution of 
vaccine) was defined as the dose that induced at least a 3-fold increase above the 
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unstimulated (dose 1) cytokine production but less than 50% of the maximal response. 
For the cytokines IL-2, IL-6, IL-8, IL-10, IFN-γ, TNF-α and IL-1β, this was achieved 
with dose between 4 and 6, corresponding to a 1,000 – 4,000 fold dilution of the 
original Pediacel vaccine. However, IL-4 and IL-1α production were only elevated 
substantially above basal level by dose 7 (200-fold dilution of vaccine). 
Table 3.4: Mean and SD values of haematological parameters. 
Parameters  Observed values Normal range 
Red blood cells (1012/L) Male  4.6 ± 0.9 4.3 – 6.2  
Female 3.9 ± 0.9 3.8 – 5.5 
Haemoglobin (g/dL) Male 14.7 ± 1.2 13.2 – 16.2 
Female 13.7 ± 1.0 12.0 – 15.2 
Haematocrit (%) Male 38.4 ± 7.6 40 – 52  
Female 33.0 ± 6.5 37 – 46  
White blood cells (109/L) 5.7 ± 1.4 4 – 11  
Neutrophils (109/L) 2.8 ± 0.8 2.0 – 8.0  
Lymphocytes (109/L) 2.1 ± 0.5 0.7 – 4.4 
Monocytes (109/L) 0.5 ± 0.2 0.1 – 0.8 
Eosinophils (109/L) 0.2 ± 0.1 0.1 – 0.4 
Basophils (109/L) 0.1 ± 0.0 0.0 – 0.1 
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Figure 3.1: IL-2 responses to different stimulant dose.  
* Significantly different from dose 1 (P < 0.05). 
 
 
Figure 3.2: IL-4 responses to different stimulant dose.  
* Significantly different from dose 1 (P < 0.05). 
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Figure 3.3: IL-6 responses to different stimulant dose.  
*, **, *** Significantly different from dose 1 (P < 0.05, P < 0.001, and P < 0.000 
respectively). 
 
 
Figure 3.4: IL-8 responses to different stimulant dose.  
*, **, *** Significantly different from dose 1 (P < 0.05, P < 0.001, and P < 0.000 
respectively). 
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Figure 3.5: IL-10 responses to different stimulant dose.  
* Significantly different from dose 1 (P < 0.05). 
 
 
Figure 3.6: Interferon-gamma (IFN-γ) responses to different stimulant dose.  
*, ** Significantly different from dose 1 (P < 0.05 and P < 0.001). 
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Figure 3.7: Tumor Necrosis Factor-alpha (TNF-α) responses to different stimulant 
dose.  
*, ** Significantly different from dose 1 (P < 0.05 and P < 0.001). 
 
 
Figure 3.8: IL-1α  responses to different stimulant dose.  
** Significantly different from dose 1 (P < 0.001). 
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Figure 3.9: IL-β1 responses to different stimulant dose.  
**, *** Significantly different from dose 1 (P < 0.001 and P < 0.000). 
 
 
Figure 3.10: Correlation graph of the data obtained from Evidence Investigator and 
ELISA for IL-10.  
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r = 0.828, r2 = 0.686, n = 38, P < 0.001 
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Figure 3.10 shows a correlation graph of the data obtained from Evidence 
Investigator and ELISA for IL-10. Since the shape of the cluster starts off narrow and 
then get wider, it violated the assumption of homoscedasticity. Thus, Spearman’s 
correlation coefficient was used instead of Pearson correlation coefficients to 
determine the relationship between data obtained from Evidence Investigator and 
ELISA for IL-10. There was a moderately strong, positive correlation between the 
two variables; r = 0.828, n = 38, P < 0.001.  
3.4 Discussion and conclusion. 
 From the results obtained, it appears that the effective dose range for most of 
the measured cytokines is between dose 4 and 6 (corresponding to a 1,000-4,000 fold 
range of dilution of the original Pediacel vaccine), hence providing a reference for the 
future studies. The correlation between data obtained from Evidence Investigator and 
ELISA was moderately strong. Thus, using Evidence Investigator for analysis is an 
acceptable alternative to ELISA. Multiple cytokine production after multiple antigen 
challenge in a single sample is a new technology which significantly helps scientists 
with their investigation. Previous methods using ELISA to give single cytokine 
production measurements at a time consumes a lot more time and cost. Moreover, 
multiple antigen challenge provides valuable information of the cytokines production 
since not all cytokines respond to the same antigen. The capacity of leukocytes to 
produce cytokines upon adequate challenge has potentially far reaching consequences 
for the entire functional capacity of the immune system. It is highly likely to reflect 
the capacity of an individual to defend itself against intruding microorganisms and 
hence is a suitable measure to examine the impact of nutritional interventions 
designed to boost immune function. 
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CHAPTER 4 
STUDY 2: The in vitro effects of various immunomodulatory nutritional 
compounds on antigen-stimulated whole blood culture cytokine production.  
Abstract 
This study investigated the effects of in vitro exposure to low and high dose of several 
immunomodulators which include alcohol (ethanol), caffeine, curcumin, echinacea, 
kaloba, and quercetin on antigen-stimulated whole blood culture cytokine production. 
Whole blood samples were taken from 5 healthy male (age: 32 ± 12 years; weight: 
75.7 ± 6.1 kg; BMI: 24.3 ± 1.5 kg/m2) following an overnight fast with no vigorous 
activity during the preceding 24 h. The whole blood was then stimulated with vaccine 
dose 5 (based on previous study – Chapter 3) and low or high dose of 
immunomodulator in the culture plate. After 20 h incubation (5% CO2, 37°C), it was 
analysed using Evidence Investigator to determine the production of cytokines  
including IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α, IL-1α, and IL-1β. Caffeine and 
quercetin showed a tendency towards decrease cytokine production as the doses were 
increased. On the other hand, an upward trend was evident with kaloba, where a high 
dose of kaloba seemed to increase the cytokine production. Nevertheless, the effects 
of alcohol, curcumin, and echinacea on cytokine production were inconclusive. 
Interleukin-6, IL-8, TNF-α, and IL-1β production were relatively similar for all the 
cultures and it was speculated that the vaccine dose used was beyond their effective 
dose range, thus they were exhibiting a maximal response. 
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4.1 Introduction. 
Immunomodulation is a therapeutic approach in which we try to intervene in 
auto regulating processes of the host defence system. Immunomodulators can be 
defined as substances (drugs and nutrients) that alter the activities of the immune 
system via dynamic regulation of messenger molecules such as cytokines, adhesion 
molecules, nitric oxide, hormones, neurotransmitters, and other peptides. 
Immunomodulators can help to increase immunity of people with a low immune 
system, and also can help to normalize an overactive immune system. Generally, 
these compounds can be divided into immunosuppressants and immunostimulants 
(Haavisto, 2009). Numerous in vitro and in vivo studies have found that 
immunomodulators modulate the secretion of multiple cytokines (Spelman et al., 
2006).  
Altering cytokine expression with immunomodulators may offer some 
therapeutic potential. As reviewed by Del-Rio-Navarro and colleagues (2006), on 
average, immunostimulants reduce the incidence of acute respiratory tract infections 
in children by 40%. Several published studies have suggested that alcohol (Nelson 
and Kolls, 2002; Szabo, 199), caffeine (Horrigan et al., 2004 and 2006), curcumin 
(Bharti et al., 2010; Shirley et al., 2008) and quercetin (Chen, 2010; Chuang et al., 
2010) as immunosuppressants while echinacea (Fusco et al., 2010; Bodinet el., 2002) 
and kaloba (Kolodziej and Kiderlen, 2007; Trun et al., 2006) as immunostimulants. 
However, current evidence concerning their efficacy is limited. Hence, this present 
study intended to investigate the effects of alcohol, caffeine, curcumin, quercetin, 
echinacea and kaloba on antigen-stimulated whole blood culture cytokine production 
in vitro.  
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4.2 Methods.  
4.2.1 Participants. 
Five healthy men were recruited as participants in this study. Mean age, 
weight, and BMI of the participants were 32 ± 12 years, 75.7 ± 6.1 kg, and 24.3 ± 1.5 
kg/m2 respectively. 
4.2.2 Procedures. 
Participants were requested to come to the laboratory between 09:00 and 
10:00 following an overnight fast from 21:00. However, they were permitted to drink 
plain water. They were also asked to refrain from any vigorous physical activity in the 
preceding 24 h. Blood samples were collected into K3EDTA and lithium heparin 
collection tubes as described in the general methods (Chapter 2, section 2.4.3). 
4.2.3 Blood analysis. 
4.2.3.1 Haematological analysis. 
Haematological analyses were carried out as described in general methods 
(Chapter 2, section 2.4.4). 
4.2.3.2 One hundred times diluted vaccine dose preparation. 
 This was prepared as described in general methods (Chapter 2, section 
2.4.5.1). 
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4.2.3.3 Immunomodulatory nutritional compounds preparation. 
Alcohol (Ethanol) 
Alcohol low blood dose was targeted at 100 mg/dL. This concentration was 20% 
higher than the current UK legal limit blood alcohol concentration for drivers.  
100 mg/dL = 1 g/L 
Alcohol solution needed = 100 x 1 g/L = 100 g/L = 1 g/10 ml 
As alcohol density is 0.79 g/ml, 1 g alcohol = 1.27 ml 
Thus, 1.27 ml alcohol was added to 8.73 ml RPMI solution. 
In the whole blood culture, low dose (1 g/L) of alcohol was achieved by adding 10 µl 
of this solution into the culture wells while for high dose (10 g/L), 100 µl was added. 
Caffeine 
Caffeine low blood dose was targeted at 9.71 mg/L (Fletcher and Bishop, 2011). 
Caffeine solution needed = 100 x 9.71 mg/L = 971 mg/L = 97.1 mg/100 ml  
Thus, 97.1 mg caffeine was added to 100 ml RPMI solution. 
In the whole blood culture, low dose (9.71 mg/L) of caffeine was achieved by adding 
10 µl of this solution into the culture wells while for high dose (97.1 mg/L), 100 µl 
was added. 
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Curcumin 
Curcumin low blood dose was targeted at 663 µg/L (Cheng et al., 2001). 
Curcumin solution needed = 100 x 663 µg/L = 66.3 mg/L 
As curcumin has low solubility in water, the solution was made up in alcohol. 
66.3 mg/ 100 ml alcohol = 663 mg/L 
Then, this solution was 10 times diluted with RPMI to make curcumin solution at 
66.3 mg/L. 
In the whole blood culture, low dose (663 µg/L) of curcumin was achieved by adding 
10 µl of this solution into the culture wells while for high dose (6630 µg/L), 100 µl 
was added. 
Quercetin  
Quercetin low blood dose was targeted at 0.02 mg/ml (Nieman et al., 2007a). 
Quercetin solution needed = 100 x 0.02 mg/ml = 2 mg/ml 
As quercetin solution has low solubility in water, the solution was made up in alcohol. 
Then, this solution was 10 times diluted with RPMI to make quercetin solution at 200 
mg/L. 
In the whole blood culture, low dose (0.02 mg/ml) of quercetin was achieved by 
adding 10 µl of this solution into the culture wells while for high dose (0.2 mg/ml), 
100 µl was added. 
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Echinacea 
Echinacea low blood dose was targeted at 10 mg/L. This dose was aimed based on the 
prescription of the supplement, as suggested by the manufacturer. 
Echinacea solution needed = 100 x 10 mg/L = 1000 mg/L = 100 mg/100 ml RPMI 
solution. 
In the whole blood culture, low dose (10 mg/L) of Echinacea was achieved by adding 
10 µl of this solution into the culture wells while for high dose (100 mg/L), 100 µl 
was added. 
Kaloba 
Kaloba low blood dose was targeted at 3 µg/ml (Conrad et al., 2007). 
Kaloba solution needed = 100 x 3 µg/ml = 300 µg/ml 
Thus, 20 mg Kaloba was added to 66.7 ml RPMI solution. 
In the whole blood culture, low dose (3 µg/ml) of Kaloba was achieved by adding 10 
µl of this solution into the culture wells while for high dose (30 µg/ml), 100 µl was 
added. 
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4.2.3.4 Whole blood culture incubation and supernatant storage. 
 As shown in the Table 4.1, required volumes of RPMI-1640 medium were 
added into the culture wells, followed by 50 µl of 100 x diluted vaccine (dose 5 – 
2,000 time dilution of the original Pediacel vaccine). Next, the appropriate amount of 
immunomodulator solution was added, followed by 0.25 ml of blood. After gently 
mixed, they were incubated for 20 h as described in the general methods (Chapter 2, 
section 2.4.5.2).  
 Table 4.1: Volume of RPMI, 100 x diluted vaccine, and immunostimulant solution 
added to each well for each blood sample. To these volumes, 0.25 ml heparinised 
blood was added. 
     L = Low dose 
     H = High dose 
Well RPMI-1640 
medium (µl) 
Immunomodulators solution 
(µl) 
Vaccine       
(50 µl) 
1 750 NO NO 
2 725 NO YES 
3 715 Alcohol (L) – 10 µl YES 
4 625 Alcohol (H) – 100 µl YES 
5 715 Caffeine (L) – 10 µl YES 
6 625 Caffeine (H) – 100 µl YES 
7 715 Curcumin (L) – 10 µl YES 
8 625 Curcumin (H) – 100 µl YES 
9 715 Echinacea (L) – 10 µl YES 
10 625 Echinacea (H) – 100 µl YES 
11 715 Kaloba (L) – 10 µl YES 
12 625 Kaloba (H) – 100 µl YES 
13 715 Quercetin (L) – 10 µl YES 
14 625 Quercetin (H) – 100 µl YES 
15  725 NO YES 
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4.2.3.5 Evidence Investigator cytokine array. 
This was carried out as described in the general methods (Chapter 2, section 
2.4.5.3). 
4.2.4 Data analysis. 
Data were analysed using the Statistical Package for Social Sciences (SPSS) 
version 17 (SPSS Inc., USA). Descriptive analysis was used to measure mean and 
standard deviation (SD). Statistical significance of differences between means was 
analysed using paired samples t-test. All the data were expressed as mean ± SD. 
4.3 Results. 
Table 4.2 presents the values of haematological parameters measured. The 
entire observed values fell within the normal range. This indicates that the participants 
recruited for the study were healthy and have no obvious haematological problem. 
Table 4.3 shows the concentrations of the cytokines produced in the whole blood 
culture after 20 h incubation with the vaccine dose 5 and immunomodulators at high 
or low dose. Control refers to the whole blood cultured with only vaccine without any 
added immunomodulators.  
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Table 4.2: Mean and SD values of haematological parameters. 
Parameters  Observed values Normal range 
Red blood cells (1012/L)   4.9 ± 0.4 4.3 – 6.2  
Haemoglobin (g/dL)  14.7 ± 1.4 13.2 – 16.2 
Haematocrit (%)  47.3 ± 4.1 40.0 – 52.0  
White blood cells (109/L) 5.1 ± 0.6 4.0 – 11.0  
Neutrophils (109/L) 2.3 ± 0.5 2.0 – 8.0  
Lymphocytes (109/L) 1.9 ± 0.2 0.7 – 4.4 
Monocytes (109/L) 0.5 ± 0.2 0.1 – 0.8 
Eosinophils (109/L) 0.2 ± 0.9 0.1 – 0.4 
Basophils (109/L) 0.0 ± 0.0 0.0 – 0.1 
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Table 4.3: Antigen-stimulated (vaccine dose 5) whole blood culture cytokine production (pg/ml) in response to alcohol, caffeine, curcumin, 
quercetin, echinacea and kaloba at low and high doses.  
 
 Dose  IL-2 IL-4 IL-6 IL-8 IL-10 
CONTROL  
 
  2.3±1.3 5.7±2.3 830±35 2460±0 27.5±11.5 
ALCOHOL  L (1 g/L) 2.2±1.1 4.1±1.9 850±0 2460±0 47.5±31.0 
  H (10 g/L) 3.9±3.6 2.7±1.7 850±0 2460±0 70.6±74.7 
CAFFEINE  L (9.71 mg/L) 2.5±1.3 5.6±3.5 850±0 2460±0 48.2±35.5 
  H (97.1 mg/L) 1.5±0.6 3.9±1.3 850±0 2460±0 47.4±29.3 
CURCUMIN  L (663 µg/L) 2.4±1.2 5.0±2.2 850±0 2460±0 27.4±9.9 
  H (6630 µg/L) 6.2±5.5 3.0±0.8 850±0 2460±0 19.5±5.2 
QUERCETIN L (20 µg/ml) 3.2±2.2 3.1±0.2 850±0 2460±0 25.9±22.2 
  H (200 µg/ml)  2.5±1.9 2.6±0.8 850±0 2460±0 44.7±54.2 
ECHINACEA  L (10 mg/L) 2.9±1.1 4.6±2.0 850±0 2460±0 35.2±23.0 
  H (100 mg/L) 3.0±1.3 4.8±2.0 850±0 2460±0 33.1±21.0 
KALOBA  L (3 µg/ml) 3.6±3.1 3.7±2.3 850±0 2460±0 25.5±11.7 
  H (30 µg/ml) 2.4±1.8 4.7±2.9 850±0 2460±0 51.9±39.9 
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Table 4.3 (continued). 
 
*’ ** significantly different from the control (antigen stimulated whole blood culture without immunomodulators) value (P < 0.05 and P < 0.001, 
respectively). 
 Dose  IFN-γ TNF-α IL-1α IL-1β 
CONTROL    792±600 885±0 175±105 650±0 
ALCOHOL  L (1 g/L) 636±525 885±0 329±188 650±0 
  H (10 g/L) 346±257 885±0 392±177** 650±0 
CAFFEINE  L (9.71 mg/L) 579±553 
 
885±0 293±172* 650±0 
  H (97.1 mg/L) 84±96 885±0 234±184 650±0 
CURCUMIN  L (663 µg/L) 800±562 885±0 236±115 650±0 
  H (6630 µg/L) 329±217 885±0 332±215 650±0 
QUERCETIN L (20 µg/ml) 196±107 844±83 193±208 650±0 
  H (200 µg/ml)  52±48 885±0 177±219 650±0 
ECHINACEA  L (10 mg/L) 741±531 885±0 340±173* 650±0 
  H (100 mg/L) 741±527 885±0 260±171** 650±0 
KALOBA  L (3 µg/ml) 768±558 885±0 237±167 650±0 
  H (30 µg/ml) 860±532 885±0 299±190** 650±0 
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4.4 Discussion. 
Conspicuously, a somewhat similar concentration of cytokine was produced 
throughout the culture plate for IL-6, IL-8, TNF-α, and IL-1β, suggesting that they were 
having their maximal response; and the response was above the upper range of the assay 
used. The best explanation for this may be because the dose of the vaccine used in this study 
is beyond their effective dose range. It is known that cytokines response to certain vaccine 
dose is not similar. In this case, somehow vaccine dose 5 is beyond their effective dose range 
but not for other cytokines (IL-2, IL-4, IL-10, IFN-γ and IL-1α). Such dose of vaccine was 
chosen based on the previous pilot study (Chapter 3). Hence, in this study, we are unable to 
see the effects of the immunomodulators on IL-6, IL-8, TNF-α, and IL-1β production in vitro. 
In general, we found that the productions of most of the measured cytokines were not 
significantly affected by the immunomodulators that we examined. However, caffeine and 
quercetin showed a tendency towards decreased cytokine production as the doses were 
increased. On the other hand, an upward trend was evident with Kaloba, where a high dose of 
Kaloba seemed to increase the cytokine production. Nevertheless, in this study, the direction 
of the effects of alcohol, curcumin, and echinacea on cytokine production were inconclusive.  
It has been pointed out that chronic alcohol consumption alters the cellular (Watson, 
1988) and humoral immune function (Cook, 1998). This present study, however, failed to 
confirm previous findings, where we found no significant effects of alcohol (ethanol) on 
whole blood culture except for IL-1α (with high dose) (P < 0.001) (Table 4.3). There was 
also no apparent tendency for any effects of alcohol on the production of other cytokines. 
Hence, it is speculated that the alcohol concentration used in this study was not enough to 
induce immune depression in the whole blood culture. Alcohol impaired immune function in 
several ways which include impair the chemotaxis; the ability of neutrophils to migrate to 
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sites of injury and infection (Bautista 2001) and alter the production of macrophages and 
cytokines (Szabo 1999). Alcohol also cause rise of circulating pro-inflammatory cytokine, 
shift the balance of Th1/Th2, increase oxidative stress, and inhibit antigen presenting capacity 
of monocytes (Szabo, 1997). 
There were no significant differences (compared with control) in cytokine production 
in response to caffeine and quercetin with low or high dose (Table 4.3). However, the results 
showed a tendency towards reduced cytokine production with high doses of both caffeine and 
quercetin. Previous studies have found that caffeine and quercetin act as immunosuppressants 
(Horrigan et al., 2004 and 2005; Chen et al., 2010; Chuang et al., 2010). Thus, this finding is 
not in contradiction to those previous findings.  
Mechanism of action of caffeine was debated. However, it is well established that 
caffeine inhibits cyclic adenosine monophosphate (cAMP)-phosphodiesterase. But, this only 
occurs with high concentration of caffeine, higher than average human consumption 
(Fredholm et al., 1999). Yet, growing evidence suggests that mechanism of action of caffeine 
is mediated by antagonism of adenosine receptors (Fredholm et al., 1999; Mandel, 2002). 
Generally, activated adenosine receptors will lead to suppress of pro-inflammatory cytokine 
(especially TNF-α) (Hasko et al., 2000; Link et al., 2000), thus if caffeine act to antagonise 
adenosine receptor (by blocking the action of endogenous adenosine), this will result in 
increased TNF-α production. However, one study found that caffeine decreased TNF-α 
production (Horrigan et al., 2004), thus they hypothesised that the suppressive effect of 
caffeine on TNF-α production observed in their study may be due to the inhibition of cAMP-
phosphodiesterase, a resultant increase in intracellular cAMP concentrations, and activation 
of protein kinase A. 
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Potential mechanism of action for anti-inflammatory action of quercetin (blocked 
TNF-α mediated inflammation or insulin resistance in adipocytes) are proposed by interfering 
TNF-α receptor (TNFR) binding, supressing TNF-α–TNFR signalling, and altering the 
activity of proteins involved in inflammation or glucose and lipid metabolism (Chuang et al., 
2010). Quercetin also was proposed to exert its effects in inflammation prevention and insulin 
resistant is via inhibition of TNF-α mediated reactive oxygen species (ROS - increases 
inflammatory gene expression) production (Goossens et al., 1999).  
There were also no significant effects of curcumin and echinacea on cytokine 
productions (Table 4.3). These findings make it inconclusive as to whether they are 
immunostimulant or immunosuppressant. Again, this may be because the dose used was not 
enough to induce a significant effect on the cytokine production. However, previous studies 
have suggested that curcumin is an immunosuppressant (Shirley et al., 2008; Bharti et al., 
2010) and echinacea is an immunostimulant (Bodinet el., 2002; Fusco et al., 2010). It was 
proposed that, though it is yet unclear, curcumin's anticancer potential is due to its ability to 
supress the proliferation of cancer cells (Matchanickal and Rafi, 2006). Curcumin was found 
to down-regulate the activity of two major transcriptor factors (nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1)), scavenge 
reactive oxygen species (ROS), suppress mitogen-activated protein kinases generated by 
inflammatory stimuli, suppress the expression of pro-inflammatory enzymes 
(cyclooxygenases and lipoxygenases), induce apoptosis in the cancer cells, and induce Phase 
II detoxification enzymes (Matchanickal and Rafi, 2006).  
The exact mechanism(s) of how echinacea exert its effects is unclear. However it has 
been shown that echinacea extracts modulate macrophage cytokine and reactive oxygen 
species (ROS) production (Rininger et al., 2000; Bodinet et al., 2002; Goel et al., 2002; 
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Morazzoni et al., 2005; Zhai et al., 2007).  Furthermore, echinacea’s antimicrobial activities 
is exert either through increasing macrophage intracellular defense (Steinmuler et al., 1993), 
or increasing macrophage antimicrobial behaviours in two models of bacterial infection 
(Roesler et al., 1991; Steinmuller et al., 1993). Studies also found that echinacea 
supplemented mice showed an enhanced phagocytosis in macrophages (Goel et al., 2002; 
Pedalino et al., 2004). 
We found no significant differences in cytokine production in response to Kaloba in 
this study. Nevertheless, there was an evident upward trend of Kaloba on cytokine production 
(Table 4.3) where a high dose of Kaloba seemed to increase the cytokine production. This is 
in agreement with previous findings which suggested Kaloba as an immunostimulant (Trun et 
al., 2006; Kolodziej and Kiderlen, 2007). 
Kaloba was reported to have multifactorial mode of action; antiviral and 
cytoprotective properties, antibacterial properties, secretomotory properties and inhibition of 
‘sickness behaviour’. Several in vitro studies found that Kaloba triggers stimulation of IFN 
synthesis (Trun et al., 2006; Kayser et al., 2007) and improve phagocyte function (Conrad et 
al., 2007). It also increased the ciliary beat frequency, thus increasing the transportation of 
mucous and pathogen from the respiratory tracts. This in turn reduced pathogen count, 
removed the nutrient medium for their subsequent proliferation and substantially improved 
respiration (Neugebauer et al., 2005).  
4.5 Conclusion. 
There were no significant differences in the production of IL-2, IL-4, IL-10, IFN-γ, 
and IL-1α in antigen-stimulated whole blood culture in the presence of the selected 
immunomodulators. Nevertheless, we found that caffeine and quercetin have potential as 
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immunosuppressants and Kaloba as immunostimulant. The production of IL-6, IL-8, TNF-α, 
and IL-1β were stable throughout the culture plate, indicating that the vaccine dose (dose 5) 
used in this study is beyond their effective range dose, where they were having their maximal 
response. Thus, further study is warranted with a lower vaccine dose to examine any 
beneficial effects of the immunomodulators on the production of these cytokines. 
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CHAPTER 5  
Study 3: The effects of Kaloba supplementation on the immune response to prolonged 
exercise. 
Abstract 
The purpose of this study was to examine the effects of Kaloba supplementation on immune 
response to prolonged exercise in 9 healthy male recreational athletes (age: 21 ± 5 years; 
weight: 73.7 ± 5.6 kg; BMI: 22.4 ± 1.5 kg/m2). In this study, participants cycled for 90 min at 
60% VO2max on two occasions (two trials separated at least by 7 days). Participants came to 
the laboratory in the morning after an overnight fast (plain water was permitted) during each 
trial. The second trial was performed after 7 days Kaloba (Schwabe GmbH, Germany) 
supplementation. Kaloba was taken as 1 tablet 3 times daily (morning, midday, and evening). 
Blood and unstimulated saliva samples were collected pre-, post-, and 1 h post-exercise. 
Participants also completed the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-
21) for 7 days after each trial. The whole blood sample was exposed to vaccine dose 5 (based 
on previous study – Chapter 3) and incubated for 20 h (5% CO2, 37°C) before being analysed 
for cytokines (IL-2, IL-6, IL-8, IL-10, IFN-γ, TNF-α, IL-1α, and IL-1β) production with the 
Evidence Investigator. Total leukocytes and differential counts (neutrophils, lymphocytes, 
monocytes, eosinophils, and basophils) were also measured. Saliva samples were analysed 
for the S-IgA by ELISA. Data analysis was carried out using SPSS (two-way ANOVA with 
repeated measure and paired t-test). However, for data sets that were not normal distributed, 
non-parametric tests were used (Friedman test and Wilcoxon test). The main findings of this 
study were that prolonged moderate intensity exercise significantly decreased S-IgA 
concentration and secretion rate post-exercise but did not affect the saliva flow rate. 
However, the values returned to baseline by 1 h post-exercise. Total leukocyte count was 
. 
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significantly increased post-exercise, and was further increased 1 h post-exercise. This was 
mainly due to a rise in the neutrophil count. Nevertheless, there were no significant 
differences between control and Kaloba trials in cytokine production, leukocyte counts, S-
IgA response, and the WURSS-21 questionnaire (numbers of sickness days, number of 
sickness symptoms and severity of sickness symptoms).  
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 5.1 Introduction. 
In Chapter 4, it was found that Kaloba showed a tendency to act as an 
immunostimulant. Thus, in this study, the intention was to further investigate the effects of 
Kaloba supplementation on the immune response to prolonged exercise in athletes. To date, 
the effectiveness of Kaloba supplementation in enhancing athletes’ immune function is very 
scarce in the literature. It is well known that athletes, who engage in heavy training and 
competition, are vulnerable to infections due to impaired immune function. This was 
explained by the ‘open window’ and ‘J curve’ theories (Nieman, 2000). Exercise-induced 
immune dysfunction (especially prolonged, high intensity exercise) is associated with the 
alteration in stress hormone and cytokine secretion. Luna and colleagues (2010) had 
investigated immune response induced by Pelargonium sidoides (Kaloba) extract in serum 
and nasal mucosa of athletes after exhaustive exercise. In that study, participants performed a 
high-intensity running session (~ 85% of VO2max) after 28 days of supplementation (3 x 30 
drops/day of a solution of 80 g of extract/100 ml in solution). They found that saliva 
secretory IgA concentration was increased suggesting that Pelargonium sidoides able to 
modulate the immune response of athletes during intense physical activity. However, the 
post-exercise sample was collected 48 h after exercise completed. The authors did not justify 
the selection of this sampling time point and it would be of interest to know if the IgA 
response to exercise was altered in the immediate post-exercise recovery period.  
Kaloba used in this study was manufactured in Germany by Schwabe GmbH. It was 
in the form of tablet where each film-coated tablet contains 20 mg of extract (as dry extract) 
from the roots of Pelargonium sidoides (EPs 7630). The extraction solvent used was 11% 
ethanol (w/w). In Germany, this product has become popular for the treatment of acute 
bronchitis, common cold, sinusitis, pharyngitis, and tonsillitis (Kolodziej and Schulz, 2003). 
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Pelargonium sidoides is a plant species that is indigenous to South Africa and was 
traditionally believed and used to treat dysentery, diarrhoea, colds, wounds, fatigue, fevers, 
hepatic complaints, generalized malaise, and respiratory tract infections such as tuberculosis, 
bronchitis, and sinusitis. Several clinical trials conducted on adults and children have 
subsequently confirmed some of these benefits (Lizogub et al., 2007; Matthys and Funk, 
2008; Bachert et al., 2009; Kamin et al, 2010a and 2010b; Matthys et al., 2010).  
Kaloba has been reported to have multifactorial mode of action; antiviral and 
cytoprotective properties, antibacterial properties, secretomotory properties and inhibition of 
‘sickness behaviour’. Several in vitro studies found that Kaloba triggers stimulation of IFN 
synthesis (Trun et al., 2006; Kayser et al., 2007) and improves phagocyte function (Conrad et 
al., 2007). It was also shown to increase the ciliary beat frequency, thus increasing the 
transportation of mucous and pathogen from the respiratory tracts. This in turn reduced 
pathogen count, removed the nutrient medium for their subsequent proliferation and 
substantially improved respiration (Neugebauer et al., 2005).  
Thus, the aim of the present study was to investigate the effects of Kaloba intake on 
immune responses to exercise in individuals engaged in regular endurance sport training.  
5.2 Methods. 
5.2.1 Participants. 
 Nine healthy active men participated in this study. All participants were recruited 
from Loughborough University students. Their mean age, weight and BMI were 22 ± 5 years, 
73.7 ± 5.6 kg, and 22.4 ± 1.5 kg/m2, respectively. They were required to abstain from 
ingesting products containing Pelargonium sidoides and also any other supplements that are 
known to affect immune function such as probiotics, etc. during the study period. 
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5.2.2 Procedures.  
 Participants visited the laboratory on 4 occasions. The first 2 visits were for the 
preliminary tests which included a maximum oxygen uptake (VO2max) test and 
familiarisation test, while the following 2 visits were the experimental trials. 
5.2.2.1 Preliminary tests. 
 Maximum oxygen uptake (VO2max) and familiarisation tests were carried out as 
described in the general methods (Chapter 2, section 2.2 and 2.3 respectively). 
5.2.2.2 Experimental trials. 
 Approximately one week after the familiarisation trial, participants visited the lab for 
the first experimental trial. Participants came to the laboratory in the morning at 9:00 after an 
overnight fast (but they were permitted to drink plain water) from 22:00. There were also 
asked to record their diet during the 24 h period before the overnight fast. Participants were 
asked to follow the same diet as before the second experimental trial.  
Each experimental trial consist of cycling at 60% VO2max for 90 min. Saliva and 
blood samples were collected (as described in general methods; Chapter 2, section 2.4.1 and 
2.4.3) pre-exercise, immediately post-exercise, and 1 h post-exercise. Before the 1 h post-
exercise sample was collected, participants were asked to rest in a comfortable room without 
doing any physical activity. Heart rate and RPE were collected pre-exercise, and at 20th, 60th, 
80th, and 90th min of exercise while expired gas was collected at 20th and 60th min of exercise. 
 At least 1 day after the first experimental trial, participants started taking 1 Kaloba 
tablet (each film-coated tablet contains 20 mg of root extract), three times daily for 7 days. 
After 7 days supplementation, participants performed the second experimental trial which 
. 
. 
. 
80 
 
was exactly the same with the first experimental trial. After each experimental trial, 
participants completed the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) 
(Barrett et al., 2002) for 7 days. 
A placebo controlled, crossover design study is known to avoid bias in the results; 
however, a pre- and post- supplementation design was used in the present study because of 
time and resource constraints. As the main outcome parameters (blood cells, plasma 
cytokines production, and salivary IgA response) measured were not subjective and could not 
be consciously controlled or influenced by the participants or researchers, the pre- and post- 
supplementation design was deemed acceptable. Thus, either study design should have no 
effect on the outcomes measured in this present study. However, if subjective parameters 
were to be important outcome measures (e.g. participants’ perceptions), a placebo controlled, 
crossover design would be much more appropriate.  
5.2.3 Blood analysis. 
5.2.3.1 Haematological analysis. 
Haematological analyses were carried out as described in the general methods 
(Chapter 2, section 2.44). 
5.2.3.2 One hundred times diluted vaccine dose preparation. 
 This was prepared as described in the general methods (Chapter 2, section 2.4.5.1). 
5.2.3.3 Whole blood culture incubation and supernatant storage. 
Heparinised blood was cultured and incubated for 20 h as described in the general 
methods (Chapter 2, section 2.4.5.2). 
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5.2.3.4 Evidence Investigator cytokine array. 
Cytokine analysis was carried out as described in the general methods (Chapter 2, 
section 2.4.5.3). 
5.2.4 Saliva Analysis. 
Saliva samples were analysed for S-IgA level by using a Salimetrics S-IgA ELISA kit 
as described in the general methods (Chapter 2, section 2.4.2.1).  
5.2.5 Data analysis. 
Data were analysed using the Statistical Package for Social Sciences (SPSS) version 
17 (SPSS Inc., USA). Two-way ANOVA with repeated measures was used for data sets that 
were normally distributed. For data sets that were not normally distributed, non-parametric 
tests were used (Friedman test and Wilcoxon test). All the data were expressed as mean ± SD. 
5.3 Results. 
5.3.1 Physiological parameters. 
Table 5.1 shows the physiological parameters measured in this study. Rating of 
perceived exertion and HR were significantly increased over the time (P < 0.05), nevertheless, 
they were not significantly different between the two trials. In each trial, the VO2 value was 
not significantly different between the two time points (P > 0.05). There was also no 
significant difference in oxygen uptake between trials at both time points.  
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5.3.2 Haematological parameters. 
 Total leukocyte counts were significantly increased post-exercise and were further 
increased 1 h post-exercise (Table 5.2). This was mainly due to a rise in neutrophils. Besides, 
the monocyte and basophil counts were also significantly increased over the time. 
Table 5.1: Physiological parameters (n = 9). 
Parameters  Value (Mean ± SD)      P value   
between trials 
VO2max (ml.kg-1.min-1) 56.1 ± 7.8 
60% VO2max (ml.kg-1.min-1) 34.4 ± 4.8 
Work Rate at 60% VO2max (W) 184.0 ± 25.0 
Rating of perceived exertion at the
end of the trial (Borg’s unit) 
Non-Kaloba Trial 13 P = 0.053 
Kaloba Trial 12 
Heart rate at the end of the trial 
(Beats.min-1) 
Non-Kaloba Trial 147 ± 13 P = 0.411 
Kaloba Trial 146 ± 13 
VO2 at 20-min (ml. kg-1.min-1) Non-Kaloba Trial 33.2 ± 3.7 P = 0.172 
Kaloba Trial 34.4 ± 3.0 
VO2 at 60-min (ml. kg-1.min-1) Non-Kaloba Trial 34.7 ± 4.0 P = 0.551 
Kaloba Trial 35.2 ± 3.3 
 
. 
. 
. 
. 
. 
83 
 
Table 5.2: Mean and SD values of haematological parameters in both non-Kaloba and 
Kaloba trials. 
*,**,*** Significantly different from respective pre-exercise value (P < 0.05, P < 0.001, and 
P < 0.000 respectively). 
+, ++ Significantly different from respective post-exercise value (P < 0.05 and P < 0.001 
respectively). 
Parameters  Trial Pre-exercise Post-exercise 1h post-exercise 
Red blood cells Non-Kaloba 4.7±0.3 4.7±0.2 4.7±0.3 
(1012/L) Kaloba 4.6±0.3 4.8±0.2** 4.7±0.3+ 
Haemoglobin Non-Kaloba 14.8±1 15.1±1.1 14.9±1.3
(g/dL) Kaloba 14.2±0.6 14.8±0.4*** 14.5±0.6*,++ 
Haematocrit Non-Kaloba 45.9±3 46.8±1.6 46.1±2.3 
(%) Kaloba 45.7±2.2 47.6±1.6** 46.6±2.5 
Total leukocytes Non-Kaloba 5.5±1.5 10±2.5** 12.7±3***,+
(109/L) Kaloba 5.1±1.7 9.1±2.2** 11.2±2.1***,+ 
Neutrophils Non-Kaloba 2.5±1 6.5±2.3** 9.5±2.4***,++ 
(109/L) Kaloba 2.5±1.1 5.9±1.9** 8.6±1.9***,++ 
Lymphocytes Non-Kaloba 2.2±0.7 2.4±0.6 2±0.7 
(109/L) Kaloba 2±0.5 2.3±0.9 1.7±0.5 
Monocytes Non-Kaloba 0.5±0.2 0.8±0.3* 0.9±0.3** 
(109/L) Kaloba 0.5±0.2 0.6±0.1* 0.7±0.1** 
Eosinophils Non-Kaloba 0.2±0.2 0.2±0.1 0.2±0.2 
(109/L) Kaloba 0.2±0.2 0.2±0.1 0.2±0.1 
Basophils Non-Kaloba 0.03±0.05 0.08±0.06* 0.1±0.07* 
(109/L) Kaloba 0.01±0.02 0.06±0.06* 0.08±0.04** 
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5.3.3 Saliva secretory immunoglobulin A (S-IgA). 
There were significant main effects of time for S-IgA concentration (P = 0.007) and 
secretion rate (P = 0.006), but not for saliva flow rate (P > 0.05) (Figures 5.2, 5.3, and 5.4). 
Following exercise, both S-IgA secretion rate and S-IgA level were decreased but then 
increased 1 h post-exercise. However, there were no significant differences between the two 
trials (non-Kaloba and Kaloba) in S-IgA level, S-IgA secretion rate, and saliva flow rate (P > 
0.05). 
 
 
Figure 5.1: Saliva flow rate (ml/min) in non-Kaloba and Kaloba trials. 
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Figure 5.2: Salivary Ig-A concentration (µg/ml) in non-Kaloba and Kaloba trials. 
** Significantly different from respective pre-exercise value (P < 0.001). 
 + Significantly different from respective post-exercise value (P < 0.05). 
 
 
 
 
Figure 5.3: Salivary Ig-A secretion rate (µg/min) in non-Kaloba and Kaloba trials. 
* Significantly different from respective pre-exercise value (P < 0.05). 
 + Significantly different from respective post-exercise value (P < 0.05). 
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5.3.4 Cytokine production. 
 Distribution of this data was not normal, thus a non-parametric test (Friedman test) 
was used to see the significant main effects of time throughout the trials separately. There 
was no significant main effect of time (P > 0.05) on cytokine production throughout both 
trials. Another non parametric test (Wilcoxon test) was then used to examine possible 
differences in cytokine production between the two trials at each time point. There were no 
significant differences between trials at any time point (P > 0.05). 
5.3.5 Questionnaire. 
As illustrated in Table 5.3, there were no significant differences in days of sickness, 
number of symptoms, and symptom scores (severity of the sickness) between both two trials. 
         Table 5.3: Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) results. 
Parameters  Value (Mean ± SD)      P value   
between trials 
Days of sickness (Duration of 
sickness) 
Non-Kaloba Trial 3.4 ± 3.0 P = 0.290 
Kaloba Trial 2.4 ± 2.9 
Number of symptoms Non-Kaloba Trial 3.6 ± 3.1 P = 0.053 
Kaloba Trial 2.0 ± 2.2 
Symptom score (Severity of 
sickness) 
Non-Kaloba Trial 33.2 ± 3.7 P = 0.172 
Kaloba Trial 34.4 ± 3.0 
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5.4 Discussion. 
The main finding of this study was that prolonged exercise at moderate intensity 
decreased S-IgA concentration and secretion rate post-exercise, but the values returned back 
to baseline by 1 h post-exercise. Prolonged exercise also induced an increase in circulating 
leukocytes which further increased 1 h post-exercise; this was mainly due to a rise in 
neutrophil counts. Cycling for 90 min at moderate intensity (60% VO2max) led to a decrease 
in S-IgA secretion rate and concentration post-exercise but then significantly increased 1 h 
post exercise (Figure 5.2). This is in agreement with previous studies following prolonged 
exercise (Walsh et al., 2002; Laing et al., 2005). The present study also found no significant 
effects of exercise on saliva flow rate. However, Allgrove et al. (2009) found that during 
prolonged cycling at 65% VO2max, saliva flow rate decreased, S-IgA concentration increased, 
and S-IgA secretion rate remained unchanged. In fact, numerous studies have reported 
significant decreases in S-IgA after exercise (Gleeson et al., 1999; Nieman et al., 2002), 
while others have reported significant increases (Blannin et al., 1998; Sari-Sarraf et al., 2007) 
or no change (Mackinnon and Hooper, 1994; Li and Gleeson, 2004). This discrepancy may 
be attributed to the different method of expressing S-IgA, nutritional status of the individual, 
and the exercise protocol employed. 
It is well known that a low level of S-IgA in athletes was associated with higher risk 
of URTI (Gleeson et al., 1999; Fahlman and Engels, 2005). However, little is known about 
how exercise influences salivary responses. Theoretically, S-IgA secretion rate is dependent 
on the production of IgA by the plasma cells in the submucosa and/or the IgA transcytosis 
rate across the epithelial cell which is determined by polymeric Ig receptor (pIgR) availability 
(Bosch et al., 2002). During chronic stress, prolonged sympathetic nervous system (SNS) 
activation may down regulate IgA synthesis and expression of pIgR, thus decreasing the 
. 
. 
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secretion of IgA. Nonetheless, in the present study, Kaloba did not influence salivary 
responses in athletes. 
In the present study, moderate, prolonged exercise resulted in increased numbers of 
circulating leukocytes, neutrophils, monocytes, and basophils counts post-exercise, and they 
had not returned to the pre-exercise value 1 h post-exercise. This leukocytosis was mainly 
due to a rise in the blood neutrophil count. This is consistent with previous findings (Nieman 
et al., 2005; Pacque et al., 2007). Exercise-induced leukocytosis is largely due to 
demargination of the leukocytes that were adhered to the blood vessel walls at rest (called the 
marginated pool of leukocytes) into the circulating pool (Gleeson, 2006b). This 
demargination is believed to be due to the exercise-induced increase in cardiac output which 
produces higher mechanical force, as well as the increase in shear stress within the capillaries. 
Furthermore, previously ‘dormant’ or ‘closed’ capillaries will also open up in the lungs and 
working muscles due to elevated blood flow, therefore releasing their leukocyte store into the 
circulating pool. Increased plasma catecholamines also may play a role in leukocytosis during 
exercise via reducing the adherence of leukocytes to the vascular endothelium. The size of 
leukocytosis is dependent on the severity of work rate; while its characteristics are dependent 
on intensity, duration, and type of exercise. It was found that magnitude of leukocytosis 
produced by prolonged exercise is larger than short term high intensity exercise, and is due to 
release of neutrophils from bone marrow. 
Despite evidence from several in vitro studies about positive beneficial effects of 
Kaloba, there are very few published studies about its supplementation effects on the immune 
response in athletes to date. This study found no effects of Kaloba on athletes’ immune 
response after prolonged exercise. We speculated that the dose of the Kaloba and 
supplementation period was not enough. Luna and colleagues (2010) suggest that 28 days of 
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Pelargonium sidoides supplementation (3 x 30 drops/day) is able to modulate the immune 
response associated with the upper airway mucosa in athletes submitted to intense physical 
activity. They found a relative increase in S-IgA concentration post-exercise, however the 
saliva samples were collected 48 h after the exercise was completed. This may raise some 
issue since post-exercise effect on S-IgA level may have been disappeared after 48 h or the S-
IgA level measured may be attributed to other factors. It would be much more meaningful if 
the post-exercise samples were collected immediately, 1 h or 2 h post-exercise. 
5.5 Conclusion. 
In brief, 7 days Kaloba supplementation had no effect on any of the parameters 
measured: salivary IgA response, blood cell counts, antigen-stimulated cytokine production, 
and respiratory tract infection symptoms. The most possible explanation for this is the 
concentration/dose and length of supplementation of Kaloba in this study was not enough to 
induce any significant effects of the Kaloba. Nevertheless, prolonged exercise at moderate 
intensity decreased S-IgA concentration and secretion rate post-exercise, but the values 
returned back to baseline by 1 h post-exercise. Prolonged exercise also induced a rise in 
circulating leukocyte counts post-exercise and further increased them 1 h post-exercise; this 
was mainly due to a rise in blood neutrophil counts. 
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CHAPTER 6 
Study 4: Effects of a 14-strain probiotic supplement on salivary antimicrobial proteins 
at rest and in response to an acute bout of prolonged exercise.  
Abstract 
This study was designed to determine the effects of a period of supplementation with a 14-
strain probiotic on salivary antimicrobial proteins at rest and in response to an acute bout of 
prolonged exercise in recreationally active, healthy adults In this study, 11 participants (age: 
22 ± 1 years, weight: 69.5 ± 12.2 kg, BMI: 23.0 ± 1.8 kg/m2) cycled for 2 h at 60% VO2max on 
two occasions (two trials separated by 30 days). During each trial, participants came to the 
lab in the morning, 2 h after having their breakfast. They were asked to have a similar 
breakfast before each trial. The second trial was performed after 30 days of supplementation 
with a 14-strain probiotic. The probiotic was in capsule form and taken as 1 capsule 3 times 
daily (morning, midday, and evening). Timed, unstimulated saliva samples were collected 
pre-, post-, 1 h post-, and 2 h post-exercise. Saliva samples were analysed for secretory 
immunoglobulin A (S-IgA), α-amylase, lactoferrin, and lysozyme concentrations. Data 
analysis was carried out using SPSS (two-way ANOVA with repeated measures). However, 
for data sets that were not normally distributed, non-parametric tests were used (Friedman 
test and Wilcoxon test). Results showed that 30 days of supplementation with the 14-strain 
probiotic did not alter salivary antimicrobial proteins at rest and in response to an acute bout 
of prolonged exercise. However, prolonged exercise significantly increased lactoferrin 
concentration and α-amylase activity post-exercise. It was concluded that the 
supplementation period and/or the dose/concentration of the 14-strain probiotic used in this 
study were insufficient to induce any beneficial effects on athletes’ salivary antimicrobial 
. 
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proteins at rest and in response to an acute bout of prolonged exercise, or simply that this 
probiotic supplement was ineffective. 
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6.1 Introduction. 
As defined by World Health Organisation (WHO), probiotics are live microorganisms 
which when administered in adequate amounts confer a health benefit on the host (FAO, 
2006). Lilly and Stillwell were reported to be the first to use the term probiotics in 1965, to 
describe substances secreted by one organism which stimulate the growth of another (Gupta 
and Garg, 2009). The efficacy of single strains of probiotic on immune function in both 
healthy individuals and clinical patients has been widely investigated. For example, two 
studies reported that regular ingestion of single strain probiotic (Lactobacillus casei) may 
modify the salivary secretory immunoglobulin A (S-IgA) level (O’Connell et al., 2010; 
Gleeson et al., 2011a).  
Nevertheless, studies on the effects of mixtures of probiotic strains are far fewer 
compared to those that have examined single strain probiotic supplements. Some have 
reported that probiotic mixtures are more effective in modifying immune function and 
preventing respiratory tract infection (Chapman et al., 2011). However, it is unknown if this 
is a result of synergistic interactions between strains or a consequences of the higher probiotic 
dose used in some studies. Most of multi-strain probiotic studies did not directly compare 
between a mixture and its component strains. This makes us unable to make a definite 
conclusion about the efficacy of the probiotic mixtures or their component strains. Potential 
modes of action of probiotics include (1) modulation of the intestinal immune system, (2) 
displacement of potential pathogens through competitive exclusion and (3) production of 
antimicrobial agents (Rowland et al., 2010), so intuitively, one might expect a combination of 
bacterial strains to be more effective than a single strain.   
The multi-strain probiotic supplement used in this study contained 14 strains of 
beneficial microorganisms at a concentration of 10 billion per gram (with a minimum of 2 
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billion probiotic microorganisms per capsule). The microorganisms it contained were 
Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactococcus lactis ssp. 
lactis, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus 
rhamnosus, Lactobacillus salivarius ssp. salivarius, Bifidobacterium breve, Bifidobacterium 
bifidum, Bifidobacterium infantis, Bifidobacterium longum, Bacillus subtilis, and 
Streptococcus thermophilus. Several multi-strain probiotic studies have reported reduced 
number of days with fever, duration of cold episode, total symptom score, reduced incidence 
of respiratory tract infections and reduction in gastrointestinal infections (Winkler et al., 2005; 
de Vrese et al., 2006; Lin et al., 2009). However, their effect on salivary antimicrobial 
proteins has not been investigated. Thus, the purpose of the present study was to investigate 
the efficacy of a multi-strain probiotic supplement on recreational athletes’ salivary 
antimicrobial proteins at rest and in response to an acute bout of prolonged exercise. 
6.2 Methods. 
6.2.1 Participants. 
Eleven healthy active Loughborough University students were involved in this study. 
Their mean age, weight and BMI were 22 ± 1 years, 69.5 ± 12.2 kg, and 23.0 ± 1.8 kg/m2 
respectively. During the study period, participants abstained from probiotic products and also 
other supplements that believed to affect immune function. 
6.2.2 Procedures.  
 Participants visited the laboratory on 3 occasions. The first visit was for a maximum 
oxygen uptake (VO2max) test, while the following 2 visits were the experimental trials. 
 
. 
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6.2.2.1 Preliminary test. 
 Maximum oxygen uptake (VO2max) test was carried out as described in the general 
methods (Chapter 2, section 2.2). 
6.2.2.2 Experimental trials. 
 Participants came to the laboratory in the morning (approximately at 11:00 am), 2 h 
after having their breakfast. They were asked to consume a similar breakfast before the 
second experimental trial. The first experimental trial consisted of cycling at 60% VO2max 
for 2 h. Participants were given plain water (3 ml/kg body weight) to drink before exercise, 
during exercise (20th, 40th, 60th, 80th and 100th min of exercise), after the second saliva 
collection, and after the third saliva collection. Rating of perceived exertion, HR and expired 
gas were collected during exercise. Saliva samples were collected (as described in the general 
methods; Chapter 2, section 2.4.1) pre-, immediately post-, 1 h post- and 2 h post-exercise. 
Saliva samples were analysed for S-IgA, lactoferrin, α-amylase, and lysozyme concentrations. 
Participants then, start taking the 14-strain probiotic supplementation for 30 days before 
coming to the laboratory for the second trial (which followed exactly the same protocol as the 
first experimental trial).  
 A placebo controlled, crossover design study is known to avoid bias in the results; 
however, a pre- and post- supplementation design was used in the present study because of 
time and resource constraints. As the main outcome parameters (salivary antimicrobial 
protein responses) measured were not subjective and could be consciously controlled or 
influenced by the participants or researchers the pre- and post- supplementation design was 
deemed acceptable. Thus, either study design should have no effect on the outcomes 
measured in this present study. However, if subjective parameters were to be important 
. 
. 
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outcome measures (e.g. participants’ perceptions), a placebo controlled, crossover design 
would be much more appropriate.  
6.2.3 Saliva Analysis. 
6.2.3.1 Saliva secretory Ig A (S-IgA) analysis. 
Salivary-IgA was analysed as described in the general methods (Chapter 2, section 
2.4.2.1).  
6.2.3.2 Alpha (α)-amylase analysis. 
Alpha-amylase was analysed as described in the general methods (Chapter 2, section 
2.4.2.4).  
6.2.3.3 Lysozyme analysis. 
Lysozyme was analysed as described in the general methods (Chapter 2, section 
2.4.2.2).  
6.2.3.4 Lactoferrin analysis. 
Lactoferrin was analysed as described in the general methods (Chapter 2, section 
2.4.2.3).  
6.2.3.5 Nitrite and Nitrate Analysis. 
To perform the assay for nitrite, 100 µl of standards (standard 1 – 8) were added in 
duplicate to the first two rows of wells. Then, 200 µl of water or assay buffer was added to 
the blank wells. After that, 100 µl of sample (x 2 dilution) was added to the chosen wells. 
Then, 50 µl of Griess Reagent R1 was added followed by addition of 50 µl Griess reagent R2 
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to each of the wells except the blank wells. After 10 min, the absorbance was measured with 
spectrophotometer Varioskan Flash (Thermo Scientific, UK) at 540 nm wavelength.  
To perform the assay for total nitrate + nitrite, 100 µl of standards (standard 1 – 8) 
were added in duplicate to the first two rows of wells. Then, 200 µl of water or assay buffer 
was added to the blank wells. After that, 80 µl of sample (x 4 dilution) was added to the 
chosen wells. Then, 10 µl of the Enzyme Cofactor Mixture was added, followed by 10 µl of 
the Nitrate Reductase Mixture to each of the wells except the blank wells. Next, the plate was 
covered and incubated at room temperature for 2 h. After incubation, 50 µl of Griess Reagent 
R1 was added followed by addition of 50 µl Griess reagent R2 to each of the wells except the 
blank wells. After 10 min, the absorbance was measured with spectrophotometer Varioskan 
Flash (Thermo Scientific, UK) at 540 nm wavelength.  
Calculations: 
The absorbance value of the blank wells was averaged, and this value was subtracted from 
the absorbance values of all the other wells. Then, the standard curves were plotted. The 
nitrate standard curve was used for determination of total nitrate + nitrite concentration, 
whereas the nitrite standard curve was used for the determination of nitrite alone. The 
following equations were used to calculate the nitrite and nitrate concentrations: 
[Nitrate + Nitrite] (µl) = ( A540 – y-intercept ) (                  200  µl                  ) x dilution 
     slope       volume of sample used (µl)  
 
[Nitrite] (µl) = ( A540 – y-intercept ) (                  200  µl                  ) x dilution 
                       slope    volume of sample used (µl)  
 
[Nitrate] (µl) = (Nitrate + Nitrite) – (Nitrite) 
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6.2.4 Data analysis. 
Data were analysed using the Statistical Package for Social Sciences (SPSS) version 
17 (SPSS Inc., USA). Descriptive analysis was used to measure mean and standard deviation 
(SD). Statistical significance of differences between means was analysed using paired 
samples t-test. Two-Way ANOVA with repeated measure was used. However, whenever the 
data was not normally distributed, the Friedman test was used to examine the main effect of 
time in each trial and the Wilcoxon signed rank test was used to find the differences between 
trials in each time point value. All the data were expressed as mean ± SD. The accepted level 
of significance was P < 0.05. 
6.3 Results. 
6.3.1 Physiological parameters. 
Table 6.1 shows the physiological parameters measured in this study. Rating of 
perceived exertion and HR were significantly increased over the time (P < 0.05), although, 
they were not significantly different between trials. However, the rate of oxygen uptake 
during the two trials was significantly different (P < 0.001). 
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Table 6.1: Physiological parameters (n = 9). 
Parameters  Value (Mean ± SD)      P value   
between trials 
VO2max (ml.kg-1.min-1) 47.5 ± 3.8 
60% VO2max (ml.kg-1.min-1) 28.5 ± 2.3 
Work Rate at 60% VO2max (W) 136 ± 24 
Rating of perceived exertion at  
the end of the trial (Borg’s unit) 
Non-probiotic Trial 13 P = 0.503 
 Probiotic Trial 12 
Heart rate at the end of the trial 
(Beats.min-1) 
Non-probiotic Trial 150 ± 11 P = 0.625 
Probiotic Trial 151 ± 9 
Average VO2 during the trial 
(ml.min-1) 
Non-probiotic Trial 
29.2 ± 3.3 
(61.6% VO2max) 
P < 0.01 
Probiotic Trial 
26.7 ± 3.1 
(56.3% VO2max) 
 
 
 
 
 
. 
. 
. 
. 
. 
. 
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6.3.2 Saliva flow rate, S-IgA concentration, and secretion rate. 
There were no significant main effects of time or treatment on saliva flow rate, S-IgA 
concentration, and S-IgA secretion rate (Figure 6.2 – 6.4). There were also no significant 
interaction effect for the probiotic on the saliva flow rate, S-IgA concentration, and secretion 
rate. 
 
Figure 6.1: Saliva flow rate in both trials. 
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Figure 6.2: S-IgA concentration in both trials. 
 
 
Figure 6.3: S-IgA secretion rate in both trials. 
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6.3.3 Lactoferrin. 
 There was a significant main effect of time on lactoferrin production in both trials (P 
< 0.05) (Figure 6.5). However, there was no significant effect of the probiotic 
supplementation on lactoferrin production. 
  
Figure 6.4: Lactoferrin concentration in both trials. 
*,** Significant difference compared to respective pre-exercise value  
(P < 0.05 and P < 0.001 respectively). 
+ Significant difference compared to respective 1h post-exercise value (P < 0.05). 
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6.3.4 Lysozyme. 
There was no significant main effect of time on lysozyme concentration in both trials 
(Figure 6.6). There was also no significant effect of the probiotic on lysozyme concentration. 
 
Figure 6.5: Lysozyme concentration in both trials. 
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6.3.5 Alpha-amylase. 
There was significant main effect of time on α-amylase concentration (P < 0.05) 
(Figure 6.7). However, there was no significant effect (P > 0.05) of the probiotic on salivary 
α-amylase concentration. 
 
Figure 6.6: α-amylase concentration in both trials. 
* Significant difference compared to respective pre-exercise value (P < 0.05). 
# Significant difference compared to respective post-exercise value (P < 0.05). 
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6.3.6 Nitrite and Nitrate. 
As shown in the Table 6.2, there was no significant effect of trial on the saliva nitrite 
and nitrate concentrations. 
Table 6.2: Nitrite and Nitrate concentration in both trials. 
 Non-probiotic Trial Probiotic Trial P value 
Nitrite 21.7 ± 7.6 16.8 ± 5.4 0.319 
Nitrate  56.3 ± 14.1 41.5 ± 7.6 0.294 
 
6.4 Discussion. 
 Average oxygen uptake (VO2) in both trials was significantly different (Table 6.1). 
However, RPE and HR were not significantly different between the trials. This suggests that 
the two trials were conducted in the similar condition, but the difference in the VO2 value 
might be due to one of these reasons; the effects of familiarisation, technical error in the 
measurement of the VO2 or difference in pre-exercise nitrite/nitrate concentration in both 
trials. 
The effect of familiarisation was unlikely because the two trials were separated by at 
least 5 weeks. Technical error in the measurement of VO2 was also unlikely because it was 
done properly with the appropriate calibration procedures. It has been suggested that nitrate 
in the food (some of which will be converted by bacteria to nitrite upon ingestion, with the 
rest will be converted to nitrite in the alimentary tract) increases the efficiency of adenosine 
triphosphate (ATP) production in mitochondria (Larsen et al., 2011). This has previously 
been shown to lead to a lower VO2 during submaximal exercise and hence improved exercise 
performance (Bailey et al., 2009 and 2010; Lansley et al., 2011; Christensen et al., 2012; 
. 
. 
. 
. 
. 
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Jones et al., 2012). Thus, it was hypothesised that the differences in the VO2 between the two 
trials in the present study might be related to this condition, where the probiotic bacteria 
ingested may have increased the reduction of nitrate to nitrite. To test this hypothesis, nitrite 
and nitrate analyses of saliva samples were carried out. However, as can be seen in Table 6.2, 
the pre-exercise saliva nitrite and nitrate concentrations were not different between the trials. 
This suggests that the 14-strain probiotic did not have any effect on the reduction of nitrate to 
nitrite. Thus, the reason why the VO2 values were different between trials is unclear. 
However, since the present study used pre- and post- supplementation design, this finding 
may be attributed to some other factor (e.g. change in diet, training, environment etc.) over 
time. 
Prolonged exercise increased lactoferrin (Figure 6.4) and α-amylase (Figure 6.6) 
concentration post-exercise but did not affect saliva flow rate (Figure 6.1), S-IgA 
concentration (Figure 6.2), S-IgA secretion rate (Figure 6.3), and lysozyme (Figure 6.5) 
concentration. As discussed before (Chapter 5, section 5.4), findings about the effects of 
exercise on S-IgA were inconsistent due to several reasons and it is quite controversial. 
However, several studies have reported that S-IgA concentration is reduced after intense 
exercise (Steerenberg et al., 1997; Fahlman et al., 2011), increased after moderate or lower 
intensity exercise (Williams et al., 2001; Dorrington et al., 2003; Li and Gleeson, 2004) or 
not affected by exercise intensity (Blannin et al., 1998; McDowell et al., 1991). The later 
studies were in agreement with the present study. It is known that S-IgA is the predominant 
immunoglobulin (Ig) in external secretions and is an important component of saliva. It is 
involved in immune exclusion (preventing antigens and microbes from adhering to and 
penetrating the epithelium), intracellular neutralization (interrupting replication of 
intracellular pathogens during transcytosis through epithelial cells), and immune excretion 
. 
. 
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(binding to antigens in the lamina propria facilitating their excretion through the epithelium 
back into the lumen) (Lamm, 1998). 
On the other hand, previous studies reported an increase in α-amylase activity in 
saliva and that this effect is related to the exercise intensity (Walsh et al., 1999; Bishop et al., 
2000). One study reported that α-amylase secretion was increased after cycling at 75% 
VO2max and after incremental exercise to exhaustion (Allgrove et al., 2008). Li and Gleeson 
(2004) also reported an increase in α-amylase activity after strenuous exercise. Alpha-
amylase accounts for about half of the total protein in saliva. It is an enzyme that breaks 
down starch into maltose, and also functions to interrupt the adherence and growth of certain 
bacteria (Scannapieco et al., 1993). It has been suggested that α-amylase can be a tool for 
evaluating the relationship between sympathetic nervous system and mucosal immunity 
following psychological and/or physical stress (Walsh et al., 1999). This is because α-
amylase is regulated by neuronal pathways and has been suggested to reflect changes in 
plasma noradrenaline and increased sympathetic activity under stressful conditions including 
exercise (Chatterton et al., 1996). In the present study, 90 min cycling at 60% VO2max 
increased α-amylase activity suggesting an increased in sympathetic activity due to stressful 
exercise. 
Lactoferrin and lysozyme both possess antimicrobial activity (bacteriocide and 
fungicide) and are part of the innate defence, mainly at mucosa (Sanchez et al., 1992). 
Following an intense training session, saliva lactoferrin (Cox et al., 1999) and lysozyme 
(Innoue et al., 2004) concentrations were reported to be decreased. However, in contrast, 
others have reported that lactoferrin (West et al., 2008) and lysozyme (Allgrove et al., 2008; 
West et al., 2008) concentrations were increased after an exhaustive bout of exercise. The 
present study found that 90 min cycling at 60% VO2max significantly increased saliva 
. 
. 
. 
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lactoferrin (Figure 7.4) concentration but had no effect on lysozyme (Figure 7.5) 
concentration. Exercise-induced increases in the concentration of AMPs are most likely 
related to sympathetic nervous system activity (Allgrove et al., 2008). Damage to epithelial 
cells through hyperventilation and subsequent exposure to environmental irritants, and the 
activation of neutrophils that follows may have led to increased secretion of these AMPs. 
Following physical damage (Dorschner et al., 2001) and contact with microbes (Duits et al., 
2003), epithelial cells increase their expression of AMPs.  
This study found that 30 days supplementation of the 14-strain probiotic did not affect 
the saliva AMPs measured. Previous studies with 4 weeks (Clancy et al., 2010; Cox et al., 
2010) and 3 weeks (Tiollier et al., 2007) of probiotic supplementation were also found to 
have no effect on the saliva S-IgA concentration. However, S-IgA concentration was reported 
to be increased after 8 weeks and 16 weeks of a single strain probiotic supplementation 
(Gleeson et al., 2011a) and Kotani and colleagues (2010) also reported an accelerated S-IgA 
secretion after 12 weeks of daily ingestion of a single strain probiotic. It appears that the 
supplementation period (30 days) and the dosage of the probiotic used in the present study 
were not enough to induce any beneficial effects of the probiotic. 
To date, there were no published studies (PubMed search) regarding the effects of 
mixtures of probiotics on AMPs. Nevertheless, there have been a few published studies 
reporting beneficial effects of multi-strain probiotics on incidence and duration of respiratory 
tract infection. Winkler and colleagues (2005) found that a mixture of probiotics decreased 
the incidence of infection by 13.6%. They also reported lower symptom severity and fewer 
numbers of days with fever in the multi-strain probiotic group compared to the placebo group. 
Similarly, de Vrese et al., (2006) reported reduced number of days with fever, duration of 
cold episode, and total symptom score in a mixtures probiotic group compared to a placebo 
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group. A meta-analysis in a recent review article found that there was a marginal beneficial 
effect of probiotics on the prevention of the common cold (Kang et al., 2013). 
It is known that probiotics modulate immune function through their effects on 
epithelial cell function, including epithelial cell barrier function, epithelial cytokine secretion, 
and their antibacterial effects relating to colonization of the epithelial layer (Boiriviant and 
Strober, 2007). Probiotics also interact with the receptors on M cells and gastro intestinal 
tract and so may influence aspects of systemic immune function (Kudsk, 2002). From the 
present study results, it may be worth investigating the effects of this multi-strain probiotic on 
salivary responses but at a higher dose and for a longer supplementation period.  
6.5 Conclusion. 
The present study found that 30 days supplementation of the 14-strain probiotic did 
not alter salivary antimicrobial proteins at rest and in response to an acute bout of prolonged 
exercise. However, prolonged exercise significantly increased lactoferrin and α-amylase 
concentration post-exercise. It appears that 30 days supplementation period and the 
dose/concentration of the 14-strain probiotic used in this study was not enough to induce any 
beneficial effects on athletes’ salivary antimicrobial proteins at rest and in response to an 
acute bout of prolonged exercise. 
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CHAPTER 7 
Study 5: Effects of a Lactobacillus probiotic on common cold infection incidence and 
mucosal immunity in endurance athletes. 
Abstract 
The purpose of this study was to assess evidence of health and immune benefit by 
consumption of a Lactobacillus probiotic in highly physically active healthy people. In a 
single-centre, population-based, randomized, double-blind placebo-controlled trial, 267 
student endurance sport athletes were randomly assigned to a liquid Lactobacillus probiotic 
(PRO) or placebo (PLA) supplement which was ingested twice daily for 16 weeks. Subjects 
completed validated questionnaires on respiratory tract infection (URTI) symptoms on a daily 
basis and on physical activity status at weekly intervals during the study period. Saliva 
samples were collected at entry and at 4, 8, 12 and 16 weeks of the intervention and analysed 
for antimicrobial protein (AMP) concentrations. Blood samples were collected before and 
after 16 weeks of the intervention for haematological analysis. Any difference in the 
proportion of subjects who presented with one or more episodes of URTI during the trial 
between the PRO and PLA groups was assessed by a chi-squared test. Comparison between 
the treatments for the number of URTI episodes was carried out using a Mann-Whitney test. 
Changes in saliva immune parameters before and after 4, 8, 12 and 16 weeks of the treatment 
period were analysed using two-way ANOVA with post hoc Sidak tests. The impact of URTI 
episodes on training volume was also evaluated by comparing physical activity levels (MET-
h/week) on weeks when an URTI episode was present with the average MET-h/week when 
the subjects were healthy. There was no significant difference in URTI incidence between 
both treatment groups. When mean (± SEM) MET-h/week physical activity during healthy 
(no URTI symptoms) weeks was compared with mean physical activity during weeks when 
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an URTI episode occurred, there was a significant decrease in both treatment groups (PRO 
65.1 ± 3.4 vs. 56.6 ± 4.5 MET-h/week, P = 0.001; PLA 71.5 ± 3.0 vs. 47.2 ± 3.4 MET-
h/week, P < 0.001). When normalized, the extent of the reduction in training load was 
somewhat lower on PRO (13%) than PLA (33%). No significant treatment or interaction 
effect of regular probiotic was observed for saliva antimicrobial proteins or their secretion 
rates except for salivary secretory immunoglobulin A (S-IgA) concentration, which was 
significantly lower at baseline in PRO than in PLA (P = 0.048). In summary, regular 
ingestion of a Lactobacillus probiotic tended to reduce the extent to which training was 
negatively affected in endurance athletes when infection was present, and increased both 
saliva S-IgA concentration and secretion rate over time but did not appear to influence URTI 
incidence or the duration and severity of URTI episodes. Two major confounding factors, 
namely the unexpectedly low incidence of URTI during the winter period and the lower 
baseline S-IgA in the PRO group may have prevented potential beneficial effects of probiotic 
supplementation from being identified. 
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7.1 Introduction.  
Probiotics are food supplements that contain live microorganisms which when 
administered in adequate amounts confer a health benefit on the host. Some probiotics are 
incorporated into food supplements including yogurts, kefir, dark chocolate, microalgae and 
tempeh (Edward, 2011). There is now a reasonable body of evidence that regular 
consumption of probiotics can modify the population of the gut microbiota and influence 
immune function (Matsuzaki, 1998; Gill and Cross, 2002; Gill and Prasad, 2008; Mengheri, 
2008; Borchers et al., 2009; Minocha, 2009) though it should be noted that such effects are 
strain specific. Suggested possible mechanism of actions of probiotics include modulation of 
the intestinal immune system, and displacement of potential pathogens through competitive 
exclusion or production of antimicrobial agents (Rowland et al., 2010). Documented health 
effects of probiotics include treatment of travellers’ diarrhoea, relief of milk allergy in 
infants, reduction in the risk of atopic diseases, treatment of some inflammatory conditions, 
increased resistance to enteric pathogens, promotion of anti-tumour activity, and alleviation 
of some allergic and respiratory disorders in children (Hatakka et al., 2001; Kopp-Hoolihan, 
2001; Saxelin et al., 2005; Rowland et al., 2010). Furthermore, it has been reported that 
probiotic supplementation enhances host resistance to upper respiratory tract infection 
(URTI) in the general population (Turchet et al., 2003; Winkler et al., 2005; de Vrese et al., 
2006; Berggren et al., 2011) and several recent studies have indicated that some 
Lactobacillus probiotics can reduce URTI incidence in athletes (Cox et al., 2010; Gleeson et 
al., 2011a; West et al., 2011) who are generally considered to be a marginally 
immunocompromised population due to the depressive effects of hard physical exercise, 
psychological stress, sleep disturbance and negative energy balance on their immune system 
(Gleeson, 2007; Walsh et al., 2011).  
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The mucosal membranes covering the oral cavity, respiratory, gastrointestinal, and 
genitourinary tracts are continuously exposed to pathogenic microorganisms, thus effective 
protection of mucosal surfaces is important in conferring resistance to infection and depends 
on several components of the innate and acquired immune system. Antimicrobial proteins 
(AMPs) including salivary secretory IgA (S-IgA), lactoferrin and lysozyme are well 
established humoral factors of the innate immune system with antibacterial, antiviral and 
fungicidal properties (West et al., 2006; Zheng et al., 2012). Reduced levels of salivary 
AMPs in athletes may contribute to their increased risk of URTI (Fahlman and Engels, 2005; 
Gleeson et al., 1999, West et al., 2006; Neville et al., 2008; Gleeson et al., 2011b; Walsh et 
al., 2011). Salivary IgA levels have been observed to fall during intensive periods of athletic 
or military training (Gleeson et al., 1999; Fahlman and Engels, 2005; Tiollier et al., 2007; 
Neville et al., 2008) but some studies suggest that probiotic supplements may increase S-IgA 
(O’Connell et al., 2010) or help to maintain S-IgA during periods of intensive physical 
activity (Tiollier et al., 2007; Gleeson et al 2011a). However, the effects of probiotic 
supplementation on other AMPs have not been extensively studied even though exercise 
induced reduction in their concentrations has previously been reported (Cox et al., 1999; 
Innoue et al., 2004). 
The aims of the present study were to examine the effects of 16 weeks of daily oral 
supplementation of a probiotic containing a Gram-positive Lactobacillus bacterium on 
infection incidence and salivary AMPs (S-IgA, lactoferrin, lysozyme and α-amylase) and 
their secretion rates in a cohort of university-based endurance athletes during a period of 
winter training and competition. Reporting URTI episodes at a phone interview or using 
weekly as opposed to daily questionnaires has raised some obvious concerns about their 
reliability (Barrett et al., 2002). Daily questionnaires have been shown to be effective in 
several investigations involving athletic populations (Peters and Bateman, 1983; Robson-
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Ansley et al., 2012).  Hence, in the present study we used a validated daily questionnaire 
(Jackson et al., 1958) to establish the occurrence of URTI episodes and used the modification 
of Predy et al. (2005) to determine the total number of days with URTI symptoms. 
7.2 Methods.  
7.2.1 Participants. 
 Two hundred and sixty seven subjects who were engaged in regular sports training 
(predominantly endurance-based activities such as running, cycling, swimming, triathlon, 
team games and racquet sports) volunteered to participate in the study. Subjects ranged from 
recreationally active to Olympic triathletes and their self-reported training loads averaged 10 
h/week. Subjects were required to complete a comprehensive health-screening questionnaire 
prior to starting the study and had not taken any regular medication, antibiotics or probiotics 
in the 3 months prior to the study. All subjects were fully informed about the rationale for the 
study and of all experimental procedures to be undertaken. Subjects provided written consent 
to participate in the study, which had earlier received the approval (document number R11-
P128) of Loughborough University ethical advisory committee. Subjects were enrolled after 
having fulfilled all inclusion criteria, and presenting none of the exclusion criteria 
(determined by both questionnaire and interview). 
Subjects could be included if they were currently healthy, had been involved in 
endurance training for at least 2 years, engaged in at least 3 sessions and at least 3 h of total 
moderate/high-intensity training time per week and were between 18 – 40 years of age. 
Subjects representing one or more of the following criteria were excluded from participation: 
smoking or use of any medication, currently taking probiotic supplements, suffered from or 
had a history of cardiac, hepatic, renal, pulmonary neurological, gastrointestinal, 
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haematological or psychiatric illness; objected to the prescription of diet (abstinence from 
fermented milk products other than the daily supplement). 
A total of 267 healthy individuals were recruited as subjects and randomly assigned to 
one of two treatments (probiotic or placebo) with stratification by gender and type of sport 
(A: endurance sports such as triathlon, swimming, cycling and distance running; B: team 
games such as football, rugby and hockey; C: individual sports such as tennis, squash and 
badminton). Under double-blind procedures 128 received the probiotic and 139 received the 
placebo preparation. Of these 267 subjects 83 were females and 184 were males with the 
mean age of the study cohort at recruitment being 20.6 ± 2.8 years (mean ± SD).  
Sample size estimation of at least 96 subjects per treatment group was based on an 
expected rate of 2.1 ± 1.2 URTI episodes (mean ± SD) during 4 winter months (Gleeson et 
al., 2011a), a target 20% reduction in number of episodes (to 1.7 ± 1.0 URTI episodes), 
statistical power of 80% and type I error of 5%. Software called GPower 3.1 was used for the 
power analysis. We initially recruited 267 volunteers to account for an estimated 25% drop-
out rate over the study period. 
7.2.2 First visit. 
For the first visit to the laboratory, subjects arrived in the morning at 08:30 – 10:30 
following an overnight fast of approximately 12 h and their body mass and height were 
recorded. Information about the study was given to them and they then signed an informed 
consent form. Subjects then sat quietly for 10 min and completed a health-screening 
questionnaire and inclusion/exclusion criteria questionnaire before providing an unstimulated 
saliva sample as described in the general methods (Chapter 2, section 2.4.1)  
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Subsequently, a resting venous blood sample (5 ml) was collected into Vacutainer 
tube containing K3EDTA as described in the general methods (Chapter 2, section 2.4.3). 
Haematological analysis was immediately carried out on this sample as described in the 
general methods (Chapter 2, section 2.4.4). Subjects eligible for inclusion in the study were 
randomly assigned to the probiotic or placebo group and asked to start taking the supplement 
the next day. 
7.2.3 Study intervention. 
Probiotic (PRO) and placebo (PLA) supplements were supplied as fermented milk in 
sealed pots of 65 ml with date stamped expiry. The PRO drink contained a minimum of 6.5 x 
109 live cells of Lactobacillus bacteria in each pot. The PLA was identical in taste and colour 
to the PRO but contained no bacteria. The supplements were stored at 3 – 7ºC and a fresh 
supply was provided by the manufacturer every 2 weeks. The name of the specific strain of 
bacteria and the name of the manufacturer cannot be disclosed at the present time due to a 
confidentiality agreement. Subjects returned to the laboratory every 2 – 3 weeks to receive a 
fresh supply of supplement. A compliance log of sample collection was taken. Subjects 
consumed the supplement twice per day; one 65 ml pot with breakfast and one with the 
evening meal for 16 weeks. Subjects were asked to keep a record of any days when they 
missed taking the supplement.  
7.2.4 Study protocol. 
During the 4-month intervention period with PRO or PLA subjects were requested to 
continue with their normal training programs. Other supplements (e.g. vitamins, minerals) 
and consumption of additional probiotics or any fermented dairy products (e.g. yoghurt, sour 
cream, crème fraiche) were not permitted during this period. Subjects completed a validated 
health (URTI symptoms) questionnaire (Jackson et al., 1958) on a daily basis. They were not 
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required to abstain from medication when they were suffering from illness symptoms but 
they were required, on a weekly basis, to report any un-prescribed medications taken, visits to 
the doctor or any prescribed medications.  
The illness symptoms listed on the questionnaire were: sneezing, headache, malaise, 
nasal discharge, nasal obstruction, sore throat, cough, ear ache, hoarseness, fever, chilliness 
and joint aches and pains. The non-numerical severity ratings of mild, moderate and severe of 
severity of symptoms were scored as 1, 2 or 3, respectively to provide a quantitative means of 
data analysis and the total symptom score for every subject each day was calculated as a sum 
of multiplied numbers of symptoms experienced by the numerical severity ratings. An URTI 
was deemed present when (i) total symptom score was ≥15 on any two consecutive days and 
(ii) when a subject positively indicated suffering a common cold on ≥ 3 days (Jackson et al., 
1958). Subjects were also asked to rate the impact of illness symptoms on their ability to train 
(above normal, at the same level, below normal or training stopped). The total number of 
URTI symptom days was also determined as the number of days with a symptom score of ≥5 
according to Predy et al. (2005). 
Subjects also completed a standard short form of International Physical Activity 
Questionnaire (IPAQ; http://www.ipaq.ki.se/downloads.htm) at weekly intervals, thus 
providing a quantitative information on training loads in metabolic equivalents (MET)-
h/week (Craig et al., 2003). Subjects attended the laboratory every 4 weeks following an 
overnight fast. Subjects were required to abstain from any strenuous physical activity for 24 h 
before coming to the laboratory. During these visits body mass was recorded/calculated and 
an unstimulated saliva sample was collected. Venous blood samples were collected during 
the final visit and analysed for haematological variables as described for the first visit to the 
laboratory. The intra-assay coefficient of variation for all blood variables was less than 3.0%. 
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7.2.5 Saliva analysis. 
The saliva volume collected and flow rate were estimated as described in the general 
methods (Chapter 2, section 2.4.1.1). Saliva samples were analysed for S-IgA, α-amylase 
activity, lactoferrin and lysozyme as described in the general methods (Chapter 2, section 
2.4.2). Secretion rates for each of the salivary AMPs were calculated as described in the 
general methods (Chapter 2, section 2.4.1.1). 
7.2.6 Data analysis. 
Any difference in the proportion of subjects who presented with one or more episodes 
of URTI during the trial between the PRO and PLA groups was assessed by a chi-squared 
test. Comparison between the treatments for the number of URTI episodes was carried out 
using a Mann Whitney test. For subjects who experienced one or more URTI episodes, 
comparison between the treatments for total symptom severity score and the mean duration of 
URTI episodes was carried out using unpaired t tests. Comparison between the treatments for 
the number of days with an URTI symptom score ≥ 5 (Predy et al., 2005) was carried out 
using an unpaired t test. Changes in saliva immune parameters before and after 4, 8, 12 and 
16 weeks of the treatment period were analysed using two-way ANOVA. Saliva AMP 
changes over time within the PRO and PLA group were assessed using repeated-measures 
ANOVA with post hoc Sidak tests. We also evaluated the impact of URTI episodes on 
training volume by comparing physical activity levels (MET-h/week) on weeks when an 
URTI episode was present with the average MET-h/week when the subjects were healthy. 
To fully appreciate the design of the current study additional analyses were performed 
focussing on time in weeks as independent parameter and incidence of common-cold 
infection, concentration and secretion rate of AMPs, and finally, physical activity as 
dependent parameter. Stepwise dummy regression was applied using a dummy factor to 
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identify the treatment (1: Probiotic; 0: Placebo), week number from the start and the 
combination of the two as an indicator for the change during the interval of the study as 
independent factors (Kleinbaum et al., 1998). This analysis enables not only to monitor a 
potential difference in incidence between both groups, but also a change in the dependent 
factor during the interval of the present study (change in time). As dependent parameters the 
incidence of common-cold infection, or the change in concentration or secretion rate of 
AMPs, or change in physical activity were taken. The change in parameter was calculated by 
subtracting the starting value per person per parameter from the values at the various intervals 
within the experimental design of the present study.  
Whenever feasible, not only a linear regression was performed, but also a quadratic or 
logarithmic. Poisson regression was done with respect to the incidence of common-cold 
infection to appreciate the discrete distribution of the dependent parameter and normal 
regression for the outcome in salivary AMPs. To minimize the impact by outliers on the 
regression outcome robust regression was performed as well (Maronna et al., 2006). 
With respect to the incidence of common-cold infection stratification in outcome was 
also done to minimize the impact by confounding factors. Three various approaches were 
used: 
- Interval (decreasing versus increasing incidence) 
- Gender (males versus females) 
- Type of sport (team games, individual sports, and endurance sports) 
Since the incidence over time revealed a parabolic curve, the time interval to be used in the 
incidence of common-cold infection was split into two segments as well: a decreasing and an 
increasing fraction. This reflects the sinusoidal character of the common cold infection 
pattern in general. 
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Data are presented as mean ± SEM. A P value of 0.05 or less was considered to show 
statistical significance, using two-sided testing. 
7.3 Results. 
7.3.1 Adherence to the study. 
Of the 267 subjects, 239 subjects (116 PRO, 123 PLA) completed the full 16 weeks of 
the study. The number of dropouts was smaller than anticipated and there were 12 dropouts 
on PRO and 16 on PLA (Table 7.1). Many of the subjects were athletes involved in national 
and international level competition and it was difficult or impossible for them to take the 
liquid supplement to competitions where air travel is needed due to airport security 
restrictions. Several subjects withdrew due to this issue. Some subjects also went abroad on 
vacation during the Christmas period which resulted in them dropping out of the study for the 
same reason or because we were unable to get the supplements to them. Other subjects 
withdrew due to injury or persistent non-respiratory illness (preventing them from performing 
training) or due to undisclosed reasons. Adherence to the intervention was good: subjects 
who completed the study reported that they missed taking the supplement on average only on 
3 days (range 0 – 14 days). Saliva samples were obtained on all 5 visits from 237 subjects. 
Blood samples were obtained pre- and post-intervention from 237 subjects, although 
sufficient blood volume to permit analyses of all variables was only obtained from 233 
subjects. 
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Table 7.1: Flow diagram showing numbers of subjects in weeks 1 and 16. 
 Total  PRO PLA 
Subjects, week 1 267 128 (91M, 37F) 139 (94M, 45F) 
Subjects, week 16    239   116 (84M, 32F)  123 (85M, 38F) 
       M = males; F = females 
 
7.3.2 Patterns in baseline characteristics. 
Baseline characteristics of the subjects who completed the study, including body 
mass, height, body mass index (BMI) and self-reported weekly training duration for the PRO 
and PLA groups are shown in Table 7.2. The baseline values were similar with no 
statistically significant difference between the two treatment groups, except for BMI which 
was higher on PRO than on PLA (P < 0.01).  
Table 7.2: Baseline characteristics of the subjects who completed the study.  
 PRO PLA 
Number (M, F)  116 (84, 32) 123 (85, 38) 
Sport (A, B, C) 70, 12, 34 66, 13, 44 
Age (years)  20.8  ± 0.3 20.5 ± 0.2 
Body mass (kg) 74.0 ± 1.1 73.1 ± 1.0 
Height (cm)  175.8 ± 0.9 177.3 ± 0.8 
BMI (kg/m2)  23.8 ± 0.2* 23.2 ± 0.2 
Training (h/week)  9.6 ± 0.4 9.7 ± 0.4 
Values are expressed as mean ± SEM. M = males; F = females. A = Endurance sports;          
B = Games players; C = Individual sports. * Significantly different from PLA, P < 0.01. 
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7.3.3 Physical activity levels. 
Mean training loads were not different for the PRO and PLA groups: 66.6 ± 3.1 and 
67.6 ± 2.6 MET-h/week, respectively (P = 0.817). This is equivalent to about 11 ± 1 h of 
moderate-vigorous activity per week (Figure 7.1). There was a significant drop in MET-
h/week in both groups from week 4 till weeks 8 – 10 after which the activity increased again 
to almost the same level as at the start. However, when a distinction was made in this 
between men and women, the decrease in physical activity for the women was significantly 
(P < 0.01) greater in the PRO group than in the PLA group. This observation was not 
encountered in that for the men.  
 
Figure 7.1: Training loads in MET-h/week over the 16-week study period for subjects who 
completed the study. Data are mean and SEM. No difference between treatments. 
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7.3.4 URTI incidence. 
Analysis of the URTI symptom questionnaires indicated that 4.0 ± 0.1 % of the cohort 
experienced an URTI episode each week (Figure 7.2). One hundred and thirty six subjects did 
not experience a single URTI episode during the study period whereas 103 subjects 
experienced at least one URTI episode during the study period. The proportion of subjects 
from the PLA group who experienced one or more weeks with URTI symptoms was 0.41 
whereas the proportion from the PRO group was 0.46. The difference in proportions was not 
significant (chi-squared test statistic = 0.618, P = 0.437).  
The mean number of URTI episodes, number of days with URTI symptom score ≥ 5 
and mean total symptom score and duration of URTI episodes were not different between 
PRO and PLA (Table 7.3). The proportion of subjects whose training was negatively affected 
when URTI was present was not different between PRO and PLA (0.63 and 0.76; chi-squared 
test statistic = 2.085, P = 0.196). When mean MET-h/week physical activity during healthy 
(no URTI symptoms) weeks was compared with mean physical activity during weeks when 
an URTI episode occurred, there was a significant decrease in both treatment groups [PRO 
65.1 ± 3.4 vs. 56.6 ± 4.5 MET-h/week, P = 0.001; PLA 71.5 ± 3.0 vs. 47.2 ± 3.4 MET-
h/week, P < 0.001]. When normalized, the extent of the reduction in training load was 
somewhat lower on PRO (13%) than PLA (33%).  
The number of URTI episodes was positively correlated (P < 0.001) with age and not 
with sex. The URTI total symptom score was not significantly higher in females than in 
males but the duration of URTI episodes was significantly (P < 0.03) higher in females than 
in males. The number of days with URTI symptom score above 5 was not significantly higher 
in females than in males (P = 0.08). There were no differences in the week number of the first 
URTI episode between males and females. 
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Figure 7.2: Percentage of the cohort reporting a URTI episode for each week of the study 
period. 
 
Table 7.3: Number of URTI episodes, number of days with URTI symptom score ≥ 5, and 
mean total symptom score and duration for URTI episodes in the 16-week period. 
 PRO PLA P 
URTI episodes 0.70 ± 0.08 0.59 ± 0.08   0.321 
Days with score ≥ 5 6 ± 1 5 ± 1   0.404 
Total symptom score 100.0 ± 7.2 94.9 ± 6.9   0.740 
URTI episode duration 13.5 ± 0.8 12.5 ± 0.7   0.534 
      Values are expressed as mean ± SEM. 
 
7.3.5 Medication and visits to the doctor during URTI episodes. 
During weeks when an URTI episode was present, the proportion of subjects who 
took medication was similar in the PRO and PLA groups (0.23 and 0.12, respectively; chi-
squared test = 2.020, P = 0.198) and the proportion who went to see their doctor was also 
similar in the PRO and PLA groups (0.02 and 0.06, respectively; chi-squared test = 1.166, P 
= 0.353). 
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7.3.6 Outcome of the dummy stepwise regression analysis for URTI incidence. 
Dummy stepwise Poisson regression revealed that the difference in incidence of 
common-cold infections was not significantly different between persons consuming the 
Probiotic drink or the Placebo during the interval of the present study (Figure 7.3), 
acknowledging the parabolic shape of the curves for both PRO as well as PLA. 
 
Figure 7.3: Number of common cold (URTI) episodes during the study period. 
 
7.3.6.1 Stratification I: time interval. 
Interestingly though, when the time interval of the study was separated in a 
significantly (week 2 – 10; P < 0.01) descending and significantly (week 11 – 16; P < 0.01) 
ascending part, the difference in the latter with respect to the number of incidences became 
higher in the PLA than in the PRO group, although this difference did not reach significance. 
In contrast the incidence in the PRO group was higher, though not significantly, than that in 
the PLA group during the descending phase which was already apparent at the start of the 
intervention. This suggests a time-dependent effect by PRO on the incidence of the common-
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cold infection. Moreover, when starting during a descent in incidence the room for 
improvement by the treatment could be too limited to detect any effect. 
7.3.6.2 Stratification II: gender. 
When the outcome for the male subjects only was examined (distinguished from those 
in the females) a significantly (P < 0.05) higher incidence in common-cold infections was 
observed in the PRO than in the PLA group throughout the interval of the study (Figure 7.4). 
However, this effect was found to be outlier-dependent (P = 0.06) as demonstrated via robust 
regression. For female subjects the situation was found to be opposite: throughout the interval 
the number of episodes was higher in the PLA than in the PRO group (P = 0.05) (Figure 7.5), 
again disappearing after robust regression (P = 0.11).  
 
Figure 7.4: Number of common cold (URTI) episodes in males during the study period. 
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Figure 7.5: Number of common cold (URTI) episodes in females during the study period. 
 
7.3.6.3 Stratification III: type of sport. 
When the type of sport was considered: team game players, individual sport players 
and endurance sport athletes, no impact on the outcome was observed. In all three sport types 
there was no difference in the incidence of common-cold infections between the PRO and 
PLA groups. A potentially beneficial effect by consumption of PRO was the strongest in the 
endurance sport athletes, but again the effect was not statistically significant. 
7.3.7 Salivary antimicrobial proteins. 
7.3.7.1 Lactoferrin. 
Saliva lactoferrin concentration (Figure 7.6A) was not different on PRO and PLA 
(time, interaction and treatment effects: F(3.779,842.752) = 0.846, P = 0.491; F(3.779,842.752) = 
0.299, P = 0.869; F(1,223) = 3.510, P = 0.062, respectively). Similarly, saliva lactoferrin 
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secretion rate (Figure 7.6B) was not different between PRO and PLA (interaction and 
treatment effects: F(3.685,821.699) = 0.363, P = 0.819; F(1,223) = 0.566, P = 0.453, respectively).  
No significant effect of time for lactoferrin concentration was found in PRO or PLA 
(F(3.594, 388.100) = 0.170, P = 0.941; F(3.729, 428.846) = 0.973, P = 0.418). A significant main effect 
of time for the lactoferrin secretion rate was found (F(3.685,821.699) = 6.101, P < 0.001). Within 
group one way ANOVA revealed no effect of time in PRO (F(3.511, 379.146) = 1.862, P = 0.125) 
but a significant effect of time was found in PLA (F(3.551, 408.398) = 4.588, P = 0.002) with 
values higher than baseline at weeks 12 and 16 (P ≤ 0.022). However, there were no 
significant differences in this between PRO and PLA. 
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Figure 7.6: Saliva lactoferrin concentration (A) and secretion rate (B) before and after 4, 8, 
12 and 16 weeks of the study. * different from week 0 in the PLA trial, P ≤ 0.022. (PRO, n = 
111; PLA, n = 121). 
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7.3.7.2 Lysozyme. 
No significant differences were observed in saliva lysozyme concentration (Figure 
7.7A) between PRO and PLA (interaction and treatment effects: F(3.740, 755.536) = 0.188, P = 
0.937, F(1,202) = 3.675, P = 0.057, respectively). No significant differences were found in 
saliva lysozyme secretion rate (Figure 7.7B) between PRO and PLA (interaction and 
treatment effects: F(3.635, 734.260) = 0.312, P = 0.853, F(1,202) = 1.447, P = 0.230, respectively).  
A significant main effect of time for the lysozyme concentration was observed (F(3.740, 
755.536) = 14.949, P < 0.001). Within group one way ANOVA revealed a significant effect of 
time was found for lysozyme concentration in PRO (F(4, 392) = 6.833, P < 0.001) with values 
higher at baseline than at weeks 8 and 16 (P ≤ 0.001). Similarly, a significant effect of time 
was found for lysozyme concentration in PLA (F(3.687, 383.498) = 8.387, P < 0.001) with values 
higher at baseline than at weeks 4, 8 and 16 and between week 8 and 12 (P ≤ 0.031). 
Additionally, a significant main effect of time for the lysozyme secretion rate was found 
(F(3.635, 734.260) = 4.586, P = 0.002). Within group one way ANOVA revealed no significant 
effect of time for lysozyme secretion rate in PRO (F(3.521, 345.071) = 1.719, P = 0.154). A 
significant effect of time for lysozyme secretion rate was found in PLA (F(3.525, 366.621) = 
3.271, P = 0.016) with a lower value at week 8 than at week 12.  
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Figure 7.7: Saliva lysozyme concentration (A) and secretion rate (B) before and after 4, 8, 12 
and 16 weeks of the study. * different from weeks 8 and 16 in the PRO trial, P ≤ 0.001; ** 
different from weeks 4, 8 and 16 in the PLA trial, P ≤ 0.031; † different from week 12 in the 
PLA trial, P = 0.003; †† different from week 12 in the PLA trial; (PRO, n = 108; PLA, n = 
114). 
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7.3.7.3 Saliva S-IgA. 
Saliva S-IgA concentration was higher on PLA than PRO (significant treatment 
effect: F(1,228) = 3.949, P = 0.048), due to t = 0 differences. This difference was evident at 
baseline but not at any other time point (Figure 7.8A). No significant differences were found 
in saliva S-IgA secretion rate (Figure 7.8B) between PRO and PLA (interaction and treatment 
effects: F(3.730, 850.391) = 0.861, P = 0.481, F(1,228) = 0.600, P = 0.439, respectively).  
A significant main effect of time for the S-IgA concentration was observed (F(4, 912) = 
6.462, P < 0.001). Within group one way ANOVA revealed a significant time effect for S-
IgA in PLA (F(4, 472) = 3.624, P = 0.006), but post hoc Sidak test showed no differences. A 
significant effect of time for S-IgA in PRO was observed (F(4, 440) = 3.919, P = 0.004) with 
values higher at week 16 than at weeks 8 and 12 (P ≤ 0.022).  
Similarly, a significant main effect of time for the S-IgA secretion rate was found 
(F(3.730, 850.391) = 15.690, P < 0.001). Within group one way ANOVA revealed a significant 
effect of time in PRO (F(3.555, 390.999) = 10.534, P < 0.001) with values higher at week 16 than 
at other time points and with week 12 higher than at baseline (P ≤ 0.032). Similarly, a 
significant time effect was found in PLA (F(4, 472) = 6.092, P < 0.001) with values higher at 
week 16 than at weeks 0, 4, 8 (P ≤ 0.013).  
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Figure 7.8: Saliva IgA concentration (A) and secretion rate (B) before and after 4, 8, 12 and 
16 weeks of the study. * P < 0.05 vs PRO; † different from weeks 8 and 12 in PRO, P ≤ 
0.022; ** different from other time points in PRO, P ≤ 0.013; $ different from week 0 in PRO, 
P = 0.032; # different from weeks 0, 4 and 8 in PLA, P ≤ 0.013. (PRO, n = 113; PLA, n = 
120). 
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7.3.7.4 Alpha-amylase. 
Saliva α-amylase activity (Figure 7.9A) was not different between PRO and PLA 
(interaction and treatment effects: F(3.780,827.852) = 0.445, P = 0.765; F(1,219) = 1.159, P = 0.283, 
respectively), Similarly, saliva α-amylase secretion rate (Figure 7.9B) was not different 
between PRO and PLA (interaction and treatment effects: F(3.764,824.335) = 0.616, P = 0.641; 
F(1,219) = 0.106, P = 0.745, respectively).  
A significant main effect of time for the α-amylase activity was found (F(3.780, 827.852) = 
16.084, P < 0.001). Within group one way ANOVA revealed a significant effect of time in 
PRO (F(3.646, 386.423) = 8.486, P < 0.001) with values higher at baseline than at weeks 4, 8 and 
16 (P ≤ 0.014) and higher at week 12 than at week 16 (P = 0.035). Likewise, a significant 
effect of time was found in PLA (F(4, 452) = 8.068, P < 0.001) with a higher value at baseline 
than at weeks 4, 8 and 16 (P < 0.001).  
Similarly, a significant main effect of time for the α-amylase secretion rate was 
observed to be different between PRO and PLA (F(3.764, 824.335) = 7.050, P < 0.001). Within 
group one way ANOVA revealed a significant effect of time in PLA (F(4, 452) = 2.940, P 
=0.020) but post hoc Sidak tests revealed no differences. A significant effect of time was 
found in PRO (F(3.695, 391.622) = 4.742, P = 0.001) with values higher at week 12 than at weeks 
4 and 8 (P ≤ 0.019).    
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Figure 7.9: Saliva amylase activity (A) and secretion rate (B) before and after 4, 8, 12 and 16 
weeks of the study. * different from week 16 in PRO, P = 0.035; # different from weeks 4, 8 
and 16 in PRO, P ≤ 0.014; ** different from weeks 4, 8 and 16 in PLA, P < 0.001; † different 
from weeks 4 and 8 in PRO, P ≤ 0.019. (PRO, n = 109; PLA, n = 114). 
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7.3.8 Outcome of the dummy stepwise regression analysis for salivary antimicrobial proteins. 
7.3.8.1 Lactoferrin. 
Not only was the absolute value at the start of the study, but also the change in either 
the concentration or the secretion rate not significantly different between both groups (Figure 
7.10). Lactoferrin concentrations (Figure 7.10A) remained stable in both groups throughout 
the interval of the study whereas the secretion rate (Figure 7.10B) increased, non-
significantly, in both. 
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Figure 7.10: Change in salivary lactoferrin concentration (A) and secretion rate (B) over the 
study period. 
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7.3.8.2 Lysozyme. 
With the absolute levels being not different at the start of the study, the decrease in 
lysozyme concentrations was similar in both groups, till the end of the intervention period 
(Figure 7.11A). However, the secretion rate of lysozyme was significantly (P < 0.03) higher 
in the PLA than in the PRO group throughout the interval of the intervention (Figure 7.11B). 
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Figure 7.11: Change in salivary lysozyme concentration (A) and secretion rate (B) over the 
study period. 
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7.3.8.3 Saliva S-IgA. 
A significant (P < 0.01) difference in concentration of S-IgA was observed at the start 
with higher values in the PLA group (Figure 7.12). During the interval of the study there was 
an initial decrease in S-IgA concentration in both groups, after which the PRO group 
increased significantly (P < 0.02) faster than the control group, reaching the same level as at 
the start after 4 months in contrast to that in the PLA group (Figure 7.12A). The S-IgA 
secretion rate was not different between both groups at the start. Interestingly though, the S-
IgA secretion rate increased significantly (P < 0.02) during the interval of the study in both 
groups (Figure 7.12B). 
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Figure 7.12: Change in S-IgA concentration (A) and secretion rate (B) over the study period. 
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7.3.8.4 Alpha-amylase. 
At the start of the intervention the absolute concentrations (measured as enzyme 
activities) were similar in both groups, during the intervention the concentration decreased in 
both groups at the same level. Similar observations were made for the amylase secretion rate 
(see Figure 7.9). 
7.3.9 Blood leukocyte counts. 
There were no significant differences either before or after the 16-week 
supplementation period between PLA and PRO in blood total or differential leukocyte counts 
(Table 7.4). 
7.3.10 Blinding. 
Of the subjects who expressed an opinion, 52% were correct and 48% were incorrect 
in their selection of treatment; hence, the study blinding was effective. 
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Table 7.4: Total and differential counts before and after 16 weeks of the intervention period. 
 Before 16 weeks After 16 weeks P value 
Leukocytes (cells x 109/L) 
PLA 
PRO 
 
6.30 ± 0.14 
6.18 ± 0.13 
 
5.82 ± 0.14 
5.85 ± 0.13 
 
0.619 
0.258 
Neutrophils (cells x 109/L) 
PLA 
PRO 
 
3.36 ± 0.12 
3.23 ± 0.12 
 
2.93 ± 0.11 
2.96 ± 0.10 
 
0.388 
0.597 
Monocytes (cells x 109/L) 
PLA 
PRO 
 
0.64 ± 0.03 
0.60 ± 0.02 
 
0.55 ± 0.02 
0.55 ± 0.01 
 
0.374 
0.492 
Lymphocytes (cells x 109/L) 
PLA 
PRO 
 
2.07 ± 0.05 
2.10 ± 0.05 
 
2.05 ± 0.05 
2.11 ± 0.05 
 
0.349 
0.282 
Values are expressed as mean ± SEM; n = 113 PRO; n = 119 PLA. 
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7.4 Discussion. 
The present study investigated the effects of regular probiotic intake on self-reported 
URTI (i.e. common cold infections) symptoms in a group of highly active individuals 
engaged in their normal level of training and competition during the period November 2011 
to March 2012. The main findings of the present study were that 4 months of daily probiotic 
supplementation resulted in improved maintenance of training volume when URTI episodes 
were present, but did not reduce incidence of URTI or the number of days with a symptom 
score ≥ 5. There was also no difference between PRO and PLA in the proportion of subjects 
who experienced at least one URTI episode. Similarly, in those who experienced one or more 
URTI episodes, the duration and severity of the episodes were not different between PRO and 
PLA. An increase in S-IgA concentration over time was found in PRO but not in PLA.  
Overall, men (n = 169) and women (n = 70) had similar URTI incidence (0.59 ± 0.06 
vs. 0.76 ± 0.11, respectively; P = 0.185) but women tended to have longer URTI episodes 
(15.1 ± 1.1 vs. 11.8 ± 0.06, respectively; P = 0.066) and more days with URTI symptom 
score 5 (6.5 ± 0.8 vs. 4.9 ± 0.4, respectively; P = 0.071). Women had lower saliva flow rates 
(P = 0.013) which was expected given that their body mass was 15 kg lower than the men. 
However, the saliva concentrations of lactoferrin, lysozyme and amylase were ~15% lower in 
women than men (all P < 0.05), though S-IgA concentration was not different. The secretion 
rates for lactoferrin, lysozyme, amylase and S-IgA were all significantly lower in women 
than men (all P < 0.03). 
These results suggest that regular Lactobacillus probiotic intake allows highly-trained 
athletes to maintain their training loads when a respiratory infection is present. Considering 
the fact that reductions in training load and interruptions of training regimens are the main 
undesirable side effects of infection for athletes (Gleeson, 2005; Bishop and Gleeson, 2009), 
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these better preserved training loads are of crucial importance. Additionally, regular probiotic 
intake increased both S-IgA concentration and its secretion rate which are known to be 
inversely correlated with URTI incidence in athletes (Fahlman and Engels, 2005; Gleeson et 
al., 1999, 2011b; Neville et al., 2008; Walsh et al., 2011; West et al., 2006). These data imply 
that probiotics may provide better protection from common colds in physically active 
individuals. However, regular probiotic intake in the present study did not appear to be 
beneficial in reducing the number of URTI episodes in a highly-trained athletic population in 
contrast with previous reports demonstrating reduced incidence and/or duration and severity 
of URTI episodes following chronic probiotic intake in endurance athletes (Cox et al., 2010; 
Gleeson et al., 2011a; West et al., 2011).  
These surprisingly opposite findings may be accounted for by several factors. The 
individuals recruited to this study were highly-trained, competitive athletes undertaking daily 
exercise and similar cohorts engaged in similar volumes of training have been shown to be at 
a higher risk of URTI when exposed to pathogens (Gleeson, 2005; Nieman, 1994). However, 
the mean number of URTI episodes in the PLA group (0.6) in the present study was far lower 
than that expected based on the results of our previous study (Gleeson et al., 2011a) where it 
was 2.1 in the PLA group. Data from the Health Protection Agency National Influenza 
Report (2012) suggest that the 2011 – 2012 winter period over which our present probiotic 
intervention study took place had an unusually low rate of common cold and flu incidence 
among the general population in the UK compared with previous years (Figure 7.13). The 
weather during the 2011 – 2012 winter was one of the driest on record and the much lower 
rate of common cold incidence than anticipated, may have prevented us from detecting a 
significant effect of probiotic supplementation on respiratory infection incidence. 
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Furthermore, despite using a fully randomized, double-blind study design, participants 
in the PRO group had, by chance, a significantly lower S-IgA concentration at baseline and 
tended to have lower S-IgA concentration at other time points (Figure 7.5; treatment main 
effect, P = 0.048). Saliva concentrations of lactoferrin and lysozyme also tended to be lower 
in the PRO group than in the PLA group (treatment main effect P values of 0.062 and 0.059, 
respectively). Considering that S-IgA concentration and/or secretion rate have been shown in 
numerous studies, involving endurance athletes, to be inversely correlated with numbers of 
URTI episodes (Fahlman and Engels, 2005; Gleeson et al., 1999; Gleeson and Pyne, 2000; 
Neville et al., 2008), such a chance effect of lower baseline S-IgA in the PRO group could 
place them in a disadvantaged position with regard to URTI risk. To put a positive spin on 
things, it could be argued that the probiotic supplementation may have prevented a higher 
incidence of URTI among this group of athletes with relatively lower levels of S-IgA and 
other AMPs. Moreover, despite lower baseline S-IgA the probiotic supplementation increased 
S-IgA concentration and secretion rate over time, illustrating its potential immune-boosting 
effects.  
The findings of the present study also suggest that other saliva AMPs did not 
compensate for reduced concentration of S-IgA, further underlining the importance of this 
salivary immunoglobulin. The concentrations of lactoferrin (r = 0.270; P < 0.05) and 
lysozyme (r = 0.265; P < 0.05) were significantly correlated with the S-IgA concentration in 
saliva in the whole subject cohort and the correlations for the secretion rates of these saliva 
AMPs were even stronger (lactoferrin vs S-IgA: r = 0.424; P < 0.01; lysozyme vs S-IgA: r = 
0.393; P < 0.01). The present study demonstrated that probiotic supplementation increases 
both concentration and secretion rates of S-IgA but not any other AMPs, which is in line with 
the previous studies showing that Lactobacillus probiotics may help maintain saliva S-IgA 
during periods of physical stress (Tiollier et al., 2007; Gleeson et al., 2011a). 
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Figure 7.13: UK Health Protection Agency Influenza Surveillance data (2012) demonstrating 
incidence of influenza-like illness in current and recent seasons (A) and proportion of calls 
for cold/flu symptoms in current and recent seasons (B). Week 42 (2011) to week 12 (2012) 
represents the present study period. 
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7.5 Conclusion. 
In summary, regular ingestion of Lactobacillus probiotic reduced the extent to which training 
was negatively affected in endurance athletes when infection was present, and increased both 
saliva S-IgA concentration and secretion rate over time but did not appear to reduce URTI 
incidence or the duration and severity of URTI episodes. Two major confounding factors, 
namely the unexpectedly low incidence of URTI during the winter period and the lower 
baseline S-IgA in the probiotic group may have prevented potential beneficial effects of 
probiotic supplementation from being identified. 
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CHAPTER 8 
GENERAL DISCUSSION 
The aim of this thesis was to examine the effects of several nutritional supplements on 
athletes’ immune function. This section presents a summary of the main findings of studies 
reported in this thesis. 
8.1 Effective stimulant (100 x dilution Pediacel vaccine) dose and Evidence Investigator. 
 The first study (Chapter 3) was carried out in order to determine which vaccine dose 
should be used to stimulate whole blood culture.  Seven different doses were introduced to 
the whole blood culture (dose 1: no vaccine, dose 2: 20,000 dilution factor, dose 3: 10,000 
dilution factor, dose 4: 4,000 dilution factor, dose 5: 2,000 dilution factor, dose 6: 1,000 
dilution factor, dose 7: 200 dilution factor) and the production of several cytokines (IL-2, IL-
4, IL-6, IL-8, IL-10, TNF-α, IFN-γ, IL-1α, and IL-1β)  were analysed with an Evidence 
Investigator biochip array after 20 h incubation. From the graphs plotted (Figure 3.1 – 3.9), it 
appeared that the effective dose was somehow between dose 4 and 6 (corresponding to a 
1,000 – 4,000 fold dilution). This was determined based on idea that the effective dose should 
induce at least a 3-fold increase above the unstimulated (dose 1) cytokine production but less 
than 50% of the maximal response. However, different cytokines give different a range of 
dose active response; hence, an effective dose for some cytokines might not be effective for 
other cytokines. Based on the findings, dose 5 was decided to be used in the next 3 studies 
that followed.  
 The Evidence Investigator (Randox, UK) was used in this study to analyse multiple 
cytokine production instead of the traditional method of ELISA. This is because Evidence 
Investigator can analyse multiple cytokines from a small sample (0.1 ml plasma), and it only 
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took 3 – 4 h to be carried out. This machine is quite new and not yet as widely used as ELISA 
methods. Thus, a simple correlation (Spearman’s correlation coefficient) was carried out to 
determine the relationship between results from the Evidence Investigator and ELISA data 
for IL-10. There was a moderately strong, positive correlation between the two variables; r = 
0.828, n = 38, P < 0.001. Thus, using the Evidence Investigator for analysis is an acceptable 
alternative to ELISA. 
8.2 Kaloba (Pelargonium sidoides) supplementation and immune response. 
In Chapter 4, several immunomodulatory nutritional compounds were used in vitro to 
determine their effects on antigen-stimulated whole blood culture cytokine production. 
Despite no noticeable effects of alcohol, curcumin, and echinacea on cytokine production, 
caffeine and quercetin showed a tendency towards decreased cytokine production as the 
doses were increased. On the other hand, an upward trend was evident with Kaloba, where a 
high dose of Kaloba seemed to increase the cytokine production. This might suggests Kaloba 
has a potential as an immunostimulant. Therefore, in Chapter 5, Kaloba was used as a 
supplement to investigate its effects on the immune response to prolonged exercise in healthy 
male recreational athletes.  
To date, effects of Kaloba on athletes’ immune function have not been extensively 
studied. Nevertheless, previous studies suggest its efficacy in treating patients with acute 
bronchitis (Kamin et al., 2010a; Kamin et al., 2010b) and common cold (Lizogub et al., 2007). 
Furthermore, studies also reported that Kaloba was successfully employed for the treatment 
of ear, nose, and throat disorders as well as respiratory tract infections (Kolodziej and 
Kiderlen, 2007; Matthys and Funk, 2008; Thale et al., 2008; Matthys et al., 2010). Kaloba has 
been reported to have a multifactorial mode of action; antiviral and cytoprotective properties, 
antibacterial properties, secretomotory properties and inhibition of ‘sickness behaviour’. 
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Several in vitro studies found that Kaloba triggers stimulation of IFN synthesis (Trun et al., 
2006; Kayser et al., 2007) and improves phagocyte function (Conrad et al., 2007). It was also 
shown to increase the ciliary beat frequency, thus increasing the transportation of mucous and 
pathogens from the respiratory tract. This in turn reduced pathogen count, removed the 
nutrient medium for their subsequent proliferation and substantially improved respiration 
(Neugebauer et al., 2005).  
However, the present study (Chapter 5) found no effects of Kaloba on cytokine 
production, leukocyte counts, S-IgA response, and UTI symptoms assessed using the 
Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21). A previous study (Luna et 
al., 2010) reported that 28 days of Kaloba supplementation (3 x 30 drops/day of a solution of 
80 g of extract/100 ml in solution) significantly increased S-IgA concentration in response to 
a high intensity running session. However, the post-exercise sample was collected 48 h after 
the exercise was completed. The authors did not justify the selection of this sampling time 
point and the study reported in this thesis indicated that the IgA response to exercise after 
Kaloba supplementation for 7 days was unaltered in the immediate post-exercise recovery 
period.  
Despite several clinical studies regarding the effectiveness of Kaloba (Lizogub et al., 
2007; Matthys and Funk, 2008; Bachert et al., 2009; Kamin et al, 2010a and 2010b; Matthys 
et al., 2010), this study failed to prove its effects on immune response in athletes. Thus, 
further study is warranted with a higher dose and a longer supplementation period with 
Kaloba. 
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8.3 A 14-strain probiotic supplementation and salivary antimicrobial proteins (AMPs). 
To date, there is no published study regarding effects of multi-strain probiotic 
(probiotic mixtures) on immune response in athletes. Although, there were a few studies 
regarding effects of a single strain of probiotic on immune response in athletes (Pujol et al., 
2000; Clancy et al., 2006; Kekkonen et al., 2007; Gleeson, 2008; Cox et al., 2010; Gleeson et 
al., 2011a; Gleeson et al., 2012). Some have reported that probiotic mixtures are more 
effective in modifying immune function and preventing respiratory tract infection (Chapman 
et al., 2011). It has been reported that probiotic mixtures reduced the number of days with 
fever, duration of cold episodes, total symptom score, and reduced incidence of respiratory 
tract and gastrointestinal infections (Winkler et al., 2005; de Vrese et al., 2006; Lin et al., 
2009). However, it is unknown if this is a result of synergistic interactions between strains or 
a consequence of the higher probiotic dose used in some of these studies. Most of multi-strain 
probiotic studies did not directly compare between a mixture and its component strains. This 
makes us unable to make a definite conclusion about the efficacy of the probiotic mixtures or 
their component strains. Potential modes of action of probiotics include (1) modulation of the 
intestinal immune system, (2) displacement of potential pathogens through competitive 
exclusion and (3) production of antimicrobial agents (Rowland et al., 2010), so intuitively, 
one might expect a combination of bacterial strains to be more effective than a single strain. 
The present study (Chapter 6) found that 30 days supplementation of the 14-strain 
probiotic did not alter salivary antimicrobial proteins (S-IgA, lactoferrin, and lysozyme 
concentrations, and α-amylase activity) at rest and in response to an acute bout of prolonged 
exercise. It was speculated that 30 days supplementation period and the dose/concentration of 
the 14-strain probiotic used in this study was not enough to induce any beneficial effects on 
athletes’ salivary antimicrobial proteins at rest and in response to an acute bout of prolonged 
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exercise. This was based on the previous studies with longer supplementation period, 16 
weeks (Gleeson et al., 2011a) and 12 weeks (Kotani et al., 2010), where they found positive 
effects of probiotics on S-IgA. Thus, further study is warranted with a higher dose and longer 
supplementation period of this 14-strain probiotic to see if it has any positive effects on an 
athlete’s immune function. 
8.4 Single strain Lactobacillus probiotic supplementation, common cold infection, and 
mucosal immunity in endurance athletes. 
 There is now a reasonable body of evidence that regular consumption of probiotics 
can modify the population of the gut microbiota and influence immune function (Matsuzaki, 
1998; Gill and Cross, 2002; Gill and Prasad, 2008; Mengheri, 2008; Borchers et al., 2009; 
Minocha, 2009). However, such effects are strain specific. Even though there were numerous 
studies of probiotics carried out on patients, studies regarding single strain probiotic effects 
on athletes’ immune function are scarce in literature. Gleeson and colleagues (2011a) found 
that a commercially available and popular probiotic (L. casei Shirota) appeared to be 
beneficial in reducing the frequency of URTI in athletes during a winter period (16 weeks) of 
training and competition, which may be related to better maintenance of S-IgA levels. 
However, during 16 weeks of spring training period, they found no effects of another strain 
of Lactobacillus probiotic (L. salivarius) on URTI and S-IgA level (Gleeson et al., 2012). It 
seems that cold weather which is associated with higher rate of common cold in the winter 
months helps in revealing potential beneficial effects of probiotics supplementation or that 
this different strain had a different (non-efficacious) effect on human immune function. 
Other study has also found no difference in incidence of respiratory infections with 
probiotic intervention (Kekkonen et al., 2007). Similarly, the present study (Chapter 7), 
despite using a larger population of athletes than most previous studies, also found that 
153 
 
regular ingestion of a Lactobacillus probiotic did not reduce URTI incidence or the duration 
and severity of URTI episodes. Two major confounding factors, namely the unexpectedly 
low incidence of URTI during the winter period of 2010-11 and the lower baseline S-IgA in 
the probiotic group compared with placebo may have prevented potential beneficial effects of 
probiotic supplementation from being identified. Nevertheless, the probiotic appeared to 
reduce the extent to which training was negatively affected in endurance athletes when 
infection was present, and increased both saliva S-IgA concentration and secretion rate over 
time. 
8.5 Prolonged exercise and immune response. 
Many studies have reported that prolonged and strenuous exercise temporarily impairs 
both innate and adaptive immune function (Pyne, 1994; Pedersen and Bruunsgaard, 1995; 
Ronsen et al., 2001), and hence increases infection risk. According to Gleeson (2006a), post-
exercise depression of immune function is most pronounced when the exercise is continuous, 
prolonged (> 1.5 h), of moderate to high intensity (55 – 75% of aerobic capacity), and 
performed without food intake. It was suggested that bouts of intense prolonged exercise 
induce decreased numbers and functions of leukocytes as a result of increased stress hormone 
secretion, thus resulting in the entry of less mature leukocytes into circulation, particularly 
NK cells (Gleeson, 2005). In addition, it was found that an intensive exercise at intensity of 
90% and 120% VO2max caused a significant decrease in plasma glutamine concentration, 
which in turn may lead to immunodepression (Keast et al., 1995) since it has been shown 
previously that amino acid glutamine is important for the function of some immune cells 
(macrophages and lymphocytes) (Newsholme et al., 1987).  
However, a review by Hiscock and Pedersen (2002) concluded that plasma glutamine 
is not likely to play a role in exercise-induced immunodepression because it was speculated 
. 
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that the magnitude of the decrease in plasma glutamine after an exercise is not sufficient to 
compromise the function of immune cells. For example, a previous study (compare the 
effects of exercise at 80% VO2max to fatigue with more prolonged exercise at 50% VO2max 
for up to 3 h) concluded that reductions in neutrophil function after exercise at 80% VO2max 
were not related to changes in plasma glutamine concentration, although both plasma 
glutamine and neutrophil function were decreased at 1 and 2.5 h post-exercise in the long 
duration exercise trial (Robson et al., 1999). 
In Chapter 5, participants cycled for 90 min at 60% VO2max. This study found that 
prolonged moderate intensity exercise significantly decreased S-IgA concentration and 
secretion rate post-exercise with the vales returned to baseline by 1 h post-exercise. However, 
total leukocyte count was significantly increased post-exercise, and was further increased 1 h 
post-exercise. This was mainly due to a rise in the neutrophil count. In Chapter 6, participants 
cycled for 2 h at 60% VO2max. However, no change was evident in S-IgA and lysozyme 
concentrations. But, lactoferrin concentration and α-amylase activity was significantly 
increased post-exercise. Findings about S-IgA in both studies were inconsistent. However, 
several studies were also reported inconsistent finding about effects of exercise on S-IgA 
concentration. Several studies have reported that S-IgA concentration is reduced after intense 
exercise (Steerenberg et al., 1997; Fahlman et al., 2001), increased after moderate or lower 
intensity exercise (Williams et al., 2001; Dorrington et al., 2003; Li and Gleeson, 2004) or 
not affected by exercise intensity (McDowell et al., 1991; Blannin et al., 1998).  
Exercise-induced increases in the concentration of AMPs are most likely related to 
sympathetic nervous system activity (Allgrove et al., 2008). Damage to epithelial cells 
through hyperventilation and subsequent exposure to environmental irritants, and the 
activation of neutrophils that follows may have led to increased secretion of these AMPs. 
. 
. 
. . 
. 
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Following physical damage (Dorschner et al., 2001) and contact with microbes (Duits et al., 
2003), epithelial cells increase their expression of AMPs. However, investigation on effects 
of exercise on AMPs is still limited in literature currently. 
8.6 Summary and future direction. 
The general finding of this thesis is that nutritional supplements (Kaloba, a 14-strain probiotic, 
and single strain probiotic) may or may not (indecisive) affect immune function of athletes. 
Further investigation need to be carried out. 
 Following findings from study 2 (Chapter 4), further investigation needs to be carried 
out for some of the cytokines since their response was unable to be measured due to 
vaccine dose used being beyond their effective dose range (thus they were exhibiting 
a maximal response). Some of the cytokine responses were inconclusive either they 
were leading to immunostimulant or immunosuppressant. 
 Following findings from study 3 (Chapter 5), further investigations with a higher dose 
of Kaloba and with a longer supplementation period is warranted. Numerous studies 
reported beneficial effects of Kaloba in vitro, thus this supplement might have 
potential effects on athletes’ immune function. 
 Following findings from study 4 (Chapter 6), further investigations is also 
recommended with longer supplementation period and higher dose. The results will 
be very valuable since to date there was no other study investigating multi-strain 
probiotics on athletes’ immune function. 
 Following findings from study 5 (Chapter 7), further investigations is encouraged 
with the hope that the two major confounding factors that may have prevented 
potential beneficial effects of probiotic supplementation from being identified are 
removed.
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[ title of the study] 
 
 
INFORMED CONSENT FORM  
(to be completed after Participant Information Sheet has been read) 
 
 
The purpose and details of this study have been explained to me. I understand that 
this study is designed to further scientific knowledge and that all procedures have 
been approved by the Loughborough University Ethical Advisory Committee. 
 
I have read and understood the information sheet and this consent form. 
 
I have had an opportunity to ask questions about my participation. 
 
I understand that I have the right to withdraw from this study at any stage for any 
reason, and that I will not be required to explain my reasons for withdrawing. 
 
I understand that all the information I provide will be treated in strict confidence and 
will be kept anonymous and confidential to the researchers unless (under the 
statutory obligations of the agencies which the researchers are working with), it is 
judged that confidentiality will have to be breached for the safety of the participant or 
others.  
 
 
I agree to participate in this study. 
 
                    Your name 
 
              Your signature 
 
                            Email 
 
              Phone number 
 
 
                               Date 
 
 
 
 
 
Signature of investigator 
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Name/Number   ...............…….  
 
Health Screen Questionnaire for Study Volunteers 
 
As a volunteer participating in a research study, it is important that you are currently in good 
health and have had no significant medical problems in the past.  This is (i) to ensure your 
own continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
If you have a blood-borne virus, or think that you may have one, please do not take part in 
this research. 
 
Please complete this brief questionnaire to confirm your fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise ............  Yes  No  
(b) attending your general practitioner ...................  Yes  No  
(c) on a hospital waiting list ....................................  Yes  No  
 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP ................................................  Yes  No  
(b) attend a hospital outpatient department ...........  Yes  No  
(c) be admitted to hospital .....................................  Yes  No  
 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy  ........................................ Yes  No  
(b) Asthma .............................................................. Yes  No  
(c) Eczema  ............................................................. Yes  No  
(d) Diabetes ............................................................ Yes  No  
(e) A blood disorder ................................................ Yes  No  
(f) Head injury ........................................................ Yes  No  
(g) Digestive problems  ........................................... Yes  No  
(h) Heart problems  ................................................. Yes  No  
(i) Problems with bones or joints     ........................ Yes  No  
(j) Disturbance of balance/coordination  ................ Yes  No  
(k) Numbness in hands or feet  ............................... Yes  No  
(l) Disturbance of vision  ........................................ Yes  No  
(m) Ear / hearing problems  ..................................... Yes  No  
(n) Thyroid problems  .............................................. Yes  No  
(o) Kidney or liver problems  ................................... Yes  No  
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(p) Allergy to nuts  ................................................... Yes  No  
 
4. Has any, otherwise healthy, member of your family under the 
age of 35 died suddenly during or soon after 
exercise?  .................................................................. 
Yes  No  
 
If YES to any question, please describe briefly if you wish (eg to confirm problem 
was/is short-lived, insignificant or well controlled.) 
...................................................................................................................................................
........ 
 
5. Allergy Information 
(a) are you allergic to any food products? Yes  No  
(b) are you allergic to any medicines? Yes  No  
(c) are you allergic to plasters? Yes  No  
 
If YES to any of the above, please provide additional information on the allergy 
………………………………………………………………………………………………………………………
……….. 
 
6. Additional questions for female participants 
(a) are your periods normal/regular?  ......................  Yes  No  
(b) are you on “the pill”?  .........................................  Yes  No  
(c) could you be pregnant?    ..................................  Yes  No  
(d) are you taking hormone replacement therapy 
(HRT)? 
Yes  No  
 
7. Are you currently involved in any other research studies at the University? 
 Yes  No  
 
If yes, please provide details of the study 
………………………………………………………………………………………………………… 
 
8. Do you smoke? 
 Yes  No  
 
 
Subject characteristics: 
 
Gender: Male / Female  
 
Body Mass: ________ kg 
 
Height: __________ cm   BMI:___________ kg/m2 
 
Age:_________ years 
 
What is your main sport? __________________________ 
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How many times per week do you train and/or compete (all sports)? __________ 
 
How many hours in total per week do you train/compete (all sports)? __________ 
 
Have you suffered any illness in the last 3 months?   Y / N     if yes, when? ________ 
 
Have you donated blood (>500 ml) in the last 3 months?   Y / N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
